Document:

exv10w49

Exhibit 10.49

Execution Copy

RESEARCH LICENSE AND OPTION AGREEMENT

     This Research License and Option Agreement (this “Agreement”) is made effective as of
June 11, 2008 (the “Effective Date”), by and between Archemix Corp, a Delaware corporation
with offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a
corporation organized under the laws of Japan with offices at Shirokanedai Usui Building, 3-16-13
Shirokanedai, Minato-ku, Tokyo 108-0071 Japan (“Ribomic”). Archemix and Ribomic are each
sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”

     WHEREAS, Archemix is the owner of or otherwise controls, certain patents related to (a) the
identification and optimization of aptamers using its proprietary SELEX Process and SELEX
Technology (each as defined herein) and (b) the use of such aptamers for controlling, curing,
treating, preventing or delaying the onset or progression of human diseases and conditions;

     WHEREAS, Ribomic desires to obtain from Archemix a non-exclusive license under such patents to
conduct Research Activities (as defined below) with respect to certain Active Targets (as defined
below) and an Option (as defined below) to obtain an exclusive license to develop and commercialize
Aptamers against such Active Targets; and

     WHEREAS, Archemix desires to grant such license and Option to Ribomic on the terms and subject
to the conditions of this Agreement.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties
hereby agree as follows:

1. DEFINITIONS

     Whenever used in the Agreement with an initial capital letter, the terms defined in this
Article 1 shall have the meanings specified.

     1.1 “Active Aptamer” means any Aptamer that binds to an Active Target and any
Aptamer(s) Derived therefrom that binds to such Active Target.

     1.2 “Active Target” means the Targets listed on the Active Target List.

     1.3 “Active Target List”means the list of up to six (6) Active Targets set forth on
Schedule 1 attached hereto, as amended from time to time by the Parties pursuant to Section
2.2.1(a).

     1.4 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly, controls or is controlled by or is under common control with, such Person. For
purposes of this definition, “control” means (a) ownership of fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors in the case of a corporation or
fifty percent (50%) or more of the equity interests in the case of any other type of legal entity,
(b) status as a general partner in any partnership, or (c) any other arrangement whereby a Person
controls or has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

 

 

     1.5 “Applicable Laws” means federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of regulatory authorities, national securities exchanges or securities listing
organizations, that may be in effect from time to time during the Term and are applicable to a
particular activity hereunder.

     1.6 “Aptamer” means (a) any naturally or non-naturally occurring oligonucleotide
identified through the SELEX Process that binds with high specificity and affinity to an Active
Target, and (b) any oligonucleotide derived from an oligonucleotide of clause (a) that has such
high specificity and affinity to such Active Target, but excluding Spiegelmers.

     1.7 “Archemix-Gilead License Agreement” means the License Agreement between Gilead
Sciences, Inc. and Archemix dated October 21, 2001, as amended.

     1.8 “Calendar Year” means the period beginning on the Effective Date and ending on
December 31 of the year in which the Effective Date falls and thereafter each successive period of
twelve (12) months commencing on January 1 and ending on December 31.

     1.9 “Challenge” means any challenge to the validity or enforceability of any Licensed
Patent Right in the absence of a breach of this Agreement including, without limitation, by (a)
filing a declaratory judgment action in which any Licensed Patent Right is alleged to be invalid or
unenforceable; (b) citing prior art pursuant to [***], filing a request for re-examination of any
Licensed Patent Right pursuant to [***] or provoking or becoming party to an interference with an
application for any Licensed Patent Right pursuant to [***]; or (c) filing or commencing any
reexamination, opposition, cancellation, nullity or similar proceedings against any Licensed Patent
Right in any country.

     1.10 “Commercially Reasonable Efforts” means, with respect to the research activities
of Ribomic under this Agreement, the efforts and resources customarily used by similarly sized
biotechnology companies in the performance of such research activities for other products owned by
such companies which are of similar market potential and at a similar stage of development, taking
into account the competitiveness of the market place, the regulatory structure involved and other
relevant and material factors.

     1.11 “Confidential Information” means all information and Technology disclosed or
provided by, or on behalf of a Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or
sublicensees (“Representatives”) pursuant to or in connection with this Agreement; provided, that,
none of the foregoing shall be Confidential Information if: (a) as of the date of disclosure, it is
known to the Receiving Party or its Representatives, as demonstrated by credible written
documentation, other than by virtue of a prior confidential disclosure to such Receiving Party; (b)
as of the date of disclosure it is in the public domain or it subsequently enters the public domain
other than through a breach by the Receiving Party or its Representatives of a contractual
obligation; (c) it is obtained by the Receiving Party from a Third Party having a lawful right to
make such disclosure free from any obligation of confidentiality to the Disclosing Party or its
Representatives; or (d) it is independently developed by or for the Receiving Party or its
Representatives without reference to or use of any Confidential Information of the Disclosing

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

2

 

Party or its Representatives as demonstrated by credible written documentation. For purposes
of clarity, unless excluded from Confidential Information pursuant to the provisos of the preceding
sentence, any scientific, technical or financial information Controlled by a Disclosing Party and
disclosed at any meeting of the Parties shall constitute Confidential Information of the Disclosing
Party.

     1.12 “Control” or “Controlled” means with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws.

     1.13 “Derived” means identified, developed, created, synthesized, designed, resulting
or generated from, conjugated to or complexed with (whether directly or indirectly, or in whole or
in part).

     1.14 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.

     1.15 “Diagnostic Product” means, collectively, In Vitro Diagnostic Agents, In Vivo
Diagnostic Agents and any aptamer product used for Diagnosis.

     1.16 “Existing License Agreements”means, collectively, (a) the Non-Exclusive IgG
Antibody Purification License Agreement dated as of October 31, 2006, by and between Ribomic and
Archemix, (b) the Exclusive License Agreement by and between Ribomic and Archemix dated as of
December 10, 2007 and (c) any License Agreement executed by the Parties upon the exercise of any
Option pursuant to this Agreement.

     1.17 “Failed Target”means any Active Target that is removed from the Active Target
List by Ribomic pursuant to Section 2.2.1(a), or is otherwise deemed to be a Failed Target pursuant
to Section 2.4.4 and/or 8.3.1(c).

     1.18 “Field” means the control, prevention, treatment, cure or delay of onset or
progression of any Indication in animals and humans, but excluding, without limitation, Diagnostic
Products, In Vivo Imaging Applications and all non-therapeutic uses.

     1.19 “FDA” means the United States Food and Drug Administration and any successor
agency or authority thereto.

     1.20 “Indication” means any indication, disease, disorder or condition in the Field,
which can be treated, controlled, prevented, cured or the onset or progression of which can be
delayed.

     1.21 “In Vitro Diagnostic Agent” means any product that uses the SELEX Process or one
or more Aptamers in the assay, testing or determination, outside of a living organism, of a
substance in a test material. In Vitro Diagnostics shall include, among other things, the use of

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

3

 

the SELEX Process or Aptamers in the assay, testing or determination: (a) outside of a living
organism, (i) of a human substance in a test material, often to identify or follow the progression
of a disease or disorder or to select a patient for treatment; (ii) of a plant substance, animal
substance or other substance in a test material, often to identify or follow the progression of a
disease, process or disorder in a human or non-human organism; and (iii) of environmental
substances (as in water quality testing); (b) of a substance on a test material such as cells (as
in FACS analysis or other measurements of pathogens within biological samples); and (c) any other
in vitro diagnostic use of the SELEX Process or Aptamers in drug development processes, including
target identification, pre-clinical and clinical testing, and the following more specific examples
of uses of Aptamer technology: (i) to observe, through protein profiling, protein levels moving up
or down in diseases or models of diseases, and to evaluate whether such proteins are sensible
targets for the development of therapeutic agents; (ii) to observe coordinated expression of
protein pathways in a variety of biological states in various systems; (iii) to study protein or
metabolite levels during pre-clinical drug candidate evaluation in response to putative therapeutic
agents during clinical trials (e.g., as markers of efficacy or response); and (iv) to study human
protein or metabolite levels in response to putative therapeutic agents during clinical trials
(e.g., as markers of efficacy or response). Notwithstanding the above, In Vitro Diagnostics shall
exclude any of the uses described in this Section 1.21(c) conducted in the conduct of Research
Activities with respect to Active Targets under this Agreement.

     1.22 “In Vivo Diagnostic Agent” means any product containing one or more Aptamers that
is used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state.

     1.23 “Joint Patent Rights”means Patent Rights that contain one or more claims that
cover Joint Technology.

     1.24 “Joint Technology”means any Technology (including, without limitation, any new
and useful process, method of manufacture or composition of matter) that is jointly conceived or
first reduced to practice (actively or constructively) by employees of or consultants to Ribomic
and employees of or consultants to Archemix at any meeting of the RC.

     1.25 “Knowledge” means, with respect to Archemix, the actual knowledge of the chief
executive officer, any vice president or the chief legal officer of Archemix.

     1.26 “License Agreement”means the license agreement substantially in the form of
Exhibit B attached hereto to be executed by the Parties upon the exercise of any Option
pursuant to Section 2.4.2.

     1.27 “Licensed Patent Rights” means all Patent Rights Controlled by Archemix or any of
its Affiliates and listed on Exhibit A to the extent that they are (a) issued patents as of
the Effective Date or (b) pending patent applications as of the Effective Date that will expire on
or before September 23, 2014 as well as any patent issuing on said pending patent applications and,
in any case, are necessary for Ribomic to practice the licenses granted to it hereunder. It is
understood that any pending patent applications listed on Exhibit A that will expire after
September 23, 2014 as well as any patent issuing thereon shall become part of the Licensed Patent
Rights only by mutual agreement of the Parties.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

4

 

     1.28 “Patent Rights” means all rights and interests in and to issued patents and
pending patent applications including, without limitation, non-provisional patent applications, and
all divisions, continuations and continuations-in-part thereof, patents issuing on any of the
foregoing, all reissues, reexaminations, renewals and extensions thereof, and supplementary
protection certificates therefor, as well as any certificates of invention or applications
therefor, and all foreign equivalents of any of the foregoing.

     1.29 “Permitted Archemix Activities”means (a) with respect to any Active Target, any
screening activities conducted by Archemix with respect to such Active Target for itself and/or for
any Third Party for the purpose of identifying aptamers that bind to a Target other than an Active
Target; and (b) any grant by Archemix to any Third Party of rights to discover, develop and/or
commercialize aptamers that bind to Targets (including Active Targets) outside of the Field.

     1.30 “Permitted Ribomic Activities”means, on a country-by-country and Valid
Claim-by-Valid Claim basis, any activity conducted by Ribomic or any of its Affiliates (a)
involving the discovery, research, development and commercialization of therapeutic aptamers in a
country for use in the Field against any Target other than the Active Targets at any time on and
after the expiration of the last to expire applicable Valid Claim of the Licensed Patent Rights in
such country or (b) pursuant to the terms of the Existing License Agreements, for so long as the
Existing License Agreements continue in full force and effect.

     1.31 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.

     1.32 “Radio Therapeutics” means any product for human therapeutic use that contains
one or more Aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or (b) any
structure or elements which develop therapeutic effects similar to the effect of linking or
incorporating radionucleotides after submission of any kind of radiation.

     1.33 “Research Activities”means the generation by Ribomic of Aptamers against Active
Targets, and/or the use by Ribomic of the SELEX Process and the SELEX Technology against Active
Targets, in either case, at the Ribomic Facility.

     1.34 “Ribomic Facility”means (a) Ribomic’s facility located at Shirokanedai Usui
Building, 3-16-13 Shirokanedai, Minato-ku, Tokyo 108-0071 Japan and (b) Ribomic’s facility located
at 4-6-1, Crest Hall, Shirokanedai, Minato-ku, Tokyo; provided, that the location of either Ribomic
Facility may be changed or added by Ribomic by providing not less
than [***] days’ prior
written notice to Archemix.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

5

 

     1.35 “Ribomic SELEX Patent Rights” means any Patent Rights that contain one or more
claims that cover Ribomic SELEX Technology. For purposes of clarity, the Ribomic SELEX Patent
Rights, as of the Effective Date, include without limitation the Patent Rights listed on
Exhibit C attached hereto.

     1.36 “Ribomic SELEX Technology” means any Technology that is Controlled by Ribomic as
of the Effective Date or during the Term relating to or constituting aptamer compositions or that
is useful for the identification, generation, modification, optimization, stabilization or use of
aptamers.

     1.37 “Ribomic Target Specific Patent Rights”means any Patent Rights Controlled by
Ribomic that contain one or more claims that cover Ribomic Target Specific Technology.

     1.38 “Ribomic Target Specific Technology”means any Technology that is Controlled by
Ribomic during the Term that is necessary or useful for the research, development, manufacture,
use, sale, importation or exportation of any Failed Target.

     1.39 “SELEX Portfolio” means those Patent Rights licensed by Gilead to Archemix
pursuant to the Archemix-Gilead License Agreement.

     1.40 “SELEX Process” means any process used for the identification or generation of a
nucleic acid that binds to a Target by means other than Watson-Crick base-pairing including,
without limitation, those that are covered by the claims in (a) the SELEX Portfolio, including,
without limitation, U.S. Patent Nos. [***] or [***], (b) any other Patent Rights Controlled by
Archemix or (c) any continuation, divisional, continuation-in-part, substitution, renewal, reissue,
re-examination or extension, or any foreign equivalent, of any of the foregoing Patent Rights.

     1.41 “SELEX Technology” means (a) oligonucleotides that bind to an Active Target by
means other than Watson-Crick base-pairing that consist of or incorporate structural elements that
are generally applicable to such oligonucleotides independent of Active Targets (e.g., a novel
nucleoside, bond or linkage or combination(s) thereof, for example, deoxypurine and 2’O-methyl
substituted prymidine compositions) as used in such oligonucleotides, and (b) any process for
modifying, optimizing and/or stabilizing oligonucleotides that bind to a Target by means other than
Watson-Crick base-pairing that is generally applicable to such oligonucleotides independent of
Active Targets wherein such modification, optimization or stabilization includes, without
limitation, minimization, truncation, conjugation, pegylation, complexation, substitution, deletion
and/or incorporation of modified nucleotides; provided, however, that SELEX Technology does not
include Active Aptamers.

     1.42 “Spiegelmer” means an oligonucleotide consisting of at least [***] percent
([***]%) [***], including any structural variations and modifications, derivatives, homologs,
analogs and/or mimetics to the [***] components (other than [***]), identified through the use of
the SELEX Process.

     1.43 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.

     1.44 “Technology” means, collectively, inventions, discoveries, improvements, trade

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

6

 

secrets and proprietary methods, whether or not patentable, including, without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including any negative results).

     1.45 “Territory” means all countries and jurisdictions of the world.

     1.46 “Third Party” means any person or entity other than Ribomic, Archemix and their
respective Affiliates.

     1.47 “ULEHI” means University License Equity Holdings, Inc., formerly known as UTC.

     1.48 “URC License Agreement” means the Restated Assignment and License Agreement,
dated July 17, 1991, by and between University Research Corporation and Gilead Sciences, Inc. as
successor in interest to NeXstar Pharmaceuticals, Inc.

     1.49 “UTC” means University Technology Corporation, the successor in interest to the
University Research Corporation.

     1.50 “Valid Claim”means any claim of a pending patent application or an issued,
unexpired patent covered under the Licensed Patent Rights which, but for the license granted by
Archemix hereunder, would be infringed by the Research Activities (a) has not been finally
cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent
jurisdiction, (b) has not been permanently revoked, held invalid or declared unpatentable or
unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable
or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through
disclaimer or otherwise, or (d) is not lost through an interference proceeding.

     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:

	 	 	 
	Definition	 	Section
	AAA
	 	9.2.1
	Active Target Replacement Notice
	 	2.2.1(a)
	Agreement
	 	Recitals
	Archemix
	 	Recitals
	Archemix Indemnitees
	 	7.1
	Archemix SELEX License
	 	2.1.2(a)
	Archemix Target License
	 	2.1.2(a)
	Bankruptcy Action
	 	8.2.4
	Chosen Courts
	 	9.2.2
	Claims
	 	7.1
	Disclosing Party
	 	1.11
	Discussioon
	 	2.4.4
	Dispute
	 	9.2.1

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

7

 

	 	 	 
	Definition	 	Section
	Effective Date
	 	Recitals
	Expired Option
	 	2.4.3
	Filing Party
	 	5.4.3
	Gilead Indemnitee
	 	7.3
	Indemnified Party
	 	7.2
	Indemnifying Party
	 	7.2
	Infringement
	 	5.5.1
	Infringement Notice
	 	5.5.1
	Non-Filing Party
	 	5.4.3
	Notice Period
	 	2.4.4
	Option
	 	2.4.1
	Option Exercise Notice
	 	2.4.2
	Option Period
	 	2.4.2
	Party
	 	Recitals
	Parties
	 	Recitals
	RC (Research Committee)
	 	2.7
	Receiving Party
	 	1.11
	Replacement Target Notice
	 	2.2.2(a)
	Replacement Target Substitution Notice
	 	2.2.2(b)
	Required Jurisdiction
	 	5.4.2
	Research License
	 	2.1.1(a)
	Ribomic
	 	Recitals
	Ribomic Patent Rights
	 	5.2
	Target Bonus Term
	 	2.2.3
	Term
	 	8.1

2. GRANT OF RIGHTS

     2.1 Licenses.

          2.1.1 Grant of Rights to Ribomic.

               (a) Grant of Research License. Subject to the terms and conditions of this Agreement,
Archemix hereby grants to Ribomic a non-exclusive, royalty-free, worldwide license during the Term,
under the Licensed Patent Rights for the sole purpose of conducting the Research Activities (the
“Research License”).

               (b) Negative Covenants. Ribomic is not granted the right under this Agreement to, and
hereby covenants and agrees that neither it nor its Affiliates will (i) use the SELEX Process or
SELEX Technology (A) on any Target that is not identified as an Active Target on the Active Target
List and (B) for any purpose other than the conduct of Research Activities at the Ribomic Facility
and/or except for the conduct by Ribomic of Permitted Ribomic Activities as expressly permitted
under this Agreement or (ii) research, develop, make, have made, use, have used, sell, offer for
sale, have sold, import, have imported, export or have exported Diagnostic Products or Spiegelmers.
Notwithstanding the foregoing, Ribomic shall not be restricted by this Section 2.1.1(b) from
engaging in any (i) Permitted Ribomic Activities or (ii) activity in which Ribomic is permitted to
engage pursuant to a license, sublicense or other right

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

8

 

granted to Ribomic in any agreement other than this Agreement (including, without limitation,
the Existing License Agreement) with respect to the SELEX Portfolio, the SELEX Process, SELEX
Technology or Aptamers, whether granted by Archemix, or any Third Party having the right to grant
such license, sublicense or other right. To the extent Ribomic or its Affiliates engages in any
activities in violation of the negative covenant set forth in this Section 2.1.1(b) during the Term
and files any patent applications or obtains any Patent Rights related to or arising out of such
activities then, without limiting any other remedy Archemix may have under this Agreement and
without any further action of either Party, Ribomic shall be deemed to have granted to Archemix,
effective as of the date of any such filing, an exclusive, fully-paid, perpetual, irrevocable,
royalty-free license under all such Patent Rights for any and all uses.

               (c) Reversion of License Rights. Ribomic acknowledges and agrees that each of the URC
License Agreement and the Gilead-Archemix License Agreement provides that the Archemix rights in
the SELEX Process or the SELEX Technology and the SELEX Portfolio may revert to Gilead or ULEHI if
Archemix, its Affiliates and all assignees and sublicensees cease to exercise reasonable efforts to
develop the commercial applications of products and services utilizing the SELEX Process or the
SELEX Technology. Ribomic further acknowledges and agrees that the URC License Agreement provides
that in the event of any termination of the URC License Agreement, the license to SELEX granted to
Ribomic hereunder shall remain in full force and effect in accordance with Section 3.4 of the URC
License Agreement; provided, that, Ribomic is not then in breach of this Agreement and Ribomic
agrees to be bound to ULEHI as the licensor under the terms and conditions of this Agreement.
Archemix shall inform Ribomic of such event immediately after the Archemix rights revert to Gilead
or ULEHI.

               (d) Gilead-Archemix License Agreement. Ribomic acknowledges and agrees that the
Gilead-Archemix License Agreement provides that in the event of any termination of the
Gilead-Archemix License Agreement, the license to SELEX granted to Ribomic hereunder shall remain
in full force and effect in accordance with Section 2.3 of the Gilead-Archemix License Agreement;
provided, that, Ribomic agrees to be bound to Gilead as the licensor under the terms and conditions
of this Agreement; provided, that, if the termination of the Gilead-Archemix License Agreement
arises out of the action or inaction of Ribomic, Gilead, at its option, may terminate such license.
Archemix shall inform Ribomic of such event promptly after the Gilead-Archemix License Agreement is
terminated.

          2.1.2 Grant of Rights to Archemix.

               (a) Grant of Licenses. Subject to the other terms and conditions of this Agreement,
Ribomic hereby grants to Archemix a non-exclusive, royalty-free, paid-up, perpetual, irrevocable,
worldwide license, with the right to grant sublicenses, (i) under all Ribomic Target Specific
Technology and Ribomic Target Specific Patent Rights to research, develop, make, have made, use,
have used, sell, offer for sale, have sold, import, have imported, export, have exported and
commercialize Aptamers against Failed Targets for any and all purposes (the “Archemix Target
License”) and (ii) under Ribomic SELEX Technology, Ribomic SELEX Patent Rights and Ribomic
Patent Rights (A) to research, develop, make, have made, use, have used, sell, offer for sale, have
sold, import, have imported, export, have exported, and commercialize Aptamers for any and all
purposes, and (B) for any and all uses of the SELEX Process and SELEX Technology (the “Archemix
SELEX License”); provided, however, that the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

9

 

license in clause (ii)(A) and (ii)(B) shall not apply to Active Aptamers or include any
specific aptamer sequences that are identified through the conduct by Ribomic of the Permitted
Ribomic Activities.

               (b) Covenant. Ribomic covenants and agrees to register the non-exclusive licenses
granted to Archemix under Section 2.1.2(a) under Japanese Patent No. 2,763,958 with the Japan
Patent Office as soon as practicable after the Effective Date and to provide Archemix with prompt
notice of such registration. Archemix shall reasonably cooperate with Ribomic to assist in the
preparation and execution of the registration and all formal documents to effect such registration,
at Ribomic’s sole cost and expense, if any.

     2.2 Selection of Active Targets.

          2.2.1 Selection of Active Targets and Replacement Targets.

               (a) Designation and Substitution of Active Targets. The Parties hereby acknowledge
and agree that six (6) Active Targets, as set forth on the Active Target List attached hereto as
Schedule 1, have been designated by Ribomic as of the Effective Date. During the Term,
Ribomic shall have the right to remove any Active Target from the Active Target List and substitute
such Active Target with a Replacement Target by providing written notice to Archemix, which notice
shall identify the Active Target to be removed and the Replacement Target selected by Ribomic to
replace the removed Active Target (the “Active Target Replacement Notice”). Subject to
Section 2.2.3, upon receipt by Archemix of an Active Target Replacement Notice, (i) the Active
Target that is selected for removal in the Active Target Replacement Notice shall be deemed to a
Failed Target for purposes of this Agreement; (ii) the Parties shall promptly amend Schedule
1 to include such Replacement Target as an Active Target and such Replacement Target shall be
deemed to be an Active Target for purposes of this Agreement; (iii) the Research License granted to
Ribomic with respect to such Failed Target set forth in Section 2.1.1(a) shall immediately
terminate; and (iv) Ribomic shall be deemed to have granted Archemix the Archemix Target License
set forth in Section 2.1.2(a)(i) with respect to such Failed Target. If Ribomic substitutes an
Active Target with a Replacement Target as described in this Section 2.2.1(a), no additional
Replacement Target may be proposed by Ribomic pursuant to Section 2.2.2 to replace such Replacement
Target.

          2.2.2 Selection of Replacement Targets.

               (a) Designation of Replacement Targets. Subject to Sections 2.2.3 and 2.4.4, during
the period commencing on the Effective Date and continuing until December 31, 2009, Ribomic shall
have the right to request that up to [***] Targets be accepted by Archemix as Replacement Targets
and included on the Target Replacement List by providing written notice to Archemix, which notice
shall identify each such proposed Replacement Target (each, a “Replacement Target Notice”).
Archemix shall determine whether to accept or reject any such proposed Replacement Target pursuant
to Section 2.2.2(c). To the extent Archemix accepts any Target for inclusion as a Replacement
Target on the Target Replacement List in accordance with Section 2.2.2(c), the Parties shall
promptly amend Schedule 2 to include such Target as a Replacement Target. To the extent
that Archemix rejects any Target for inclusion as a Replacement Target on the Target Replacement
List in accordance with Section 2.2.2(c), such Target will not be included on Schedule 2 as
a Replacement Target and Ribomic shall have no

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

10

 

rights under this Agreement with respect to such Target.

               (b) Substitution of Replacement Targets. During the Term, Ribomic shall have the
right on [***] for each of the [***] Replacement Targets originally identified by Ribomic pursuant
to Section 2.2.2(a) to replace such Replacement Target on the Target Replacement List by a new
Target by providing written notice to Archemix, which notice shall identify the Replacement Target
to be removed and the Target being proposed by Ribomic in substitution for the removed Replacement
Target (the “Replacement Target Substitution Notice”). Archemix shall determine whether to
accept or reject any such proposed Replacement Target pursuant to Section 2.2.2(c). To the extent
Archemix accepts any such new Target for inclusion on the Target Replacement List in accordance
with Section 2.2.2(c), (i) the Parties shall promptly amend Schedule 2 to include such new
Target as a Replacement Target and remove the substituted Replacement Target and (ii) all rights
granted to Ribomic under this Agreement (including, without limitation, pursuant to Section
2.1.1(a)) with respect to such substituted Replacement Target shall immediately terminate. To the
extent that Archemix rejects any Target for inclusion as a Replacement Target on the Target
Replacement List in accordance with Section 2.2.1(c), such Target will not be included on
Schedule 2 as a Replacement Target and Ribomic shall have no rights under this Agreement
with respect to such Target.

               (c) Acceptance/Rejection of Targets by Archemix. To the extent Ribomic requests the
inclusion of a Target as a Replacement Target pursuant to Sections 2.2.2(a) or (b), Archemix shall
accept or reject the proposed Target as a Replacement Target by providing Ribomic with written
notice within [***] days after receipt of notice from Ribomic; provided, that, Ribomic hereby
acknowledges and agrees that a Target proposed by Ribomic for inclusion as a Replacement Target on
the Target Replacement List may be rejected by Archemix for any reason or for no reason in its sole
discretion.

          2.2.3 Limitation on Number of Active Targets and Replacement Targets. Notwithstanding
anything to the contrary in this Agreement, under no circumstances shall Ribomic have, at any one
time, (a) more than [***] Active Targets on the Active Target List and (b) subject to the
immediately subsequent sentence of this Section 2.2.3 and the fourth sentence of Section 2.4.4,
more than [***] Replacement Targets on the Replacement Target List. Notwithstanding anything to
the contrary in this Agreement, during the period commencing on the [***] and continuing until
[***] (the “Target Bonus Term”), Ribomic shall have the right to designate [***] for
inclusion on the Target Replacement List pursuant to Section 2.2.2(a) for every [***] Options
exercised by Ribomic pursuant to Section 2.4.2 during the Target Bonus Term. By way of example, if
Ribomic exercises [***] Options pursuant to Section 2.4.2 on or before expiration of the Target
Bonus Term, Ribomic would have the right to designate [***] additional Replacement Targets for
inclusion on the Target Replacement List at any time before expiration of the Target Bonus Term.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

11

 

     2.3 No Other Rights. Ribomic is not granted any rights to use or otherwise exploit
Licensed Patent Rights except as set forth in this Agreement or the Existing License Agreements and
Archemix is not granted any rights to use or otherwise exploit Ribomic SELEX Technology, Ribomic
SELEX Patent Rights or Ribomic Patent Rights, Ribomic Target Specific Technology or Ribomic Target
Specific Patent Rights except as set forth in this Agreement or the Existing License Agreements.

     2.4 Grant of Option to Ribomic.

          2.4.1 Option Grant. Archemix hereby grants Ribomic, with respect to each Active
Target, an option (each an “Option”) to obtain an exclusive royalty-bearing license in the
Territory under Licensed Patent Rights for the purpose of researching, developing, making, having
made, using, having used, selling, having sold, offering for sale, importing, having imported,
exporting and having exporting Active Aptamers directed to such Active Target, for any and all uses
within the Field. For purposes of clarity, (a) Options shall only be available with respect to
Active Targets that are listed on the Active Target List and (b) under no circumstances shall
Ribomic have any rights to obtain an Option under this Agreement to any Target listed on the
Replacement Target List unless and until it is designated as an Active Target pursuant to Section
2.2.1(a).

          2.4.2 Option Exercise. Subject to Sections 2.4.3 and 2.4.4, Ribomic shall have the
right to exercise each Option at any time during the period commencing on the Effective Date and
continuing until expiration of the Term (the “Option Period”), by (a) delivering written
notice of exercise thereof (the “Option Exercise Notice”) on or before the expiration of
the Option Period, which Option Exercise Notice shall specify the Active Target that is the subject
of the Option, and (b) executing a License Agreement in the form attached hereto as Exhibit
B. Upon the exercise of an Option with respect to an Active Target as provided in this Section
2.4.2, (a) such Active Target shall be removed from the Active Target List, (b) the Research
License applicable to such Active Target set forth in Section 2.1.1(a) shall immediately terminate
and (c) such Active Target shall become a Licensed Target (as defined in the License Agreement) and
the Licensed Patent Rights (as defined in the License Agreement) shall be exclusively licensed with
respect to such Licensed Target to Ribomic on the terms and subject to the conditions set forth in
the relevant License Agreement.

          2.4.3 Option Expiration. In the event that Ribomic fails to exercise any Option on or
before the expiration of the Option Period (each, an “Expired Option”), all rights granted
by Archemix to Ribomic pursuant to this Agreement with respect to each such Expired Option shall
terminate.

          2.4.4 Archemix Notification Obligations; Reinstatement Right.

               (a) Notice of Discussion; Designation Right. If at any time during the Term, a Third
Party initiates good faith discussions with Archemix for purposes of (inter alia) acquiring a
license with respect to therapeutic applications of any Active Target or Replacement Target (each,
a “Discussion”), Archemix shall provide written notice to Ribomic which shall identify the
Active Target or Replacement Target that is the subject of the Discussion and include the name and
e-mail address of the person or persons at Archemix to whom Ribomic may provide

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

12

 

its response pursuant to the next sentence (the “Section 2.4.4 Contact Person(s)”).
Ribomic shall have a period of up to [***] days following the date of receipt of Archemix’s notice
pursuant to this section (the “Notice Period”) to (i) notwithstanding anything to the
contrary in this Agreement, with respect to any such Replacement Target, designate the Replacement
Target as an Active Target pursuant to Section 2.2.1(a) and exercise the Option applicable to such
Replacement Target pursuant to Section 2.4.2 and (ii) with respect to any such Active Target,
exercise the Option applicable to such Active Target pursuant to Section 2.4.2. Notwithstanding
anything to the contrary in this Agreement, any response provided by Ribomic pursuant to this
Section 2.4.4 may be made by Ribomic by e-mail to the Section 2.4.4 Contact Persons(s). If Ribomic
fails to give notice pursuant to Section 10.1(i), (ii) or (iii) of its exercise of the Option with
respect to a Replacement Target or Active Target as provided above within the Notice Period,
Ribomic’s Option with respect to such Active Target shall immediately terminate and Archemix shall
thereafter have the unencumbered right to (inter alia) negotiate and execute one or more agreements
with any Third Party or provide an existing Third Party licensee with rights that provide for the
conduct of one or more research, development and/or commercialization programs with such Third
Party with respect to the applicable Active Target. Should Archemix execute an agreement with a
Third Party or provide an existing Third Party licensee with rights with respect to such Active
Target or Replacement Target, (a) subject to any confidentiality obligations, Archemix shall
promptly notify Ribomic of such agreement or other grant of rights, (b) the Replacement Target or
Active Target, as the case may be, shall be deemed to be a Failed Target for purposes of this
Agreement and shall be removed from the Active Target List or Target Replacement List, as the case
may be; (c) Ribomic shall be deemed to have granted Archemix the Archemix Target License set forth
in Section 2.1.2(a)(i) with respect to such Failed Target; and (d) Ribomic shall have the right to
designate an Active Target in substitution for such Failed Target by providing written notice
pursuant to Section 2.2.1(a) or a Replacement Target in substitution for such Failed Target by
providing written notice to Archemix pursuant to Section 2.2.2(a), as the case may be.
Notwithstanding anything to the contrary in this Agreement, if an Active Target becomes a Failed
Target pursuant to this Section 2.4.4(a) or Section 2.4.4(b) within (a) [***] months of the
Effective Date, with respect to the Active Targets listed on Schedule 1 attached hereto as
of the Effective Date; and (b) within [***] months of the designation of any Active Target, with
respect to any other Active Target, Ribomic shall have the right to designate an additional
Replacement Target for inclusion on the Target Replacement List pursuant to Sections 2.2.2(a) and
2.2.2(c).

               (b) Reinstatement of Active Targets or Replacement Targets. If at any time during the
Term, Archemix determines in its sole discretion that it does not wish to execute an agreement with
a Third Party with respect to an Active Target or Replacement Target that has become the subject of
its Third Party negotiation right pursuant to this Section 2.4.4, (i) Archemix shall provide
written notice to Ribomic which shall identify the applicable Active Target or Replacement Target
and include the Section 2.4.4 Contact Person(s) and (ii) Ribomic shall have a period of up to [***]
days following the date of receipt of Archemix’s notice (the “Reinstatement Notice Period”)
pursuant to this section to reinstate its Option with respect to such Active Target or Replacement
Target by providing written notice, which may be made by e-mail to the Section 2.4.4 Contact
Person(s). If Ribomic reinstates the Option with respect to a Replacement Target or Active Target
as provided above, Schedule 1 or Schedule 2 shall be immediately amended to include
such Target as a Replacement Target or Active Target, as the case may be, and Sections 2.4.2
through 2.4.4 shall apply once again to such Replacement Target or Active Target

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

13

 

commencing with the date of such reinstatement. Notwithstanding anything to the contrary in
this Agreement, Ribomic shall have the right at any time after the expiration of the Notice Period
and prior to the expiration of the Reinstatement Notice Period to waive its right to reinstate the
Active Target or Replacement Target identified in Archemix’s notice by providing written notice,
which may be made by e-mail to the Section 2.4.4 Contact Person(s). If Ribomic waives its right to
reinstate any such Active Target or Replacement Target as provided above, (a) the Replacement
Target or Active Target, as the case may be, shall be deemed to be a Failed Target for purposes of
this Agreement and shall be removed from the Active Target List or Target Replacement List, as the
case may be; (b) Ribomic shall be deemed to have granted Archemix the Archemix Target License set
forth in Section 2.1.2(a)(i) with respect to such Failed Target; and (c) Ribomic shall have the
right to designate an Active Target in substitution for such Failed Target by providing written
notice pursuant to Section 2.2.1(a) or a Replacement Target in substitution for such Failed Target
by providing written notice to Archemix pursuant to Section 2.2.2(a), as the case may be.

     2.5 Diligence. From and after the Effective Date, Ribomic shall have full control and
authority over the conduct of all Research Activities, which Research Activities shall be
undertaken at Ribomic’s sole cost and expense. Ribomic will exercise Commercially Reasonable
Efforts to conduct such Research Activities.

     2.6 Progress Reports. Ribomic shall provide Archemix with written reports every [***]
months during the Term that describes in reasonable detail its progress with respect to the
Research Activities which shall include, at minimum, information reasonably sufficient to enable
Archemix to satisfy its reporting obligations to Gilead under the Gilead-Archemix License Agreement
with respect to this Agreement and to assess the progress made by Ribomic toward meeting the
diligence obligations of Section 2.5 above.

     2.7 Research Committee. To facilitate the providing of progress reports by Ribomic
with respect to the Research Activities contemplated by this Agreement, at Archemix’s sole option
and request the Parties will establish a Research Committee (the “RC”), which will be
comprised of equal numbers of representatives of each of the Parties. The RC will meet on dates
mutually agreed to by the Parties not less than [***] per Calendar Year, in person or by
teleconference which, if in person, shall alternate between the offices of Cambridge, Massachusetts
and Tokyo, Japan.  Intellectual property representatives of each Party may be invited to
participate in RC meetings and such meetings will provide a forum to discuss any patent prosecution
and enforcement issues that arise under this Agreement. Each Party will be responsible for the
costs and expenses incurred by its representative in participating on the RC. Notwithstanding
anything to the contrary in this Section 2.7, (i) the RC shall have no authority to make any
decisions binding on the Parties with respect to either Party’s performance under this Agreement
and (ii) the RC shall not meet more than [***] per Calendar Year unless the Parties mutually agree
to do so.

3. PAYMENTS AND ROYALTIES

     3.1 Research License Fee. In consideration for the rights granted to Ribomic
hereunder, Ribomic hereby agrees to pay Archemix an upfront technology access and license fee in
the aggregate amount of Six Million Dollars (U.S. $6,000,000), of which (i) Three Million Dollars
(US $3,000,000) shall be payable within thirty (30) days of the Effective Date; (ii) One Million
Dollars (US $1,000,000) shall be payable on or before December 31, 2008 and (iii) Two

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

14

 

Million Dollars (US $2,000,000) shall be payable on or before December 31, 2009. All such
payments shall be made by wire transfer of immediately available funds and shall be non-refundable
and non-creditable.

     3.2 Overdue Payments. Subject to the other terms of this Agreement, any payments not
paid within the time period set forth in this Article 3 shall bear interest at a rate of [***]
percent ([***]%) per month from the due date until paid in full; provided, that, in no event shall
said annual rate exceed the maximum interest rate permitted by law in regard to such payments. Any
such overdue payment shall, when made, be accompanied by, and credited first to, all interest so
accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right
of Archemix to any other remedy, legal or equitable, to which it may be entitled because of the
delinquency of the payment.

     3.3 Accounting; Taxes. All payments hereunder shall be made in the United States in
United States dollars and shall be made free and clear of any taxes, duties, levies, fees or
charges.

4. TREATMENT OF CONFIDENTIAL INFORMATION

     4.1 Confidentiality Obligations. Archemix and Ribomic each recognizes that the other
Party’s Confidential Information constitutes highly valuable assets of such other Party. Archemix
and Ribomic each agrees that, subject to the remainder of this Article 4, it will hold in
confidence and will not disclose, and will cause its Affiliates and sublicensees not to disclose,
any Confidential Information of the other Party and it will not use, and will cause its Affiliates
and sublicensees not to use, any Confidential Information of the other Party except as expressly
permitted hereunder; provided, that, such obligations shall apply during the Term and for an
additional [***] ([***]) years thereafter.

     4.2 Limited Disclosure and Use. Archemix and Ribomic each agrees that disclosure of
its Confidential Information may be made by the other Party to any employee, consultant, contractor
or Affiliate of such other Party to enable such other Party to exercise its rights or to carry out
its responsibilities under this Agreement; provided, that, any such disclosure or transfer shall
only be made to Persons who are bound by written obligations as described in Section 4.3. In
addition, Archemix and Ribomic each agrees that the other Party may disclose its Confidential
Information (a) on a need-to-know basis to such other Party’s legal and financial advisors, (b) as
reasonably necessary in connection with an actual or potential (i) permitted sublicense of such
other Party’s rights hereunder, (ii) debt or equity financing of such other Party or (iii) transfer
or sale of all or substantially all of such Party’s assets or business or in the event of its
merger, consolidation, change in control or similar transaction, and (c) for any other purpose with
the other Party’s written consent, not to be unreasonably withheld, conditioned or delayed. In
addition, each Party agrees that the other Party may disclose such Party’s Confidential Information
as required by Applicable Laws; provided, that, in the case of any such disclosure, the disclosing
Party shall (i) if practicable, provide the other Party with reasonable advance notice of and an
opportunity to comment on any such required disclosure and (ii) if requested by the other Party,
cooperate in all reasonable respects with the other Party’s efforts to obtain confidential
treatment or a protective order with respect to any such disclosure, at the other Party’s expense.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

15

 

     4.3 Employees and Consultants. Ribomic and Archemix each hereby represents that all
of its employees, consultants and contractors, and all of the employees, consultants and
contractors of its Affiliates, who have access to Confidential Information of the other Party are
or will, prior to their participation or access, be bound by written obligations to maintain such
Confidential Information in confidence and not to use such information except as expressly
permitted hereunder. Each Party agrees to use, and to cause its Affiliates to use, reasonable
efforts to enforce such obligations.

     4.4 Publicity. The Parties acknowledge and agree that (a) the terms of this Agreement
constitute Confidential Information of each Party and may only be disclosed (i) as permitted by
Section 4.2, and (ii) to investment bankers, investors, and potential investors, lenders and
potential lenders and other sources and other potential sources of financing, licensees and
potential licensees, acquirers or merger partners and potential acquirers or merger partners of
such Party, and, with respect to Archemix, to Gilead and University License Equity Holdings, Inc.;
and (b) a copy of this Agreement may be filed by either Party with the Securities and Exchange
Commission if such filing is required by Applicable Laws; provided, that, in connection with any
such filing, such Party shall endeavor to obtain confidential treatment of economic and trade
secret information, and shall provide the other Party with the proposed confidential treatment
request with reasonable time for such other Party to provide comments, which comments shall be
reasonably considered by the filing Party. Notwithstanding anything to the contrary in Section
4.1, except as required by Applicable Laws, neither Party shall issue a press or news release or
make any similar public announcement related to this Agreement without the prior written consent of
the other Party.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

16

 

5. INTELLECTUAL PROPERTY RIGHTS AND PROVISIONS

     5.1 Licensed Patent Rights. Archemix shall have sole and exclusive ownership of all
right, title and interest on a worldwide basis in and to any Licensed Patent Rights.

     5.2 Ribomic Patent Rights. Ribomic shall have sole and exclusive ownership of all
right, title and interest on a worldwide basis in and to any and all Patent Rights arising out of
the practice by Ribomic of the license pursuant to Section 2.1.1(a) (“Ribomic Patent
Rights”).

     5.3 Joint Technology; Joint Patent Rights. Ribomic and Archemix shall jointly own all
Joint Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained in
this Agreement or under Applicable Laws, except to the extent exclusively licensed to one Party
under this Agreement, the Parties hereby agree that either Party may use or license or sublicense
to Affiliates or Third Parties all or any portion of its interest in Joint Technology, Joint Patent
Rights or jointly owned Confidential Information for any purposes without the prior written consent
of the other Party, without restriction and without the obligation to provide compensation to the
other Party, except as otherwise provided under this Agreement, provided, that, to the extent that
any Joint Technology and/or Joint Patent Rights are necessary or useful for the research,
development, manufacture, use, sale, importation or exportation of an Active Aptamer being
commercialized by Ribomic pursuant to an executed License Agreement, Archemix shall not use or
license to a Third Party its interest in such Joint Technology and/or Joint Patent Rights to
develop or commercialize any Aptamers that were selected against and bind to the applicable Active
Target with high specificity and affinity.

     5.4 Prosecution of Patent Rights.

          5.4.1 Licensed Patent Rights. Archemix, at its sole expense and acting through patent
counsel or agents of its choice, shall be solely responsible for the preparation, filing,
prosecution and maintenance of the Licensed Patent Rights.

          5.4.2 Ribomic SELEX Patent Rights. Ribomic and/or its Affiliates, as applicable, at
its sole expense and acting through patent counsel or agents of its choice, shall have the sole
responsibility and obligation for the preparation, filing, prosecution and maintenance of the
Ribomic SELEX Patent Rights in the countries listed on Schedule 3 (the “Required
Jurisdictions”). In the event that Ribomic determines not to file or to abandon any of the
Ribomic SELEX Patent Rights in any of the Required Jurisdictions, Ribomic shall notify Archemix
sufficiently in advance so that Archemix can, without any loss of rights, and Archemix shall have
the right to, file, prosecute and maintain such Ribomic SELEX Patent Rights in Ribomic’s name at
Archemix’s expense in such Required Jurisdictions.

          5.4.3 Joint Patent Rights. Unless the Parties otherwise agree, each Party, acting
through patent counsel or agents of its choice, shall be jointly responsible for the preparation,
filing, prosecution and maintenance of all Joint Patent Rights as follows: (a) Ribomic shall be
responsible for the preparation, filing, prosecution and maintenance of any such claims that
specifically claim any Active Aptamer; (b) Archemix shall be responsible for the preparation,
filing, prosecution and maintenance of any such claims that do not specifically claim any Active
Aptamer; (c) the Parties shall discuss in good faith whether and how to pursue those claims for
which they have primary responsibility under this Section 5.4.3 in separate patent

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

17

 

applications; (d) each Party that has responsibility for filing and prosecuting any Patent
Rights under this Section 5.4.3 (a “Filing Party”) shall provide the other Party (the
“Non-Filing Party”) and its patent counsel with an opportunity to consult with the Filing
Party and its patent counsel regarding the filing and contents of any application, amendment,
submission or response filed pursuant to this Section 5.4.3; and (e) each Party shall be
responsible for all expenses incurred by it for the preparation, filing prosecution and maintenance
of any Joint Patent Rights for which it has primary responsibility pursuant to this Section 5.4.3.
The Filing Party shall (a) regularly provide the Non-Filing Party with copies of all patent
applications filed hereunder for Joint Patent Rights and other material submissions and
correspondence with the patent offices, in sufficient time to allow for review and comment by the
Non-Filing Party; and (b) provide the Non-Filing Party and its patent counsel with an opportunity
to consult with the Filing Party and its patent counsel regarding the filing and contents of any
such application, amendment, submission or response, and the advice and suggestions of the
Non-Filing Party and its patent counsel shall be taken into consideration in good faith by such
Filing Party and its patent counsel in connection with such filing. Each Filing Party shall pursue
in good faith all reasonable claims and take such other reasonable actions, as may be requested by
the Non-Filing Party in the prosecution of any Joint Patent Rights under this Section 5.4.3;
provided, however, if the Filing Party incurs any additional expense as a result of any such
request, the Non-Filing Party shall be responsible for the cost and expenses of pursuing any such
additional claim or taking such other activities.

     5.5 Infringement.

          5.5.1 Notice. In the event that during the Term either Party becomes aware of any
possible infringement of any Licensed Patent Rights, Ribomic SELEX Patent Rights or Joint Patent
Rights, including the submission by any Third Party of an abbreviated new drug application under
the Hatch-Waxman Act or its equivalent outside the United States for a generic product (each, an
“Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”).

          5.5.2 Infringement of Licensed Patent Rights. Archemix shall have the sole right, but
not the obligation, in its sole discretion, at its own expense and with legal counsel of its own
choice, to bring suit (or take other appropriate legal action) against any actual, alleged or
threatened Infringement of the Licensed Patent Rights.

          5.5.3 Infringement of Ribomic SELEX Patent Rights. Ribomic shall have the first
right, but not the obligation, at its own expense and with legal counsel of its own choice, to
bring suit (or take other appropriate legal action) against any actual, alleged or threatened
Infringement of the Ribomic SELEX Patent Rights. Archemix shall have the right, at its own
expense, to be represented in any such action by Ribomic by counsel of Archemix’s own choice;
provided, that, under no circumstances shall the foregoing affect the right of Ribomic to control
the suit as described in the first sentence of this Section 5.5.3. If Ribomic does not file any
action or proceeding against any such Infringement within [***] months (or [***] days in the case
of an Infringement resulting from the submission by any Third Party of an abbreviated new drug
application under the Hatch-Waxman Act or its equivalent outside the United States) after the later
of (i) Ribomic’s notice to Archemix under Section 5.5.1 above, (ii) Archemix’s notice to Ribomic
under Section 5.5.1 above or (iii) a written request from Archemix to take action with

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

18

 

respect to such Infringement, then Archemix shall have the right (but not the obligation), at
its own expense, to bring suit (or take other appropriate legal action) against such actual,
alleged or threatened infringement, with legal counsel of its own choice. If a Party brings any
such action or proceeding hereunder, the other Party agrees to be joined as party plaintiff if
necessary to prosecute such action or proceeding, and to give the Party bringing such action or
proceeding reasonable assistance and authority to file and prosecute the suit; provided, that,
neither Party shall be required to transfer any right, title or interest in or to any property to
the other Party or any Third Party to confer standing on a Party hereunder. Any damages, monetary
awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit,
proceeding or other legal action taken under this Section 5.5.3, shall belong to [***].

          5.5.4 Infringement of Joint Patent Rights. In the event of an Infringement of a Joint
Patent Right, the Parties shall enter into good faith discussions as to whether and how to
eliminate the Infringement. Each Party shall bear [***] of the cost of any action, suit or
proceeding instituted under this Section 5.5.4 and [***] of all amounts recovered shall be received
by each Party; provided, that, if the Parties are unable to determine whether and how to institute
an action, suit or proceeding for Infringement of any such Joint Patent Right, either Party shall
have the right to prosecute such Infringement, in which event that Party shall bear [***] and be
entitled to retain [***]. Each Party shall have the right to be represented by counsel of its own
selection in any action, suit or proceeding instituted under this Section 5.5.4 by the other Party.
If a Party lacks standing and the other Party has standing to bring any such action, suit or
proceeding, then the Party with standing shall bring such suit at the request and expense of the
other Party.

6. REPRESENTATIONS AND WARRANTIES

     6.1 Mutual Representations and Warranties. Archemix and Ribomic each represents and
warrants to the other, as of the Effective Date, as follows:

          6.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.

          6.1.2 Authorization. The execution and delivery of this Agreement and the performance
by it of the transactions contemplated hereby have been duly authorized by all necessary corporate
action and will not violate (a) such Party’s certificate of incorporation or bylaws, (b) any
agreement, instrument or contractual obligation to which such Party is bound in any material
respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction,
decree, determination or award of any court or governmental agency presently in effect applicable
to such Party.

          6.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.

          6.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

19

 

     6.2 Acknowledgment of Ribomic. Ribomic acknowledges that the licenses and rights
granted to Ribomic hereunder are subject to certain limitations and restrictions set forth in the
Archemix-Gilead License Agreement and agrees that Ribomic shall comply with the terms of the
Archemix-Gilead License Agreement that Archemix is subject to thereunder.

     6.3 Additional Representations and Warranties.

          6.3.1 Additional Representations and Warranties of Archemix.

               (a) Authority. Archemix represents and warrants to Ribomic that Archemix Controls the
Licensed Patent Rights and has the right to grant the license and Option granted to Ribomic on the
terms set forth herein.

               (b) No Litigation. Archemix represents and warrants to Ribomic that, as of the
Effective Date and with no further duty to update, to Archemix’s Knowledge, there is no pending
litigation against Archemix that seeks to invalidate or oppose any of the patents or patent
applications included in the Licensed Patent Rights.

               (c) Archemix-Gilead License Agreement. Archemix represents and warrants to Ribomic
that the Archemix-Gilead License Agreement as heretofore delivered by Archemix to Ribomic
represents the complete agreement and understanding between Gilead Sciences, Inc. and Archemix
relating to the Licensed Patent Rights which are the subject of the Archemix-Gilead License
Agreement; the Archemix-Gilead License Agreement has not been modified, supplemented or amended in
any manner that would adversely affect the rights granted to Ribomic under this Agreement, other
than by amendments thereto provided to Ribomic prior to the Effective Date; and the Archemix-Gilead
License Agreement is in full force and effect and Archemix is in compliance in all material
respects with its obligations thereunder.

               (d) No Infringement. Archemix represents and warrants to Ribomic that to its
Knowledge, there is no litigation pending or threatened that alleges that (i) the practice of the
SELEX Process and/or the use of SELEX Technology as contemplated by this Agreement infringes the
Patent Rights of any Third Party, (ii) the Licensed Patent Rights are invalid or unenforceable; or
(iii) the use of the Licensed Patent Rights as contemplated by this Agreement infringes the Patent
Rights of any Third Party.

               (e) No Conflict with Existing Active Targets. Archemix hereby represents and warrants
as of the Effective Date that none of the Active Targets listed on the Active Target List on the
Effective Date are the subject of an ongoing internal research program being conducted by Archemix
as of the Effective Date.

          6.3.2 Additional Representations and Warranties of Ribomic.

               (a) Authority. Ribomic represents and warrants to Archemix that Ribomic has the right
to grant the Archemix Target License and the Archemix SELEX License granted to Archemix on the
terms set forth herein.

               (b) No Litigation. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update (except as otherwise stated), there is no pending
litigation against Ribomic or any Affiliate of Ribomic that seeks to invalidate or oppose

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

20

 

any of the patents or patent applications included in the Ribomic SELEX Patent Rights.

               (c) No Conflict. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update, it is not researching, developing or
commercializing Aptamers that bind to a Target other than its research, development and/or
commercialization of Aptamers pursuant to this Agreement and the Existing License Agreements.

               (d) IP Rights. Ribomic represents and warrants to Archemix that Ribomic has obtained
appropriate written agreements from all individuals involved in the conduct of Research Activities
at the Ribomic Facility, which agreements require that all discoveries and inventions conceived or
reduced to practice by such individuals in the conduct of the Research Activities shall be promptly
disclosed and assigned to Ribomic.

7. INDEMNIFICATION AND INSURANCE

     7.1 Indemnification of Archemix by Ribomic. Ribomic shall indemnify, defend and hold
harmless Archemix, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “Archemix Indemnitees”), against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of
litigation) incurred by or imposed upon the Archemix Indemnitees, or any one of them, as a direct
result of claims, suits, actions or demands by Third Parties (collectively, the “Claims”)
arising out of (a) the conduct by it or any Person of the Research Activities or (b) the gross
negligence or willful misconduct of Ribomic or any of its Affiliates.

     7.2 Conditions to Indemnification. An Archemix Indemnitee seeking recovery under this
Article 7 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of such
Claim to the indemnifying party (the “Indemnifying Party”) and provided that the
Indemnifying Party is not contesting its obligation under this Article 7, shall permit the
Indemnifying Party to control any litigation relating to such Claim and the disposition of such
Claim (including without limitation any settlement thereof); provided, that, the Indemnifying Party
shall not settle or otherwise resolve such Claim without the prior written consent of such
Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed, unless
such settlement includes a full release of the Indemnified Party, in which case the indemnifying
Party may settle or otherwise resolve such Claim without the prior written consent of such
Indemnified Party. Each Indemnified Party shall cooperate with the Indemnifying Party in its
defense of any such Claim in all reasonable respects and shall have the right to be present in
person or through counsel at all legal proceedings with respect to such Claim.

     7.3 Indemnification of Gilead and UTC by Ribomic. If and solely to the extent, legally
required by the Archemix-Gilead License Agreement, Ribomic shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors, officers, employees
and agents (each, a “Gilead Indemnitee”), from and against any losses that are incurred by
a Gilead Indemnitee as a result of any Claims, to the extent such Claims arise out of the
possession, research, development, storage or transport, by Ribomic or its Affiliates of (a) any
Active Aptamers, or (b) any other products, services or activities developed by Ribomic relating to
the Licensed Patent Rights, including any Active Aptamers.

     7.4 Warranty Disclaimer. NEITHER PARTY MAKES ANY WARRANTY WITH

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

21

 

RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT
AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. NEITHER PARTY
MAKES ANY WARRANTIES AS TO THE VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS LICENSED BY SUCH
PARTY TO THE OTHER PARTY.

     7.5 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
EXCEPT WITH RESPECT TO RIBOMIC’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 7.1 AND/OR 7.3, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST
REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER
ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

8. TERM AND TERMINATION

     8.1 Term; Expiration. The term of this Agreement (the “Term”) shall commence
on the Effective Date and continue, unless earlier terminated as provided herein, until June 10,
2011.

     8.2 Termination.

          8.2.1 Unilateral Right to Terminate. Ribomic shall have the right to terminate this
Agreement, for any reason, upon (a) at least ninety (90) days’ prior written notice to Archemix,
such notice to state the date following the date of receipt of such notice by Archemix upon which
termination is to be effective, (b) the payment by Ribomic of all amounts due to Archemix pursuant
to Section 3.1 through January 1, 2010 and (c) the payment by Ribomic of all other amounts due to
Archemix through such termination effective date.

          8.2.2 Termination for Challenge. In the event Ribomic, its Affiliates and/or
Sublicensees initiates a Challenge or assists a Third Party in initiating a Challenge, Archemix
shall have the right to terminate this Agreement, effective immediately upon written notice to
Ribomic.

          8.2.3 Termination for Breach. Except as set forth herein, either Party may terminate
this Agreement, effective immediately upon written notice to the other Party, for a material breach
by the other Party of this Agreement that, if curable, remains uncured for [***] days ([***] days
in the event that the breach is a failure of a Party to make any payment required hereunder) after
the non-breaching Party first gives written notice to the other Party of such breach and its intent
to terminate this Agreement if such breach is not cured.

          8.2.4 Termination for Insolvency. Each Party shall give the other Party reasonable
prior notice of the filing with respect to itself of any voluntary petition, and prompt notice of
the filing with respect to itself of any involuntary petition, under any bankruptcy laws.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

22

 

In the event that either Party: (a) files for protection under bankruptcy laws; (b) makes an
assignment of all or substantially all of its assets for the benefit of creditors; (c) appoints or
suffers appointment of a receiver or trustee over all or substantially all of its assets; and (d)
files a petition under any bankruptcy or insolvency act or has any such petition filed against it
which is not discharged within [***] days of the filing thereof (each of (a)-(d), a “Bankruptcy
Action”), then the other Party may terminate this Agreement effective immediately upon written
notice to such Party. All rights and licenses granted under or pursuant to this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code. Upon filing such protection or petition by Archemix, Archemix shall, without any delay,
perform all necessary procedures under any then-applicable laws including, but not limited to,
Section 365(n) of the United States Bankruptcy Code, to protect all rights and licenses granted to
Ribomic under Section 2.1.1 hereof in order for retaining and defending such rights and license.
Notwithstanding any provision contained in this Agreement to the contrary, if any Bankruptcy Action
takes place with respect to Archemix, and the trustee in bankruptcy of Archemix, or Archemix as a
debtor-in-possession, properly elects to reject this Agreement, Ribomic may, pursuant to Section
365(n) of the Bankruptcy Code, retain and enforce any and all rights hereunder granted to Ribomic
to the maximum extent permissible by law. All rights, powers and remedies of Ribomic, as a
licensee hereunder, provided herein are in addition to and not in substitution for any and all
other rights, powers and remedies now or hereafter existing at law or in equity (including, without
limitation, the Bankruptcy Code) in the event of the commencement of a Bankruptcy Action with
respect to Archemix. Ribomic, in addition to the rights, powers and remedies expressly provided
herein, shall be entitled to exercise all other such rights and powers and resort to all other such
remedies as may now or hereafter exist at law or in equity (including the Bankruptcy Code) in such
event.

     8.3 Consequences of Termination of Agreement. In the event of the termination of this
Agreement pursuant to this Article 8, the following provisions shall apply:

          8.3.1 If this Agreement is terminated by Ribomic pursuant to Section 8.2.1 or by Archemix
pursuant to Sections 8.2.2, 8.2.3 or 8.2.4:

               (a) all licenses granted by Archemix to Ribomic under this Agreement shall immediately
terminate and Archemix shall have no further obligations under Sections 2.1.1 or 2.4;

               (b) all licenses granted by Ribomic to Archemix prior to the termination of this Agreement
hereunder shall continue and survive in full force and effect;

               (c) all Active Targets shall be deemed to be Failed Targets; and

               (d) Ribomic shall promptly return all Confidential Information of Archemix; provided, that,
Ribomic may retain one (1) copy of Confidential Information of Archemix in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

          8.3.2 If this Agreement is terminated by Ribomic pursuant to Sections 8.2.3 or 8.2.4, all
licenses granted by Archemix to Ribomic shall survive, subject to Ribomic’s continued payment of
all installments of the Research License Fee due and payable to Archemix pursuant

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

23

 

to Article 4; and Ribomic shall promptly return all Confidential Information of Archemix that
is not subject to a continuing license hereunder; provided, that Ribomic may retain one (1) copy of
each such Confidential Information of Archemix in it archives solely for the purpose of
establishing the contents thereof and ensuring compliance with its obligations hereunder.

     8.4 Remedies. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article 8 are in addition to any other relief and remedies available
to either Party at law.

     8.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the
rights and obligations of the Parties set forth in Articles 4, 7 and 9 and Sections 5.1, 5.2, 5.3,
5.4 5.5.4, 8.3 and 10.2, as well as any rights or obligations otherwise accrued hereunder
(including any accrued payment obligations), shall survive the expiration or termination of the
Term.

9. DISPUTES

     9.1 Negotiation. The Parties recognize that a bona fide dispute as to certain matters
may from time to time arise during the Term that relates to either Party’s rights and/or
obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by
written notice to the other Party, have such dispute referred to their respective senior officials
designated below or their successors or designees, for attempted resolution by good faith
negotiations within [***] days after such notice is received. Said designated senior officials are
as follows:

	 	 	 	 	 
	 

	 	For Ribomic:
	 	[***]
	 
	 	 	 	 
	 

	 	For Archemix:
	 	[***]

In the event the designated senior officials or their successors or designees are not able to
resolve such dispute within the [***] day period, either Party may invoke the provisions of
Section 9.2.

     9.2 Arbitration; Litigation.

          9.2.1 Arbitration. Subject to Section 9.2.2 below, any dispute, controversy or claim
initiated by either Party arising out of, resulting from or relating to this Agreement or the
performance by either Party of its obligations under this Agreement (excluding actions under
Article 8 and bona fide Third Party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party) (a “Dispute”), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party
shall decide to institute arbitration proceedings, it shall give written notice to that effect to
the other Party. Any such arbitration shall be conducted under the Commercial Arbitration Rules of
the American Arbitration Association (the “AAA”) by a panel of three arbitrators appointed
in accordance with such rules. Any such arbitration shall be held in Boston, Massachusetts if such
arbitration is demanded by Ribomic and in Honolulu, Hawaii if such arbitration is demanded by
Archemix. The method and manner of discovery in any such arbitration proceeding shall be governed
by the laws of the New York. The arbitrator shall have the authority to grant injunctions and/or
specific performance and to allocate between the Parties the costs of arbitration in such equitable
manner as they determine. Judgment upon the award so rendered

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

24

 

may be entered in any court having jurisdiction or application may be made to such court for
judicial acceptance of any award and an order of enforcement, as the case may be. In no event
shall a demand for arbitration be made after the date when institution of a legal or equitable
proceeding based upon such claim, dispute or other matter in question would be barred by the
applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the
right, without waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional
relief that is necessary or desirable to protect the rights or property of such Party, pending the
selection of the arbitrator hereunder or pending the arbitrators’ determination of any dispute,
controversy or claim hereunder.

          9.2.2 Litigation; Venue; Jurisdiction. Each of the Parties hereto hereby (a)
irrevocably and unconditionally agrees that any action or proceeding in respect of any claim
arising out of or related to this Agreement or the transactions contained in or contemplated by
this Agreement that is not a Dispute, whether in tort or contract or at law or in equity, shall be
brought by such Party exclusively in the state and federal courts of the State of New York (the
“Chosen Courts”); (b) irrevocably submits to the exclusive jurisdiction of the Chosen
Courts; (c) waives any objection to laying of venue in any such action or proceeding in the Chosen
Courts; (d) waives any objection that the Chosen Courts are an inconvenient forum or do not have
jurisdiction over any Party hereto; (e) agrees that service of process upon such Party in any such
action or proceeding shall be effective if notice is given in accordance with this Agreement; and
(f) agrees that a final judgment in any such action or proceeding shall be conclusive and may be
enforced by suit on the judgment or in any other manner provided by Applicable Laws or at equity.

10. MISCELLANEOUS

     10.1 Notification. All notices, requests and other communications hereunder shall be
in writing, shall be addressed to the receiving Party’s address set forth below or to such other
address as a Party may designate by notice hereunder, and shall be either (a) delivered by hand,
(b) made by facsimile transmission, (c) sent by private courier service providing evidence of
receipt or (d) sent by registered or certified mail, return receipt requested, postage prepaid.
The addresses and other contact information for the parties are as follows:

	 	 	 
	If to Ribomic:

	 	If to Archemix:
	 
	Ribomic, Inc.

	 	Archemix Corp.
	Shirokanedai Usui Building

	 	300 Third Street
	3-16-13 Shirokanedai

	 	Cambridge, MA 02142
	Minato-ku

	 	Tel: (617) 621-7700
	Tokyo 108-0071

	 	Fax: (617) 621-9300
	Japan

	 	Attention: Chief Executive Officer
	Tel: (03) 3440-3303

	 	Attention: Legal Department
	Fax: (03) 3440-3729
	 	 
	Attention: President
	 	 
	Attention: Legal Department
	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

25

 

	 	 	 
	 

	 	With a copy to:
	 
	 	 
	 

	 	Mintz Levin Cohn Ferris Glovsky
and Popeo, P.C.
	 

	 	One Financial Center
	 

	 	Boston, MA 02110
	 

	 	Tel: (617) 542-6000
	 

	 	Fax: (617) 542-2241
	 

	 	Attn: John J. Cheney, Esq.

     All notices, requests and other communications hereunder shall be deemed to have been given
either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of
such Party set forth above, (ii) if made by facsimile transmission, at the time that confirmation
of receipt thereof has been received by the Party delivering such notice, (iii) if sent by an
internationally recognized courier service which provides a delivery receipt on the day of actual
receipt by the recipient, or (iv) if sent by registered or certified mail, on the seventh
(7th) business day following the day such mailing is made.

     10.2 Governing Law. This Agreement will be construed, interpreted and applied in
accordance with the laws of the State of New York (excluding its body of law controlling conflicts
of law).

     10.3 English Language. All data, results and information that is in a language other
than English and that is provided by either Party to the other Party and/or to the RC under this
Agreement shall be provided both in its original format, without translation, and in an English
translation within ten (10) business days (which translation shall be made at the providing Party’s
sole cost and expense).

     10.4 Limitations. Except as expressly set forth in this Agreement, neither Party
grants to the other Party any right or license to any of its intellectual property.

     10.5 Entire Agreement. This Agreement is the entire agreement between the Parties
with respect to the subject matter hereof and supersedes all prior representations, understandings
and agreements between the Parties with respect to the subject matter hereof. No modification or
amendment shall be effective unless in writing with specific reference to this Agreement and signed
by the Parties.

     10.6 Waiver. The terms or conditions of this Agreement may be waived only by a
written instrument executed by the Party waiving compliance. The failure of either Party at any
time or times to require performance of any provision hereof shall in no manner affect its rights
at a later time to enforce the same. No waiver by either Party of any condition or term shall be
deemed as a continuing waiver of such condition or term or of another condition or term.

     10.7 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form part of this Agreement.

     10.8 Assignment. Neither this Agreement nor any right or obligation hereunder may be
assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

26

 

express written consent of the other; provided, that, either Party may, without the written
consent of the other, assign this Agreement and its rights and delegate its obligations hereunder
to its Affiliates or in connection with the transfer or sale of all or substantially all of such
Party’s assets or business to which this Agreement relates or in the event of its merger,
consolidation, change in control or similar transaction. Any permitted assignee shall assume all
obligations of its assignor under this Agreement. Any purported assignment in violation of this
Section 10.8 shall be void. The terms and conditions of this Agreement shall be binding upon and
inure to the benefit of the permitted successors and assigns of the parties.

     10.9 Force Majeure. Neither Party shall be liable for failure of or delay in
performing obligations set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes beyond the
reasonable control of such Party. In event of such force majeure, the Party affected thereby shall
use reasonable efforts to cure or overcome the same and resume performance of its obligations
hereunder.

     10.10 Construction. The Parties hereto acknowledge and agree that: (a) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are
resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties
hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement.

     10.11 Severability. If any provision(s) of this Agreement are or become invalid, are
ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current
applicable law from time to time in effect during the Term hereof, it is the intention of the
Parties that the remainder of this Agreement shall not be affected thereby; provided, that, a
Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and
agree to renegotiate any such term, covenant or application thereof in good faith in order to
provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or
the application thereof that is invalid, illegal or unenforceable, it being the intent of the
Parties that the basic purposes of this Agreement are to be effectuated.

     10.12 Status. Nothing in this Agreement is intended or shall be deemed to constitute
a partner, agency, employer-employee or joint venture relationship between the Parties.

     10.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

     10.14 Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

[Remainder of page intentionally left blank.]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

27

 

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective
duly authorized representative in 

two (2) originals.

	 	 	 	 	 	 	 	 	 	 	 
	RIBOMIC, INC.	 	ARCHEMIX CORP.
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	 /s/ Michi Nishiyawa	 	By:	 	 /s/ John A. Harre	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Name:

	 	 Michi Nishiyawa	 	Name:	 	 John A. Harre	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	Title:

	 	 President and CEO	 	Title:	 	 Vice President I.P. and Legal
Affairs	 	 	 	 
	 

	 	 
	 	 	 	 	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

28

 

Schedule 1

Active Target List

     [***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 1-1

 

Schedule 2

Replacement Target List

        .

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 2-1

 

Schedule 3

Required Jurisdiction

[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 3-1

 

Exhibit A (dated May 19, 2008)

Licensed Patent Rights

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-1

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-2

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-3

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-4

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-5

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-6

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-7

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-8

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-9

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-10

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-11

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-12

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-13

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-14

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-15

 

Exhibit B

Form of Exclusive License Agreement

FORM OF EXCLUSIVE LICENSE AGREEMENT

     This Exclusive License Agreement (this “Agreement”) is made effective as of ___
___, 2008 (the “Effective Date”), by and between Archemix Corp, a Delaware corporation with
offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a
corporation organized under the laws of Japan with offices at Shirokanedai Usui Building, 3-16-13
Shirokanedai Usui Building, Shirokanedai, Minato-ku, Tokyo 108-0071 Japan (“Ribomic”).
Archemix and Ribomic are each sometimes hereinafter referred to individually as a “Party” and
collectively as the “Parties.”

     WHEREAS, the Parties entered into a Research License and Option Agreement dated as of May ___,
2008 (the “License and Option Agreement”) pursuant to which Archemix granted Ribomic a
non-exclusive license to conduct research activities with respect to certain Active Targets (as
defined in the License and Option Agreement) and an Option (as defined in the License and Option
Agreement) to obtain an exclusive license under Licensed Patent Rights Controlled by Archemix to
develop and commercialize Aptamers against such Active Targets; and

     WHEREAS, Ribomic has exercised an Option pursuant to the License and Option Agreement with
respect to an Active Target; and

     WHEREAS, pursuant to the terms of the License and Option Agreement, the Parties have agreed,
upon exercise by Ribomic of such Option, to enter into this Agreement pursuant to which Archemix
will grant to Ribomic an exclusive license under such Licensed Patent Rights to develop and
commercialize Aptamers against such specified Active Target.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties
hereby agree as follows:

11. DEFINITIONS

     Whenever used in the Agreement with an initial capital letter, the terms defined in this
Article 1 shall have the meanings specified.

     11.1 “Acceptance”means (a) with respect to the United States, [***] days from the
date an NDA is received by the FDA if no refuse-to-file order is issued by the FDA or, to the
extent issued, such later date on which the deficiencies referred in such refuse-to-file notice are
corrected or the NDA is otherwise deemed “filed” by the FDA; and (b) with respect to an E5 Country
or Japan, the equivalent of the above or any other action or non-action that allows a party to
proceed with a product launch.

     11.2 “Active Aptamer” means any Aptamer that binds to a Licensed Target and any
Aptamer(s) Derived therefrom that binds to such Licensed Target.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-1

 

     11.3 “Adverse Event” means any untoward, undesired or unplanned medical occurrence in
a human clinical trial subject or patient, which occurrence has a temporal relationship to
administration of a Licensed Product, whether or not considered related to the Licensed Product,
including, without limitation, any undesirable sign (including abnormal laboratory findings of
clinical concern), symptom or disease that may be associated with the use of such Licensed Product.

     11.4 “Affiliate” means, with respect to any Person, any other Person that, directly or
indirectly, controls or is controlled by or is under common control with, such Person. For
purposes of this definition, “control” means (a) ownership of fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors in the case of a corporation or
fifty percent (50%) or more of the equity interests in the case of any other type of legal entity,
(b) status as a general partner in any partnership, or (c) any other arrangement whereby a Person
controls or has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

     11.5 “Annual Net Sales” means, with respect to any Calendar Year, the aggregate amount
of the Net Sales for such Calendar Year.

     11.6 “Applicable Laws” means federal, state, local, national and supra-national laws,
statutes, rules and regulations, including any rules, regulations, guidance, guidelines or
requirements of regulatory authorities, national securities exchanges or securities listing
organizations, that may be in effect from time to time during the Term and are applicable to a
particular activity hereunder.

     11.7 “Applicable Sublicense Income Rate”means (a) with respect to any Early Stage
Sublicense Agreement, [***] percent ([***]%) and (b) with respect to any Late Stage Sublicense
Agreement, [***] percent ([***]%).

     11.8 “Aptamer” means (a) any naturally or non-naturally occurring oligonucleotide
identified through the SELEX Process that binds with high specificity and affinity to a Licensed
Target, and (b) any oligonucleotide Derived from an oligonucleotide of clause (a) that has such
high specificity and affinity to such Licensed Target, but excluding Spiegelmers.

     1.1 “Aptamer-Antidote Combination Product” means a product consisting of the
combination of (a) an aptamer that modulates fibrin deposition, platelet adhesion, or platelet
aggregation and (b) a paired oligonucleotide antidote that reverses the functional activity of such
aptamer.

     11.9 “Archemix-Gilead License Agreement” means the License Agreement between Gilead
Sciences, Inc. and Archemix dated October 21, 2001, as amended.

     11.10 “Calendar Quarter” means the period beginning on the Effective Date and ending
on the last day of the calendar quarter in which the Effective Date falls, and thereafter each
successive period of three (3) consecutive calendar months ending on March 31, June 30, September
30 or December 31.

     11.11 “Calendar Year” means the period beginning on the Effective Date and ending on
December 31 of the year in which the Effective Date falls and thereafter each successive period of
twelve (12) months commencing on January 1 and ending on December 31.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-2

 

     11.12 “Challenge” means any challenge to the validity or enforceability of any
Licensed Patent Right in the absence of a breach of this Agreement including, without limitation,
by (a) filing a declaratory judgment action in which any Licensed Patent Right is alleged to be
invalid or unenforceable; (b) citing prior art pursuant to [***], filing a request for
re-examination of any Licensed Patent Right pursuant to [***] or provoking or becoming party to an
interference with an application for any Licensed Patent Right pursuant to [***]; or (c) filing or
commencing any reexamination, opposition, cancellation, nullity or similar proceedings against any
Licensed Patent Right in any country.

     11.13 “Commercially Reasonable Efforts” means, with respect to activities of Ribomic
under this Agreement, the efforts and resources customarily used by similarly sized biotechnology
companies in the performance of such activities for other products owned by such companies which
are of similar market potential and at a similar stage of development, taking into account the
competitiveness of the market place, the regulatory structure involved and other relevant and
material factors.

     11.14 “Commercialization Regulatory Approval” means, with respect to any Licensed
Product, the Regulatory Approval required by Applicable Laws to sell such Licensed Product for use
in the Field in a country or region in the Territory. “Commercialization Regulatory Approval”
shall include, without limitation, the approval of any Drug Approval Application. For purposes of
clarity, “Commercialization Regulatory Approval” in the United States shall mean final approval of
an NDA for the first Indication in the United States, “Commercialization Regulatory Approval” in
the European Union shall mean marketing authorization for the applicable Licensed Product pursuant
to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended and
“Commercialization Regulatory Approval” in Japan shall mean final approval of an application
submitted to the Ministry of Health, Labor and Welfare and the publication of a New Drug Approval
Information Package permitting marketing of the applicable Licensed Product in Japan, as any of the
foregoing may be amended from time to time.

     11.15 “Commercialization Regulatory Filing”means, with respect to any Licensed
Product, the filing required to obtain Commercialization Regulatory Approval for use in the Field
in a country or region in the Territory.

     11.16 “Completion” means, with respect to a clinical trial, the closing of the
database with respect to the applicable clinical trial.

     11.17 “Confidential Information” means all information and Technology disclosed or
provided by, or on behalf of a Party (the “Disclosing Party”) to the other Party (the
“Receiving Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or
sublicensees (“Representatives”) pursuant to or in connection with this Agreement; provided, that,
none of the foregoing shall be Confidential Information if: (a) as of the date of disclosure, it is
known to the Receiving Party or its Representatives, as demonstrated by credible written
documentation, other than by virtue of a prior confidential disclosure to such Receiving Party; (b)
as of the date of disclosure it is in the public domain or it subsequently enters the public domain
other than through a breach by the Receiving Party or its Representatives of a contractual
obligation; (c) it

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-3

 

is obtained by the Receiving Party from a Third Party having a lawful right to make such
disclosure free from any obligation of confidentiality to the Disclosing Party or its
Representatives; or (d) it is independently developed by or for the Receiving Party or its
Representatives without reference to or use of any Confidential Information of the Disclosing Party
or its Representatives as demonstrated by credible written documentation. For purposes of clarity,
unless excluded from Confidential Information pursuant to the provisos of the preceding sentence,
any scientific, technical or financial information Controlled by a Disclosing Party and disclosed
at any meeting of the Parties or disclosed through an audit report shall constitute Confidential
Information of the Disclosing Party.

     11.18 “Control” or “Controlled” means with respect to Technology or Patent
Rights, the possession by a Party of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without the payment of additional consideration to, and without
violating the terms of any agreement or arrangement with, any Third Party and without violating any
Applicable Laws.

     11.19 “Defined Territory” means, collectively, the United States, any E5 Country and
Japan.

     11.20 “Derived” means identified, developed, created, synthesized, designed, resulting
or generated from, conjugated to, or complexed with (whether directly or indirectly or in whole or
in part).

     11.21 “Development” and “Develop” means, with respect to any Licensed Product,
all activities with respect to such Licensed Product relating to the development in connection with
seeking, obtaining and/or maintaining Commercialization Regulatory Approval for such Licensed
Product in the Field in the Territory, including, without limitation, all pre-clinical research and
development activities, all human clinical studies, all activities relating to developing the
ability to manufacture any Licensed Product or any component thereof (including, without
limitation, process development work), and all other activities relating to seeking, obtaining
and/or maintaining any Regulatory Approvals from the FDA and/or any Foreign Regulatory Authority.

     11.22 “Diagnosis” means (a) the determination or monitoring of (i) the presence or
absence of a disease, (ii) the stage, progression or severity of a disease or (iii) the effect on a
disease of a particular treatment; and/or (b) the selection of patients for a particular treatment
with respect to a disease.

     11.23 “Diagnostic Product” means, collectively, In Vitro Diagnostic Agents, In Vivo
Diagnostic Agents and any aptamer product used for Diagnosis.

     11.24 “Early Stage Sublicense Agreement”means any Sublicense Agreement involving a
Licensed Product that is executed before Initiation of a [***] Clinical Trial with respect to such
Licensed Products.

     11.25 “E5 Country” means each of the United Kingdom, Germany, France, Italy and
Spain.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-4

 

     11.26 “Existing License Agreements”means, collectively, (a) the Non-Exclusive IgG
Antibody Purification License Agreement dated as of October 31, 2006, by and between Ribomic and
Archemix; (b) the Exclusive License Agreement by and between Ribomic and Archemix dated as of
December 10, 2007; (c) the Research License and Option Agreement by and between Ribomic and
Archemix dated as of May ___, 2008; and (d) any license agreement other than this Agreement entered
into by and between Archemix and Ribomic pursuant to the License and Option Agreement.

     11.27 “FDA” means the United States Food and Drug Administration and any successor
agency or authority thereto.

     11.28 “Field” means the control, prevention, treatment, cure or delay of onset or
progression of any Indication in animals and humans, but excluding, without limitation, Diagnostic
Products, In Vivo Imaging Applications and all non-therapeutic uses.

     11.29 “First Commercial Sale” means, on a country-by-country basis, the date of the
first arm’s length transaction, transfer or disposition for value to a Third Party of a Licensed
Product by or on behalf of, Ribomic, its Affiliate(s) or Sublicensee(s) in such country after
obtaining the Commercialization Regulatory Approval for the Licensed Product. For purposes of
clarity, the use of any Licensed Product in clinical trials, pre-clinical studies or other research
or development activities or the disposal or transfer of a Licensed Product for a bona fide
charitable purpose or for purposes of a commercially reasonable sampling program shall not be
deemed to be an arm’s length transaction, transfer or disposition for value for purposes of this
definition.

     11.30 “Full Royalty Net Sales”means Net Sales in any country in which the Full
Royalty Term has not expired.

     11.31 “Full Royalty Term”means, with respect to each Licensed Product in each country
in the Territory, the period beginning on the date of First Commercial Sale of such Licensed
Product in such country and ending on the expiration of the last to expire Valid Claim of
the Licensed Patent Rights that covers the discovery, research, manufacture, use, delivery, import,
offer for sale or sale of such Licensed Product in such country.

     11.32 “IND” means an investigational new drug application (as defined in Title 21 of
the United States Code of Federal Regulations, as amended from time to time) filed or to be filed
with the FDA with regard to any Licensed Product and any counterpart of an investigational new drug
application that is required in any other country or region in the Territory before beginning
clinical testing of a Licensed Product in humans in such country or region.

     11.33 “Indication” means any indication, disease, disorder or condition in the Field,
which can be treated, controlled, prevented, cured or the onset or progression of which can be
delayed.

     11.34 “Initiation” means, with respect to a human clinical trial, the first date that
a subject or patient is dosed in such clinical trial.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-5

 

     11.35 “In Vitro Diagnostic Agent” means any product that uses the SELEX Process or one
or more Aptamers in the assay, testing or determination, outside of a living organism, of a
substance in a test material. In Vitro Diagnostics shall include, among other things, the use of
the SELEX Process or Aptamers in the assay, testing or determination: (a) outside of a living
organism, (i) of a human substance in a test material, often to identify or follow the progression
of a disease or disorder or to select a patient for treatment; (ii) of a plant substance, animal
substance or other substance in a test material, often to identify or follow the progression of a
disease, process or disorder in a human or non-human organism; and (iii) of environmental
substances (as in water quality testing); (b) of a substance on a test material such as cells (as
in FACS analysis or other measurements of pathogens within biological samples); and (c) any other
in vitro diagnostic use of the SELEX Process or Aptamers in drug development processes, including
target identification, pre-clinical and clinical testing, and the following more specific examples
of uses of Aptamer technology: (i) to observe, through protein profiling, protein levels moving up
or down in diseases or models of diseases, and to evaluate whether such proteins are sensible
targets for the development of therapeutic agents; (ii) to observe coordinated expression of
protein pathways in a variety of biological states in various systems; (iii) to study protein or
metabolite levels during pre-clinical drug candidate evaluation in response to putative therapeutic
agents during clinical trials (e.g., as markers of efficacy or response); and (iv) to study human
protein or metabolite levels in response to putative therapeutic agents during clinical trials
(e.g., as markers of efficacy or response). Notwithstanding the above, In Vitro Diagnostics shall
exclude any of the above-described uses in this Section 1.34(c) conducted in the Development of
Active Aptamers under this Agreement.

     11.36 “In Vivo Diagnostic Agent” means any product containing one or more aptamers
that is used for any human in vivo diagnostic purpose related to (inter alia) the identification,
quantification or monitoring of the propensity toward, or actual existence of, any disease state.

     11.37 “Joint Patent Rights” means Patent Rights that contain one or more claims that
cover Joint Technology.

     11.38 “Joint Technology” means any Technology (including, without limitation, any new
and useful process, method of manufacture or composition of matter) that is jointly conceived or
first reduced to practice (actively or constructively) by employees of or consultants to Ribomic
and employees of or consultants to Archemix at any meeting of the DC.

     11.39 “Knowledge” means, with respect to Archemix, the actual knowledge of the chief
executive officer, any vice president or the chief legal officer of Archemix.

     11.40 “Late Stage Sublicense Agreement”means any Sublicense Agreement involving a
Licensed Product that is executed on or after the [***] of a [***] Clinical Trial with respect to
such Licensed Product.

     11.41 “Licensed Patent Rights” means all Patent Rights Controlled by Archemix or any
of its Affiliates and listed on Exhibit A attached hereto to the extent that they are (a) issued
patents as of the Effective Date or (b) pending patent applications as of the Effective Date that
will expire on or before September 23, 2014 as well as any patent issuing on said pending patent

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-6

 

applications and, in any case, are necessary for Ribomic to practice the licenses granted to
it hereunder. It is understood that any pending patent applications listed on Exhibit A that will
expire after September 23, 2014 as well as any patent issuing thereon shall become part of the
Licensed Patent Rights by mutual agreement of the Parties.

     11.42 “Licensed Product” means any pharmaceutical product containing, incorporating,
comprised of, identified through the material use of or Derived from, in whole or in part, any
Active Aptamer.

     11.43 “Licensed Target” means the Licensed Target described on Schedule 1
attached hereto.

     11.44 “Major Market Country”means each of the United States, the United Kingdom,
Germany, Spain, France, Italy, Canada and Japan.

     11.45 “Net Sales” means the gross amount billed or invoiced by Ribomic or any of its
Affiliates or Sublicensees to Third Parties throughout the Territory for sales or other
dispositions or transfers for value of Licensed Products less (i) allowances for normal and
customary trade, quantity and cash discounts actually allowed and taken, and inventory management
fees paid to wholesalers and distributors; (ii) transportation, insurance and postage charges, if
paid by Ribomic or any Affiliate or Sublicensee and included on any such Person’s bill or invoice
as a separate item; (iii) credits, chargebacks, retroactive price reductions, rebates and returns,
to the extent actually allowed; (iv) negotiated payments made to private sector and government
Third Party payors (e.g., PBMs, HMOs and PPOs) and purchasers/providers (e.g., staff model HMOs,
hospitals and clinics), regardless of the payment mechanism, including, without limitation,
off-invoice, rebate, chargeback and credit mechanisms, including, without limitation, with respect
to any Net Sales in Japan, any sales-based contribution for “Drug Induced Suffering” and any
sales-based contribution for “Contribution for Measure for Drug Safety,” in each case as required
by Applicable Laws or any regulatory authority, in the amount determined by and payable to the
Pharmaceuticals and Medical Devices Agency (so-called “KIKO”); (v) discounts paid under discount
prescription drug programs and reductions for coupon and voucher programs; and (vi) any tax,
tariff, customs duty, excise or other duty or other governmental charge (other than a tax on
income) levied on the sale, transportation or delivery of Licensed Product and actually paid by
Ribomic or any of its Affiliates or Sublicensees. In addition, Net Sales are subject to the
following:

          (a) If Ribomic or any of its Affiliates or Sublicensees effects a sale, disposition or
transfer of a Licensed Product to a customer in a particular country as part of a package of
Licensed Products and services (but not in a Combination Product), the Net Sales of such Licensed
Product to such customer shall be deemed to be “the fair market value” of such Licensed Product
less applicable discounts pursuant to this definition of Net Sales. For purposes of this
subsection (a), “fair market value” shall mean the fraction (A/A+B), where A equals the value that
would have been derived had such Licensed Product been sold as a separate Licensed Product to
another customer in the country concerned on customary commercial terms, during the applicable
Calendar Quarter in the country concerned, and B equals the aggregate value that would have been
derived had the other components of such package been sold as separate products to another customer
in the country concerned on customary commercial terms, during

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-7

 

the applicable Calendar Quarter in the country concerned.

          (b) In the case of pharmacy incentive programs, hospital performance incentive program
chargebacks, disease management programs, similar programs or discounts on “bundles” of Licensed
Products, all discounts and the like shall be allocated among Licensed Products on the basis of
which such discounts and the like were actually granted or, if such basis cannot be determined, in
proportion to the respective list prices of such Licensed Products.

          (c) For clarity, use of any Licensed Product in clinical trials, pre-clinical studies or other
research or development activities or disposal or transfer of Licensed Products for a bona fide
charitable purpose or purposes of a commercially reasonable sampling program shall not give rise to
any Net Sales.

          (d) Sales or transfers of Licensed Product among Ribomic, its Affiliates and Sublicensees for
the purpose of subsequent resale to Third Parties shall not be included in Net Sales; with respect
to such sales or transfers, the gross amounts billed or invoiced in connection with the subsequent
resale to Third Parties will be included in the calculation of Net Sales.

          In the event that a Licensed Product under this Agreement is sold in combination
(“Combination Product”) with another ingredient or component having independent,
supplementary or enabling therapeutic effect (e.g., as a catalyst or adjuvant) or diagnostic
utility or that has independent function as a medical device or means of administration (a
“Supplemental Component”), then “Net Sales,” for purposes of determining royalty payments
on the Combination Product, shall be calculated using one of the following methods:

          (y) By multiplying the Net Sales of the Combination Product (calculated prior to the
application of this formula) by the fraction C/C+D, where C is the average gross selling price,
during the applicable Calendar Quarter in the country concerned, of the Licensed Product when sold
separately, and D is the average gross selling price, during the applicable Calendar Quarter in the
country concerned, of the Supplemental Component(s) when sold separately; or

          (z) In the event that no such separate sales are made of the Licensed Product or any of the
Supplemental Components in such Combination Product during the applicable Calendar Quarter in the
country concerned, Net Sales, for the purposes of determining royalty payments, shall be calculated
using the above formula where C is the reasonably estimated commercial value of the Licensed
Product sold separately, during the applicable Calendar Quarter in the country concerned, and D is
the reasonably estimated commercial value of the Supplemental Components sold separately, during
the applicable Calendar Quarter in the country concerned. Any such estimates shall be determined
using criteria to be mutually agreed upon by the Parties. Such estimates shall be reported to
Archemix in the reports to be provided pursuant to Section 4.5.1 hereof. If the Parties are unable
to agree on the criteria for determining such estimates, either Party may submit such dispute for
resolution pursuant to the provisions of Section 10.2.2.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-8

 

     11.46 “Non-Royalty Term” means, with respect to each Licensed Product that has been
sublicensed under a Sublicense Agreement, the period commencing on the Effective Date and
continuing on a Licensed Product-by-Licensed Product and country-by-country basis until the date on
which no further payments of Sublicense Income are received by Ribomic.

     11.47 “Partial Royalty Net Sales”means Net Sales in any country in which the Full
Royalty Term has expired but the Partial Royalty Term has not expired.

     11.48 “Partial Royalty Term”means, with respect to each Licensed Product in each
country in the Territory, the period commencing on the day after the last day of the Full Royalty
Term for such Licensed Product in such country and expiring ten (10) years from the date of the
First Commercial Sale of such Licensed Product in such country.

     11.49 “Patent Rights” means all rights and interests in and to issued patents and
pending patent applications including, without limitation, non-provisional patent applications, and
all divisions, continuations and continuations-in-part thereof, patents issuing on any of the
foregoing, all reissues, reexaminations, renewals and extensions thereof, and supplementary
protection certificates therefor, as well as any certificates of invention or applications
therefor, and all foreign equivalents of any of the foregoing.

     11.50
“Permitted Archemix Activitiesx”means (a) with respect to any Licensed Target,
any screening activities conducted by Archemix with respect to such Licensed Target for itself
and/or for any Third Party for the purpose of identifying aptamers that bind to a Target other than
a Licensed Target; and (b) any grant by Archemix to any Third Party of rights to discover, develop
and/or commercialize aptamers that bind to Targets (including the Licensed Target) outside of the
Field.

     11.51 “Permitted Ribomic Activities”means, on a country-by-country and Valid
Claim-by-Valid Claim basis, any activity conducted by Ribomic or any of its Affiliates or
Sublicensees (a) involving the discovery, research, development and commercialization of
therapeutic aptamers in a country for use in the Field against any Target other than the Licensed
Target at any time on and after the expiration of the last to expire applicable Valid Claim of the
Licensed Patent Rights in such country or (b) pursuant to the terms of the Existing License
Agreements, for so long as the Existing License Agreements continue in full force and effect.

     11.52 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust,
joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a
government.

     11.53 “Phase I Clinical Trial” means a clinical trial conducted in healthy humans,
which clinical trial is designed to initially explore the safety, drug-drug interactions and/or
pharmacokinetics of an investigational drug given its intended use, and to support continued
testing of such drug in Phase II Clinical Trials.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-9

 

     11.54 “Phase II Clinical Trial” means a clinical trial conducted in patients with a
particular disease or condition, which clinical trial is designed to establish the safety,
appropriate dosage and pharmacological activity of an investigational drug given its intended use,
and to initially explore its efficacy for such disease or condition.

     11.55 “Phase IIa Clinical Trial”means, as to a particular Licensed Product, the
portion of a Phase II Clinical Trial which contains a sufficient number of subjects to generate
sufficient data (if successful) to commence a Phase IIb or a Phase III Clinical Trial of
such Licensed Product or otherwise satisfies the proof of concept applicable to such Licensed
Product.

     11.56 “Phase IIb Clinical Trial”means, as to a particular Licensed Product, the
portion of a Phase II Clinical Trial which contains a sufficient number of subjects to generate
sufficient data (if successful) to commence a Phase III Clinical Trial of such Licensed Product or
act as a basis for obtaining Commercialization Regulatory Approval of such Licensed Product.

     11.57 “Phase III Clinical Trial” means a pivotal clinical trial conducted in patients
with a particular disease or condition, which clinical trial is designed to ascertain efficacy and
safety of an investigational drug for its intended use and to define warnings, precautions and
Adverse Events that are associated with the investigational drug in the dosage range intended to be
prescribed, with the purpose of preparing and submitting applications for Regulatory Approval or
label expansion to the FDA in the United States or pertinent Foreign Regulatory Authority in a
country outside the United States.

     11.58 “Radio Therapeutics” means any product for human therapeutic use that contains
one or more Aptamers that targets specifically any diseased tissue, cells or disease-specific
molecules or any tissue or cells which are affected by a disease or located in the close
neighborhood of a disease process and is linked to or incorporates (a) radionucleotides or (b) any
structure or elements which develop therapeutic effects similar to the effect of linking or
incorporating radionucleotides after submission of any kind of radiation.

     11.59 “Regulatory Approval” means any and all approvals (including pricing and
reimbursement approvals), product and establishment licenses, registrations or authorizations of
any kind of the FDA or any foreign regulatory authority necessary for the development, pre-clinical
and/or human clinical testing, manufacture, quality testing, supply, use, storage, importation,
export, transport, marketing and sale of a Licensed Product (or any component thereof) for use in
the Field in any country or other jurisdiction in the Territory.

     11.60 Ribomic SELEX Patent Rights” means any Patent Rights that contain one or more
claims that cover Ribomic SELEX Technology. For purposes of clarity, the Ribomic SELEX Patent
Rights, as of the Effective Date, include without limitation the Patent Rights listed on
Exhibit B attached hereto.

     11.61 Ribomic SELEX Technology” means any Technology that is Controlled by Ribomic as
of the Effective Date or during the Term relating to or constituting aptamer compositions or that
is useful for the identification, generation, modification, optimization, stabilization or use of
aptamers.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-10

 

     11.62 “ROFR Period”means the period commencing on the [***] and continuing until the
date of [***] by Ribomic of a Sublicense Agreement involving any Licensed Product and containing
Minimum Acceptable Financial Terms.

     11.63 “Royalty Term”means, with respect to each Licensed Product in each country in
the Territory, the period beginning on the first day of the Full Royalty Term for such Licensed
Product in such country and ending on the last day of the Partial Royalty Term for such Licensed
Product in such country.

     11.64 “SELEX Portfolio” means those Patent Rights licensed by Gilead to Archemix
pursuant to the Archemix-Gilead License Agreement.

     11.65 “SELEX Process” means any process used for the identification or generation of a
nucleic acid that binds to a Target by means other than Watson-Crick base-pairing including,
without limitation, those that are covered by the claims in (a) the SELEX Portfolio, including,
without limitation, U.S. Patent Nos. [***] or [***], (b) any other Patent Rights Controlled by
Archemix or (c) any continuation, divisional, continuation-in-part, substitution, renewal, reissue,
re-examination or extension, or any foreign equivalent, of any of the foregoing Patent Rights.

     11.66 “SELEX Technology” means (a) oligonucleotides that bind to the Licensed Target
by means other than Watson-Crick base-pairing that consist of or incorporate structural elements
that are generally applicable to such oligonucleotides independent of the Licensed Target (e.g., a
novel nucleoside, bond or linkage or combination(s) thereof, for example, deoxypurine and
2’O-methyl substituted prymidine compositions) as used in such oligonucleotides, and (b) any
process for modifying, optimizing and/or stabilizing oligonucleotides that bind to the Licensed
Target by means other than Watson-Crick base-pairing that is generally applicable to such
oligonucleotides independent of the Licensed Target wherein such modification, optimization or
stabilization includes, without limitation, minimization, truncation, conjugation, pegylation,
complexation, substitution, deletion and/or incorporation of modified nucleotides; provided,
however, that SELEX Technology does not include Active Aptamers.

     11.67 “Spiegelmer” means an oligonucleotide consisting of at least [***] percent
([***]%) [***], including any structural variations and modifications, derivatives, homologs,
analogs and/or mimetics to the [***] components (other than [***]), identified through the use of
the SELEX Process.

     11.68 “Sublicense Agreement”means any agreement between Ribomic and a Sublicensee.

     11.69 “Sublicensee” means any Third Party to which Ribomic grants a sublicense of some
or all of the rights granted to Ribomic under this Agreement.

     11.70 “Sublicense Income”means [***] consideration and payments (including all
upfront payments, milestone payments, and license or maintenance payments) received by Ribomic from
any Sublicensees excluding (a) payments [***] a Sublicensee which are required

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-11

 

to be used to [***] or [***] to be [***] by such Party [***] to a [***] for [***] which has
been agreed to with the Sublicensee to the extent that the payments made for such research do not
exceed the then Fair Market Value thereof, (b) payments [***] of the [***] of Ribomic to the extent
that the [***] for [***] does not [***] the then [***] thereof and (c) [***] by such Sublicensee
made to Ribomic pursuant to the terms of the applicable sublicense agreement. Notwithstanding the
foregoing, if a Sublicensee purchases equity of Ribomic and the purchase price of such equity
exceeds [***]% of the Fair Market Value of such equity or if payments to fund research and
development activities exceed the Fair Market Value of such activities (such excess being referred
to as the “Premium”), then such Premium shall be included as Sublicense Income. For
purposes of Section 1.71(b), the “Fair Market Value” of Ribomic’s shares on the date of sale shall
be determined as follows: (i) if such shares are publicly traded on a recognized securities
exchange or over the counter market, the fair market value of such shares shall be the closing
price of such shares reported on the applicable date of sale; (ii) if such shares are not publicly
traded on a recognized securities exchange or over the counter market, the Fair Market Value shall
be the price per share of such shares paid on the date of sale or within [***] months prior to the
date of sale by a third party having no interest in Ribomic other than as a result of having
purchased such shares; and (iii) if neither (i) or (ii) are applicable, the Fair Market Value shall
be the price per share that a willing buyer would pay to a willing seller in an arm’s length
transaction. If the Parties are unable to agree on Fair Market Value under clause (iii), the matter
will be resolved in accordance with Section 10.2.2. For purposes of Section 1.71(a), the term
“Fair Market Value” with respect to research and development funding shall mean the reasonable
value of the applicable research and development activities based on full-time equivalent or other
cost-accounting methodologies that are consistent with the approved budget and then-applicable
current industry practices.

     11.71 “Target” means a protein, cytokine, enzyme, receptor, transducer, transcription
factor, antigen or any other non-nucleic acid molecule.

     11.72 “Technology” means, collectively, inventions, discoveries, improvements, trade
secrets and proprietary methods, whether or not patentable, including, without limitation: (a)
methods of production or use of, and structural and functional information pertaining to, chemical
compounds and (b) compositions of matter, data, formulations, processes, techniques, know-how and
results (including any negative results).

     11.73 “Territory” means all countries and jurisdictions of the world.

     11.74 “Third Party” means any person or entity other than Ribomic, Archemix and their
respective Affiliates.

     11.75 “ULEHI” means University License Equity Holdings, Inc., formerly known as UTC.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-12

 

     11.76 “URC License Agreement” means the Restated Assignment and License Agreement,
dated July 17, 1991, by and between University Research Corporation and Gilead Sciences, Inc. as
successor in interest to NeXstar Pharmaceuticals, Inc.

     11.77 “UTC” means University Technology Corporation, the successor in interest to the
University Research Corporation.

     11.78 “Valid Claim” means any claim of a pending patent application or an issued,
unexpired patent covered under the Licensed Patent Rights which, but for the license granted by
Archemix hereunder, would be infringed by the discovery, research, manufacture, use, delivery,
import, offer for sale or sale of a Licensed Product or any component thereof, to the extent that
such application or patent (a) has not been finally cancelled, withdrawn, abandoned or rejected by
any administrative agency or other body of competent jurisdiction, (b) has not been permanently
revoked, held invalid or declared unpatentable or unenforceable in a decision of a court or other
body of competent jurisdiction that is unappealable or unappealed within the time allowed for
appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, or (d) is not lost
through an interference proceeding.

     Additional Definitions. In addition, each of the following definitions shall have the
respective meanings set forth in the section of this Agreement indicated below:

	 	 	 
	Definition	 	Section
	AAA
	 	10.2.1
	Agreement
	 	Recitals
	Archemix
	 	Recitals
	Archemix License
	 	2.1.2(a)
	Archemix Indemnitees
	 	8.1
	Bankruptcy Action
	 	9.2.4
	Claims
	 	8.1
	Chosen Courts
	 	10.2.3
	Combination Product
	 	1.45(d)
	DC (Diligence Committee)
	 	3.3
	Disclosing Party
	 	1.17
	Dispute
	 	10.2.1
	Early Stage-Sublicensed Product
	 	4.2.2(a)
	Effective Date
	 	Recitals
	Expert
	 	10.2.2(a)
	Filing Party
	 	6.4.3
	Gilead Indemnitee
	 	8.3
	Indemnified Party
	 	8.2
	Indemnifying Party
	 	8.2
	Infringement
	 	6.5.1
	Infringement Notice
	 	6.5.1
	Late Stage-Sublicensed Product
	 	4.2.3
	License and Option Agreement
	 	Recitals
	Minimum Acceptable Financial Terms
	 	3.5

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-13

 

	 	 	 
	Definition	 	Section
	Non-Filing Party
	 	6.4.3
	Oncology Option
	 	3.6
	Oncology Option Notice
	 	3.6
	Oncology Option Termination Date
	 	3.6
	Party
	 	Recitals
	Parties
	 	Recitals
	Receiving Party
	 	1.17
	Required Jurisdictions
	 	6.4.2
	Ribomic
	 	Recitals
	Ribomic Patent Rights
	 	6.2
	ROFR Notice
	 	3.5
	ROFR Response
	 	3.5
	Specific Diligence Obligations
	 	3.1.2(b)
	Sublicense Income Payments
	 	4.4.1
	Supplemental Component
	 	1.45(d)
	Term
	 	9.1
	Third Party Negotiation Period
	 	3.5
	Third Party Non-Spiegelmer Product
	 	4.3.4(a)
	Third Party Spiegelmer Product
	 	4.3.4(b)

12. GRANT OF RIGHTS

     12.1 Licenses.

          12.1.1 Grant of Rights to Ribomic.

               (a) Grant of License. Archemix hereby grants to Ribomic an exclusive, royalty-bearing
license, including the right to grant sublicenses in accordance with Section 2.1.1(c), under the
Licensed Patent Rights, to Develop, have Developed, make, have made, use, have used, sell, offer
for sale, distribute for sale, have sold, import, have imported, export and have exported Licensed
Products in the Territory, for any and all uses within the Field, subject to the terms and
conditions of this Agreement. For purposes of clarity, Ribomic shall have no rights under this
Agreement to use the SELEX Process and SELEX Technology, alone or with a Third Party, except for
the sole purpose of identifying and modifying Active Aptamers for use in the Field.

               (b) Negative Covenant. Ribomic is not granted the right to, and hereby covenants and
agrees that neither it nor its Affiliates will (i) use the SELEX Process or SELEX Technology (A) on
any Target other than the Licensed Target and (B) except for the purpose of identifying or
modifying Active Aptamers and/or for the conduct by Ribomic of Permitted Ribomic Activities as
expressly permitted under this Agreement, (ii) research, develop, make, have made, use, have used,
sell, offer for sale, have sold, distribute for sale, import, have imported, export or have
exported any Diagnostic Product or Spiegelmer or (iii) perform any research or development on
Active Aptamers for any use outside of the Field. Notwithstanding the foregoing, Ribomic shall not
be restricted by this Section 2.1.1(b) from engaging in any (i) Permitted Ribomic Activities or
(ii) activity in which Ribomic is permitted to engage pursuant to a license, sublicense or other
right granted to Ribomic in any agreement other than this

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-14

 

Agreement (including, without limitation, the Existing License Agreements) with respect to the
SELEX Portfolio, the SELEX Process, SELEX Technology or Aptamers, whether granted by Archemix, or
any Third Party having the right to grant such license, sublicense or other right. To the extent
Ribomic or its Affiliates engages in any activities in violation of the negative covenant set forth
in this Section 2.1.1(b) during the Term and files any patent applications or obtains any Patent
Rights related to or arising out of such activities then, without limiting any other remedy
Archemix may have under this Agreement and without any further action of either Party, Ribomic
shall be deemed to have granted to Archemix, effective as of the date of any such filing, an
exclusive, fully-paid, perpetual, irrevocable, royalty-free license under all such Patent Rights
for any and all uses.

               (c) Right to Sublicense. Ribomic shall have the right to grant sublicenses to all or
any portion of its rights under the license granted pursuant to Section 2.1.1(a); provided, that,
(i) Archemix shall be notified of the grant of each such sublicense, (ii) each such sublicense
shall be subject to, and consistent with, the terms and conditions of this Agreement, (iii) each
such sublicense shall include the following provisions of this Agreement (with appropriate
modifications to account for the identities of the parties to such sublicense): Sections 2.1.1(b)
(Negative Covenant), 2.1.1(d) (Reversion of License Rights), 2.1.1(e) (Gilead-Archemix License
Agreement), Section 3.5 (Notice of Certain Events), 6.6 (Effect of Challenge) and 9.2.2
(Termination for Challenge), (iv) upon termination of this Agreement, any such sublicense shall be
considered a direct license from Archemix as provided in Section 9.3(d) hereof, and (v) Ribomic
shall provide Archemix with a copy of each Sublicense Agreement within thirty (30) days of
execution.

               (d) Reversion of License Rights. Ribomic acknowledges and agrees that each of the URC
License Agreement and the Gilead-Archemix License Agreement provides that the Archemix rights in
the SELEX Process or the SELEX Technology and the SELEX Portfolio may revert to Gilead or ULEHI if
Archemix, its Affiliates and all assignees and sublicensees cease to exercise reasonable efforts to
develop the commercial applications of products and services utilizing the SELEX Process or the
SELEX Technology. Ribomic further acknowledges and agrees that the URC License Agreement provides
that in the event of any termination of the URC License Agreement, the license to SELEX granted to
Ribomic hereunder shall remain in full force and effect in accordance with Section 3.4 of the URC
License Agreement; provided, that, Ribomic is not then in breach of this Agreement and Ribomic
agrees to be bound to ULEHI as the licensor under the terms and conditions of this Agreement.
Archemix shall inform Ribomic of such event immediately after the Archemix rights revert to Gilead
or ULEHI.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-15

 

               (e) Gilead-Archemix License Agreement. Ribomic acknowledges and agrees that the
Gilead-Archemix License Agreement provides that in the event of any termination of the
Gilead-Archemix License Agreement, the license to SELEX granted to Ribomic hereunder shall remain
in full force and effect in accordance with Section 2.3 of the Gilead-Archemix License Agreement;
provided, that, Ribomic agrees to be bound to Gilead as the licensor under the terms and conditions
of this Agreement; provided, that, if the termination of the Gilead-Archemix License Agreement
arises out of the action or inaction of Ribomic, Gilead, at its option, may terminate such license.
Archemix shall inform Ribomic of such event promptly after the Gilead-Archemix License Agreement is
terminated.

          12.1.2 Grant of Rights to Archemix.

               (a) Grant of License. Subject to the other terms of this Agreement, Ribomic hereby
grants to Archemix a non-exclusive, royalty-free, paid-up, perpetual, irrevocable, worldwide
license, with the right to grant sublicenses, under Ribomic SELEX Technology, Ribomic SELEX Patent
Rights and Ribomic Patent Rights (i) to research, develop, make, have made, use, have used, sell,
offer for sale, have sold, import, have imported, export, have exported, and commercialize Aptamers
for any and all purposes, and (ii) for any and all uses of the SELEX Process and SELEX Technology
(the “Archemix License”); provided, however, that the licenses in clause (i) and (ii) shall
not apply to Active Aptamers or include any specific aptamer sequences that are identified through
the conduct by Ribomic of the Permitted Ribomic Activities.

               (b) Covenant. Ribomic covenants and agrees to register the non-exclusive license
granted to Archemix under Section 2.1.2(a) under Japanese Patent No. 2,763,958 with the Japan
Patent Office as soon as practicable after the Effective Date and to provide Archemix with prompt
notice of such registration. Archemix shall reasonably cooperate with Ribomic to assist in the
preparation and execution of the registration and all formal documents to effect such registration,
at Ribomic’s sole cost and expense, if any.

     12.2 No Other Rights. Ribomic is not granted any rights to use or otherwise exploit
Licensed Patent Rights except as set forth in this Agreement or the Existing License Agreements and
Archemix is not granted any rights to use or otherwise exploit Ribomic SELEX Technology, Ribomic
SELEX Patent Rights or Ribomic Patent Rights except as set forth in this Agreement or the Existing
License Agreements. Without limiting the generality of the foregoing, Ribomic shall have no right
under this Agreement to (a) research, make, use, sell, offer for sale, import or export Diagnostic
Products, Radio Therapeutics, or Aptamer-Antidote Combination Products; or (b) research, make, use,
sell, offer for sale, import or export any aptamers for any in vivo imaging applications; or (c)
research, make, use, sell, offer for sale, import or export any aptamers for any non-therapeutic
uses (including, without limitation, for any use as an affinity purification agent).

     12.3 Exclusivity.

          12.3.1 Exclusivity.

               (a) Archemix Restrictions. During the Term, neither Archemix nor any of its
Affiliates will, alone or with a Third Party, conduct any activity, or grant any Third Party a
license to conduct any activity, for the purpose of researching, developing or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-16

 

commercializing any Active Aptamer or Licensed Product in the Field in the Territory.
Notwithstanding anything to the contrary set forth in this Agreement, the restrictions set forth in
this Section 2.3.1(a) shall not apply to the conduct by Archemix or any of its Affiliates of
Permitted Archemix Activities.

               (b) Ribomic Restrictions. During the period commencing on the Effective Date and
continuing until the later of the termination or expiration of this Agreement and the expiration of
the Full Royalty Term, neither Ribomic nor any of its Affiliates will, alone or with a Third Party,
conduct any activity or grant any Third Party a license to conduct any activity, for the purpose of
researching, developing or commercializing any aptamer other than a Active Aptamer for use in the
Field in the Territory as contemplated by this Agreement. Notwithstanding the above, Ribomic may
conduct the Permitted Ribomic Activities.

13. RESEARCH, DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS.

     13.1 Research, Development and Commercialization.

          13.1.1 Responsibility. From and after the Effective Date, Ribomic shall have full
control and authority over the research, Development and commercialization of Licensed Products in
the Field in the Territory, including, without limitation, (a) all pre-clinical research activities
(including any pharmaceutical development work on formulations or process development relating to
any Licensed Product), (b) all activities related to the conduct of human clinical trials relating
to any Licensed Product, (c) all activities relating to manufacture and supply of Licensed Products
(including all required process development and scale up work with respect thereto), (d) all
marketing, promotion, sales, distribution, import and export activities relating to any Licensed
Product, and (e) all activities relating to any regulatory filings, registrations, applications and
Regulatory Approvals relating to any of the foregoing. Ribomic shall own all data, results and all
other information arising from any such activities under this Agreement, including, without
limitation, all regulatory filings, registrations, applications and Regulatory Approvals relating
to Licensed Products, and all of the foregoing information, documentation and materials shall be
considered Confidential Information and Technology solely owned by Ribomic. All activities
relating to Development and commercialization of Licensed Products under this Agreement shall be
undertaken at Ribomic’s sole cost and expense, except as otherwise expressly provided in this
Agreement.

          13.1.2 Diligence.

               (a) General Diligence Obligations. Ribomic will exercise Commercially Reasonable
Efforts in Developing and commercializing Licensed Products in the Field, and in undertaking
investigations and actions required to obtain Regulatory Approvals necessary to market such
Licensed Products in the Field, in each of the United States, each of the E5 Countries and in
Japan, and in any other ex-United States markets, in addition to the E5 Countries and Japan, where
Ribomic determines, in the exercise of Commercially Reasonable Efforts, that it is commercially
reasonable to do so. In the event that Ribomic fails to use Commercially Reasonable Efforts as
required hereunder then, on a Licensed Product-by-Licensed Product and country–by-country basis as
to such Licensed Product in the United States or Japan

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-17

 

and, with respect to any E5 Country, in all of the E5 Countries, (i) Archemix may, in its sole
discretion (A) terminate the licenses granted under Section 2.1.1 of this Agreement for breach
under Section 9.2.3 below or (B) convert the licenses granted under Section 2.1.1 of this Agreement
from exclusive licenses to non-exclusive licenses, in either case only as such licenses apply to
such Licensed Product in such country(ies) and, with respect to any E5 Country, in all of the E5
Countries, and (ii) to the extent Archemix exercises its rights under Section 3.1.2(a)(i)(A) or (B)
with respect to a Licensed Product, Archemix’s exclusivity obligations under Section 2.3.1(a) shall
terminate with respect to such Licensed Product in such country(ies).

               (b) Specific Diligence Obligations. [Note: To be negotiated.]

     13.2 Progress Reports. Ribomic shall provide Archemix with written reports every six
(6) months during the Term that describes in reasonable detail its progress with respect to its
Development and commercialization activities under this Agreement which shall include, at minimum,
information reasonably sufficient to enable Archemix to satisfy its reporting obligations to Gilead
under the Gilead-Archemix License Agreement with respect to this Agreement and to assess the
progress made by Ribomic toward meeting the diligence obligations of Section 3.1 above.

     13.3 Diligence Committee. To facilitate the providing of progress reports by Ribomic
with respect to the research and Development of Licensed Products contemplated by this Agreement,
at Archemix’s sole option and request and subject to the mutual agreement of the Parties, the
Parties will establish a Diligence Committee (the “DC”), which will be comprised of equal numbers
of representatives of each of the Parties. The DC will meet on dates mutually agreed to by the
Parties not more than twice per Calendar Year, in person or by teleconference which, if in person,
shall alternate between the Parties’ respective offices in Cambridge, Massachusetts and Tokyo,
Japan.  Intellectual property representatives of each Party may be invited to participate in DC
meetings and such meetings will provide a forum to discuss any patent prosecution and enforcement
issues that arise under this Agreement. The DC may be established at any time within three (3)
years of the Effective Date and if established, the DC will terminate three (3) years after the
Effective Date, subject to extension by mutual written agreement of the Parties. Each Party will
be responsible for the costs and expenses incurred by its representative in participating on the
DC. Notwithstanding anything to the contrary in this Section 3.3, the DC shall have no authority
to make any decisions binding on the Parties with respect to either Party’s performance under this
Agreement.

     13.4 Notice of Certain Events. In addition to the progress reports required pursuant
to Section 3.3 above, Ribomic shall provide Archemix with written notice within thirty (30) days of
the occurrence of (a) the First Commercial Sale in each country, (b) the Initiation and Completion
of each Phase I Clinical Trial, Phase II Clinical Trial and Phase III Clinical Trial of a Licensed
Product, and the final reports thereof, (c) each milestone set forth in Section 4.2 below, (d) any
Regulatory Approval and Commercialization Regulatory Approval in each country, (e) any other
material event other than as set forth in the foregoing clauses (a)-(d) related to the Development
or commercialization of Licensed Products, and (f) any Adverse Event or product complaint
information relating to Licensed Products as compiled and prepared by Ribomic in the normal course
of business in connection with the Development, commercialization or sale of any Licensed Product,
within time frames consistent with reporting obligations under Applicable

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-18

 

Laws. Archemix may provide such Adverse Event information (i) to the extent reasonably
necessary to licensees of Archemix that are researching, developing or commercializing Aptamers for
therapeutic purposes and have agreed to maintain the confidentiality thereof and (ii) to Third
Parties as required by Applicable Laws.

     13.5 Right of First Refusal. In the event that Ribomic at any time during the ROFR
Period determines to enter into an agreement with a Third Party to Develop and/or commercialize any
Licensed Product that includes aggregate upfront fees and milestones payments that are less than
[***] Dollars ($[***]) (the “Minimum Acceptable Financial Terms”), it shall provide written
notice of same to Archemix, which notice shall include a copy of the term sheet or letter of intent
or other written evidence of the proposed terms of such transaction (the “ROFR Notice”).
Archemix shall have [***] days from the date of the ROFR Notice to provide a written response (the
“ROFR Response”) as to whether or not it wishes to participate in the Development and
commercialization of such Licensed Product on the terms set forth in the ROFR Notice. If the ROFR
Response is not provided by Archemix within the [***] day response period, Ribomic shall thereafter
have the right to negotiate and enter into an agreement with such Third Party with respect to the
Development and/or commercialization of such Licensed Product on the terms set forth in the ROFR
Notice for a period of up to [***] days (the “Third Party Negotiation Period”); provided,
that, if Ribomic and such Third Party do not enter into such agreement on or before the expiration
of the Third Party Negotiation Period, the Licensed Product shall once again be subject to this
Section 3.6. If the ROFR Response states that Archemix wishes to enter into negotiations with
Ribomic, the Parties shall negotiate in good faith for, and complete such negotiations within, a
period of up to [***] days from the date of the ROFR Response with respect to the terms and
conditions applicable to the Development and/or commercialization by Archemix of such Licensed
Product on the terms set forth in the ROFR Notice. In the event the Parties fail to execute and
deliver the agreement within the [***] day period, the Parties shall (a) use reasonable efforts to
complete such negotiations and to execute and deliver the agreement or amendment as soon as
possible after such [***] day period and (b) without limiting the generality of the foregoing,
after the expiration of such [***] day period, each produce a list of issues on which they have
failed to reach agreement and submit its list to be resolved in accordance with Section 10.2.2.
Notwithstanding the foregoing, the Parties hereby acknowledge and agree that once Ribomic has
successfully concluded an agreement with a Third Party for any or all Indications of a Licensed
Product meeting the Minimum Acceptable Financial Terms, the ROFR Period shall [***] terminate and,
thereafter, Archemix will [***] set forth herein above for [***] for any [***] involving the [***]
of any [***].

     13.6 Oncology Opt-In Right. Archemix shall have the option (the “Oncology
Option”), in its sole discretion, to jointly Develop and commercialize any Licensed Product for
oncology Indications on a Major Market Country-by-Major Market Country basis by providing written
notice (the “Oncology Option Notice”) at any time during the period commencing on the [***]
and continuing until the earlier of the Initiation of the first [***] Clinical Trial with respect
to that Licensed Product and the [***] by Ribomic of a Sublicense Agreement which includes the
grant to a Third Party of the right to Develop and commercialize any Licensed Product in a Major
Market Country (the “Oncology Option Termination Date”), which notice shall identify the
Licensed Product which Archemix elects to jointly Develop and commercialize. In connection
therewith, Ribomic shall provide Archemix with written notice not less than [***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-19

 

days prior to the expected occurrence of any Oncology Option Termination Date. If Archemix
exercises the Oncology Option with respect to any Licensed Product, the Parties shall negotiate an
agreement and/or an amendment to this Agreement and the terms applicable thereto in good faith and
with sufficient diligence as is required to execute and deliver the agreement or amendment within
[***] days after Archemix provides the Oncology Option Notice. In the event the Parties fail to
execute and deliver the agreement or amendment within the [***] day period, the Parties shall (a)
use reasonable efforts to complete such negotiations and to execute and deliver the agreement or
amendment as soon as possible after such [***] day period and (b) without limiting the generality
of the foregoing, after the expiration of such [***] day period, each produce a list of issues on
which they have failed to reach agreement and submit its list to be resolved in accordance with
Section 10.2.2. The Parties hereby acknowledge and agree that in the event Ribomic is in
compliance with the notice provisions of this Section 3.7 and enters into a Sublicense Agreement
with a Third Party which includes the grant to such Third Party of the right to Develop and
commercialize any Licensed Product in the applicable Major Market Country(ies), the Oncology Option
will [***] and thereafter be [***].

14. PAYMENTS AND ROYALTIES

     14.1 Access and License Fee. In consideration for the rights granted to Ribomic
hereunder, Ribomic hereby agrees to pay Archemix an upfront access and license fee in the amount of
[***] Dollars (U.S. $[***]), payable within [***] days of the Effective Date by wire transfer of
immediately available funds, which payment shall be non-refundable and non-creditable.

     14.2 Milestone Payments.

               14.2.1 All Licensed Products. Ribomic shall make the corresponding non-refundable,
non-creditable payments to Archemix by wire transfer according to instructions that Archemix shall
provide within [***] ([***]) days of the occurrence of the following milestone events for a
Licensed Product Developed by Ribomic or any Affiliate or Sublicensee of Ribomic:

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

          14.2.2 Early Stage-Sublicensed Products.

               (a) In the event Ribomic enters into an Early-Stage Sublicense

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-20

 

Agreement, then, in addition to the milestone payments contemplated by Section 4.2.1, but in
lieu of making any milestone payments for the milestone events contemplated by Section 4.2.3,
Ribomic shall make the corresponding non-refundable, non-creditable payments to Archemix by wire
transfer according to instructions that Archemix shall provide within [***] days of the occurrence
of the following milestone events for any Licensed Product that is Developed under such Early-Stage
Sublicense Agreement (an “Early Stage-Sublicensed Product”):

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 

               (b) Adjustment to Milestone Payments. In the event that any [***] provides for the
payment to Ribomic of, or if Ribomic otherwise receives under any [***], aggregate [***] Income in,
an amount, in excess of [***] Dollars (US $[***]), the aggregate milestone payments included in
Section 4.2.2(a) shall be increased by [***] percent ([***]%) of the amount by which such aggregate
[***] Income exceeds [***] Dollars (US $[***]), which increase shall be apportioned equally across
each of the Milestone Events set forth in Section 4.2.2(a). By way of example, if Ribomic enters
into an [***] and receives aggregate [***] Income in the amount of [***] Dollars (US $[***]), (i)
the aggregate Milestone Payments in Section 4.2.2(a) will by increased by [***] Dollars (US $[***])
([***] percent ([***]%) of [***] Dollars (US $[***])), (ii) the Milestone Payments due and payable
in Japan pursuant to Section 4.2.3(a) shall be increased in the aggregate by [***] Dollars (US
$[***]), (iii) the Milestone Payments due and payable in the United States shall be increased in
the aggregate by [***] Dollars (US $[***]) and (iv) the Milestone Payments due and payable in the
E5 Countries shall be increased in the aggregate by [***] Dollars (US $[***]).

          14.2.3 Late Stage-Sublicensed Products. In the event Ribomic enters into a [***]
that, in addition to the milestone payments described in Section 4.2.1 above, but in lieu of making
any milestone payments for the milestone events contemplated by Section 4.2.2, Ribomic shall make
the corresponding non-refundable, non-creditable payments to Archemix by wire transfer according to
instructions that Archemix shall provide within [***] days of the occurrence of the following
milestone events for any Licensed Product that is Developed under such [***] (a “[***]
Product”):

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-21

 

	 	 	 	 	 
	Milestone Event	 	Milestone Payment
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	$	[***]	 
	[***]
	 	 	[***]	 

     For purposes of clarity, (i) any Sublicense Agreement that includes a Late Stage-Sublicensed
Product shall be considered a Late Stage Sublicense Agreement regardless of whether other Licensed
Products that are not Late Stage-Sublicensed Products are included in such Sublicense Agreement and
(ii) all Licensed Products included in such Late Stage Sublicense Agreement shall be subject to
Section 4.2.3 and not Section 4.2.2.

          14.2.4 Skipped Milestones; Crediting of Certain Milestone Payments.

               (a) Skipped Milestones. If at the time any given milestone payment set forth in
Section 4.2 is due and one or more preceding milestone payments for logically antecedent milestones
have not been paid, then such unpaid antecedent milestone payments shall be paid at such time as
well. For example, if at the time an [***] milestone payment is due for a Licensed Product, an
[***] milestone payment has not been paid for a Licensed Product, then such [***] milestone payment
shall be paid at such time as well.

               (b) Crediting of Certain Milestone Payments. In the event that Ribomic enters into
one or more Sublicense Agreements covering a Licensed Product, all Milestone Payments for Milestone
Events achieved by Ribomic and/or the Sublicensee with respect to that Licensed Product on and
after the effective date of the Sublicense Agreement shall be fully creditable against Sublicense
Income Payments payable by Ribomic with respect to that Sublicense Agreement.

               (c) Milestones Payable Once Per Licensed Target. All of the milestone payments set
forth in Section 4.2 shall be payable only once per Licensed Target, regardless of how many
Licensed Products achieve such milestones and no milestone payment already made for a Licensed
Product shall be paid for any subsequent Licensed Product or any subsequent Indication for the same
Licensed Product with respect to said particular milestone.

          14.2.5 Determination that Payments are Due. In the event that Archemix believes any
milestone payment is due pursuant to Section 4.2.1, 4.2.2 and/or 4.2.3, it shall so notify Ribomic
and shall provide to Ribomic the data and information supporting its belief that

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-22

 

the conditions for payment have been achieved. If Ribomic disputes that such milestone
payment is due, either Party may submit such dispute for resolution pursuant to the provisions of
Section 10.2.2.

     14.3 Payment of Royalties; Royalty Rates. 

          14.3.1 Royalty Rates in Defined Territory. For each Licensed Product, Ribomic shall
pay Archemix a royalty based on Annual Net Sales of such Licensed Product in each Calendar Year (or
partial Calendar Year) in any country in the Defined Territory commencing with the First Commercial
Sale of such Licensed Product in any country in the Defined Territory and ending upon the last day
of the last Royalty Term for such Licensed Product, at the following rates:

	 	 	 	 	 	 	 	 	 
	 	 	Full Royalty Net	 	Partial Royalty 
	 	 	Sales	 	Net Sales
	Annual Net Sales	 	Royalty Rate (%)
	Up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***] and up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***] and up to $[***]
	 	 	[***]	%	 	 	[***]	%
	Above $[***]
	 	 	[***]	%	 	 	[***]	%

          14.3.2 Royalty Rates Outside Defined Territory. For each Licensed Product, Ribomic
shall pay Archemix a royalty based on Annual Net Sales of such Licensed Product in each Calendar
Year (or partial Calendar Year) in any country outside the Defined Territory commencing with the
First Commercial Sale of such Licensed Product in any country outside the Defined Territory and
ending upon the last day of the last Royalty Term for such Licensed Product, at a royalty rate
equal to [***] percent ([***]%) for Full Royalty Net Sales and [***] percent ([***]%) for Partial
Royalty Net Sales.

          14.3.3 Acknowledgements. Ribomic recognizes and acknowledges that each of the
following, separately and together, has substantial economic benefit to Ribomic: (a) the licenses
granted to Ribomic under Patent Rights Controlled by Archemix; (b) the restrictions on Archemix
pursuant to Section 2.3.1(a); and (c) the “head start” afforded to Ribomic by each of the
foregoing. The Parties agree that the royalty rates set forth in Sections 4.3.1 and 4.3.2 reflect
an efficient and reasonable blended allocation of the royalty amounts to be paid by Ribomic to
Archemix in its totality.

          14.3.4 Royalty and Milestone Reductions.

               (a) Non-Spiegelmer Third Party Products (Royalty Reduction). In the event that a
Third Party sells an aptamer product that is not a Third Party Spiegelmer Product that binds to the
Licensed Target (a “Third Party Non-Spiegelmer Product”) in a country in which an Active
Aptamer or Licensed Product is then being sold by Ribomic and such Third Party Non-Spiegelmer
Product is not covered by a Valid Claim under the Licensed Patent Rights in such country, then,
during the period in which sales of the Third Party Non-Spiegelmer Product are

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-23

 

equal to at least [***] percent ([***]%) of Ribomic’s volume-based market share of the Active
Aptamer or Licensed Product in such country (as measured by prescriptions or other similar
information available in such country) all applicable royalties in effect with respect to such
Active Aptamer or Licensed Product in such country as specified in Section 4.3.1 shall be reduced
by [***] percent ([***]%). Notwithstanding the foregoing, Ribomic’s obligation to pay royalties at
the full royalty rates shall be reinstated on the first day of the Calendar Quarter immediately
following the Calendar Quarter in which sales of such Third Party Non-Spiegelmer Product account
for less than [***] percent ([***]%) of Ribomic’s volume-based market share in such country.

               (b) Third Party Spiegelmer Products (Royalty Reduction). In the event that a Third
Party sells a Spiegelmer that binds to the Licensed Target (a “Third Party Spiegelmer
Product”) in a country in which an Active Aptamer or Licensed Product is then being sold by
Ribomic then all applicable royalties in effect with respect to such Active Aptamer or Licensed
Product in such country as specified in Section 4.3.1 shall be reduced by [***] percent ([***]%).
Notwithstanding the foregoing, Ribomic’s obligation to pay royalties at the full royalty rates
shall be reinstated on the first day of the Calendar Quarter immediately following the Calendar
Quarter in which sales of such Third Party Spiegelmer Product cease in such country.

               (c) Third Party Spiegelmer Product (Milestone Payment Reduction). In the event that a
Third Party initiates clinical trials of a Third Party Spiegelmer Product in any country of the
Defined Territory, then each applicable Milestone payment payable after the Initiation of Phase I
Clinical Trial with respect to any Active Aptamer or Licensed Product as specified in Section 4.2
hereof shall be reduced by [***] percent ([***]%) to the extent such Third Party is developing
and/or commercializing the Third Party Spiegelmer Product in any country of the Defined Territory
at the time such Milestone payment becomes due and payable.

     14.4
Sublicense Income.

          14.4.1 Sublicense Income Payments. In consideration for the rights granted to Ribomic
hereunder, during the Non-Royalty Term applicable to each Licensed Product, Ribomic shall pay
Archemix a percentage of all Sublicense Income received by Ribomic under each Sublicense Agreement
entered into with respect to such Licensed Product equal to the Applicable Sublicense Income Rate
(“Sublicense Income Payments”).

          14.4.2 Crediting of Milestones. Notwithstanding anything to the contrary in this
Agreement, Ribomic shall have the right to credit any Milestone Payment it makes with respect to a
Licensed Product on and after the date of execution of any Sublicense Agreement against Sublicense
Income Payments due and payable to Archemix with respect to that Licensed Product under that
Sublicense Agreement.

     14.5
Payment Terms.

          14.5.1 Payment of Royalties and Sublicense Income Payments. Unless otherwise
expressly provided, Ribomic shall make any royalty and Sublicense Income payments owed to Archemix
hereunder in arrears, within [***] days from the end of the Calendar Quarter in which

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-24

 

such payment accrues. For purposes of determining when a sale of any Licensed Product occurs
under this Agreement, the sale shall be deemed to occur on the date the invoice is provided by
Ribomic, its Affiliates or Sublicensees. Each royalty payment shall be accompanied by a report for
each country in the Territory in which sales of Licensed Products occurred in the Calendar Quarter
covered by such statement, specifying: (a) the gross sales (if available) and Net Sales in each
country’s currency; (b) the applicable royalty rate under this Agreement; (c) an accounting of
deductions taken in the calculation of Net Sales made in the United States and in any other country
in which such accounting is reasonably available; (d) the applicable exchange rate to convert from
each currency other than United States dollars to United States dollars under this Section 4.5; and
(e) the royalties payable in United States dollars. Each Sublicense Income Payment will be
accompanied by a report for each country in the Territory in which Sublicense Income is received in
the Calendar Quarter covered by such statement, specifying: (a) all consideration and payments
received by Archemix under such Sublicense Agreement; (b) the Applicable Sublicense Income Rate;
and (c) an accounting of any deductions taken in the calculation of the amount of the Sublicense
Income.

          14.5.2 Overdue Payments. Subject to the other terms of this Agreement, any payments
not paid within the time period set forth in this Article 4 shall bear interest at a rate of [***]
percent ([***]%) per month from the due date until paid in full; provided, that, in no event shall
said annual rate exceed the maximum interest rate permitted by law in regard to such payments. Any
such overdue royalty or milestone payment shall, when made, be accompanied by, and credited first
to, all interest so accrued. Said interest and the payment and acceptance thereof shall not negate
or waive the right of Archemix to any other remedy, legal or equitable, to which it may be entitled
because of the delinquency of the payment.

          14.5.3 Accounting. All payments hereunder shall be made in the United States in
United States dollars. Conversion of foreign currency to United States dollars shall be made at
the conversion rate existing in the United States (as reported in The Wall Street Journal) on the
last business day of the applicable Calendar Quarter. If The Wall Street Journal ceases to be
published or if the Parties agree otherwise, then the rate of exchange to be used shall be that
reported in such other business publication of national circulation in the United States as the
Parties reasonably agree.

          14.5.4 Withholding Taxes; Restrictions on Payment. All payments hereunder shall be
made free and clear of any taxes, duties, levies, fees or charges, except for withholding taxes (to
the extent applicable), Ribomic shall make any applicable withholding payments due on behalf of
Archemix and shall provide Archemix upon request with such written documentation regarding any such
payment available to Ribomic relating to an application by Archemix for a foreign tax credit for
such payment with the United States Internal Revenue Service.

     14.6 Records Retention; Review.

          14.6.1 Records; Audit. Ribomic and its Affiliates and Sublicensees shall keep and
maintain for [***] years from the date of each payment of royalties and Sublicense Income Payments
hereunder complete and accurate records of gross sales and Net Sales by Ribomic and its Affiliates
and Sublicensees of each Licensed Product, in sufficient detail to allow royalty

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-25

 

payments and Sublicense Income Payments to be determined accurately. Archemix shall have the
right for a period of [***] years after receiving any such royalty payment and Sublicense Income
Payments to appoint at its expense an independent certified public accountant reasonably acceptable
to Ribomic to audit the relevant records of Ribomic and its Affiliates and Sublicensees to verify
that the amount of such payment was correctly determined. Ribomic and its Affiliates and
Sublicensees shall each make its records available for audit by such independent certified public
accountant during regular business hours at such place or places where such records are customarily
kept, upon [***] days written notice from Archemix, solely to verify that royalty payments and
Sublicense Income Payments hereunder were correctly determined. Such audit right shall not be
exercised by Archemix more than once in any Calendar Year or more than [***] with respect to sales
of a particular Licensed Product in a particular period. All records made available for audit
shall be deemed to be Confidential Information of Ribomic or its Affiliates or Sublicensees, as
applicable. The results of each audit, if any, shall be binding on both Parties. In the event
there was an underpayment by Ribomic hereunder, Ribomic shall promptly (but in any event no later
than [***] days after Ribomic’s receipt of the report so concluding) make payment to Archemix of
any shortfall. Archemix shall bear the full cost of such audit unless such audit discloses an
underreporting by Ribomic of more than [***] percent ([***]%) of the aggregate amount of royalty
payments and/or Sublicense Income Payments payable in any Calendar Year, in which case Ribomic
shall reimburse Archemix for all costs incurred by Archemix in connection with such audit.

          14.6.2 Other Parties. Ribomic shall include in any agreement with its Affiliates or
Sublicensees terms requiring such party to retain records as required in this Section 4.6 and to
permit Archemix to audit such records as required by this Section 4.6.

15. TREATMENT OF CONFIDENTIAL INFORMATION

     15.1 Confidentiality Obligations. Archemix and Ribomic each recognizes that the other
Party’s Confidential Information constitutes highly valuable assets of such other Party. Archemix
and Ribomic each agrees that, subject to the remainder of this Article 5, it will not disclose, and
will cause its Affiliates and sublicensees not to disclose, any Confidential Information of the
other Party and it will not use, and will cause its Affiliates and sublicensees not to use, any
Confidential Information of the other Party except as expressly permitted hereunder; provided,
that, such obligations shall apply during the Term and for an additional [***] years thereafter.

     15.2 Limited Disclosure and Use. Archemix and Ribomic each agrees that disclosure of
its Confidential Information may be made by the other Party to any employee, consultant,
contractor, Affiliate or Sublicensee of such other Party to enable such other Party to exercise its
rights or to carry out its responsibilities under this Agreement; provided, that, any such
disclosure or transfer shall only be made to Persons who are bound by written obligations as
described in Section 5.3. In addition, Archemix and Ribomic each agrees that the other Party may
disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and
financial advisors, (b) as reasonably necessary in connection with an actual or potential (i)
permitted sublicense of such other Party’s rights hereunder, (ii) debt or equity financing of such
other Party or (iii) transfer or sale of all or substantially all of such Party’s assets or
business or in the event of its merger, consolidation, change in control or similar transaction,
and (b) for any

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-26

 

other purpose with the other Party’s written consent, not to be unreasonably withheld,
conditioned or delayed. In addition, each Party agrees that the other Party may disclose such
Party’s Confidential Information as required by Applicable Laws; provided, that, in the case of any
such disclosure, the disclosing Party shall (1) if practicable, provide the other Party with
reasonable advance notice of and an opportunity to comment on any such required disclosure and (2)
if requested by the other Party, cooperate in all reasonable respects with the other Party’s
efforts to obtain confidential treatment or a protective order with respect to any such disclosure,
at the other Party’s expense.

     15.3
Employees and Consultants. Ribomic and Archemix each hereby represents that all
of its employees, consultants and contractors, and all of the employees, consultants and
contractors of its Affiliates and sublicensees (including, without limitation, Sublicensees), who
have access to Confidential Information of the other Party are or will, prior to their
participation or access, be bound by written obligations to maintain such Confidential Information
in confidence and not to use such information except as expressly permitted hereunder. Each Party
agrees to use, and to cause its Affiliates and sublicensees (including, without limitation,
Sublicensees) to use, reasonable efforts to enforce such obligations.

     15.4 Publicity. The Parties acknowledge and agree that (a) the terms of this
Agreement constitute Confidential Information of each Party and may only be disclosed (i) as
permitted by Section 5.2, and (ii) to investment bankers, investors, and potential investors,
lenders and potential lenders and other sources and other potential sources of financing, licensees
and potential licensees, acquirers or merger partners and potential acquirers or merger partners of
such Party, and, with respect to Archemix, to Gilead and University License Equity Holdings, Inc.;
and (b) a copy of this Agreement may be filed by either Party with the Securities and Exchange
Commission if such filing is required by Applicable Laws; provided, that, in connection with any
such filing, such Party shall endeavor to obtain confidential treatment of economic and trade
secret information, and shall provide the other Party with the proposed confidential treatment
request with reasonable time for such other Party to provide comments, which comments shall be
reasonably considered by the filing Party. Notwithstanding anything to the contrary in Section
5.1, except as required by Applicable Laws, neither Party shall issue a press or news release or
make any similar public announcement related to this Agreement without the prior written consent of
the other Party.

16. INTELLECTUAL PROPERTY RIGHTS AND PROVISIONS

     16.1 Licensed Patent Rights. Archemix shall have sole and exclusive ownership of all
right, title and interest on a worldwide basis in and to any and all Licensed Patent Rights.

     16.2 Ribomic Patent Rights. Ribomic shall have sole and exclusive ownership of all
right, title and interest on a worldwide basis in and to any and all Patent Rights arising out of
the practice by Ribomic of the license pursuant to Section 2.1.1(a) (“Ribomic Patent
Rights”).

     16.3 Joint Technology; Joint Patent Rights. Ribomic and Archemix shall jointly own all
Joint Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained in
this Agreement or under Applicable Laws, except to the extent exclusively licensed to one Party
under this Agreement, the Parties hereby agree that either Party may use or license

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-27

 

or sublicense to Affiliates or Third Parties all or any portion of its interest in Joint
Technology, Joint Patent Rights or jointly owned Confidential Information or Proprietary Materials
for any purposes without the prior written consent of the other Party, without restriction and
without the obligation to provide compensation to the other Party, except as otherwise provided
under this Agreement; provided, that, to the extent that any Joint Technology and/or Joint Patent
Rights are necessary or useful for the research, development, manufacture, use, sale, importation
or exportation of a Licensed Product being commercialized by Ribomic pursuant to this Agreement,
Archemix shall not use or license to a Third Party its interest in such Joint Technology and/or
Joint Patent Rights to develop or commercialize any Aptamers that were selected against and bind to
the applicable Licensed Target with high specificity and affinity.

     16.4 Prosecution of Patent Rights.

          16.4.1 Licensed Patent Rights. Archemix, at its sole expense and acting through
patent counsel or agents of its choice, shall be solely responsible for the preparation, filing,
prosecution and maintenance of the Licensed Patent Rights.

          16.4.2 Ribomic SELEX Patent Rights. Ribomic, its Affiliates and/or any Sublicensee,
as applicable, at its sole expense and acting through patent counsel or agents of its choice, shall
have the sole responsibility and obligation for the preparation, filing, prosecution and
maintenance of the Ribomic SELEX Patent Rights in the countries listed on Schedule 2 (the
“Required Jurisdictions”). In the event that Ribomic and/or any Sublicensee, as
applicable, determines not to file or to abandon any of the Ribomic SELEX Patent Rights in any of
the Required Jurisdictions, Ribomic shall notify Archemix sufficiently in advance so that Archemix
can, without any loss of rights, and Archemix shall have the right to, file, prosecute and maintain
such Ribomic SELEX Patent Rights in Ribomic’s name at Archemix’s expense in such Required
Jurisdictions.

          16.4.3 Joint Patent Rights. Unless the Parties otherwise agree, each Party, acting
through patent counsel or agents of its choice, shall be jointly responsible for the preparation,
filing, prosecution and maintenance of all Joint Patent Rights as follows: (a) Ribomic shall be
responsible for the preparation, filing, prosecution and maintenance of any such claims that
specifically claim any Active Aptamer; (b) Archemix shall be responsible for the preparation,
filing, prosecution and maintenance of any such claims that do not specifically claim any Active
Aptamer; (c) the Parties shall discuss in good faith whether and how to pursue those claims for
which they have primary responsibility under this Section 6.4.3 in separate patent applications;
(d) each Party that has responsibility for filing and prosecuting any Patent Rights under this
Section 6.4.3 (a “Filing Party”) shall provide the other party (the “Non-Filing
Party”) and its patent counsel with an opportunity to consult with the Filing Party and its
patent counsel regarding the filing and contents of any application, amendment, submission or
response filed pursuant to this Section 6.4.3; and (e) each Party shall be responsible for all
expenses incurred by it for the preparation, filing prosecution and maintenance of any Joint Patent
Rights for which it has primary responsibility pursuant to this Section 6.4.3. The Filing Party
shall (a) regularly provide the Non-Filing Party with copies of all patent applications filed
hereunder for Joint Patent Rights and other material submissions and correspondence with the patent
offices, in sufficient time to allow for review and comment by the Non-Filing Party; and (b)
provide the

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-28

 

Non-Filing Party and its patent counsel with an opportunity to consult with the Filing Party
and its patent counsel regarding the filing and contents of any such application, amendment,
submission or response, and the advice and suggestions of the Non-Filing Party and its patent
counsel shall be taken into consideration in good faith by such Filing Party and its patent counsel
in connection with such filing. Each Filing Party shall pursue in good faith all reasonable claims
and take such other reasonable actions, as may be requested by the Non-Filing Party in the
prosecution of any Joint Patent Rights under this Section 6.4.3; provided, however, if the Filing
Party incurs any additional expense as a result of any such request, the Non-Filing Party shall be
responsible for the cost and expenses of pursuing any such additional claim or taking such other
activities.

     16.5 Infringement.

          16.5.1 Notice. In the event that during the Term either Party becomes aware of any
possible infringement of any Licensed Patent Rights, Ribomic SELEX Patent Rights or Joint Patent
Rights, including the submission by any Third Party of an abbreviated new drug application under
the Hatch-Waxman Act or its equivalent outside the United States for a generic product (each, an
“Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”).

          16.5.2 Infringement of Licensed Patent Rights. Archemix shall have the sole right,
but not the obligation, in its sole discretion, at its own expense and with legal counsel of its
own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or
threatened Infringement of the Licensed Patent Rights.

          16.5.3 Infringement of Ribomic SELEX Patent Rights. Ribomic and/or any Sublicensee,
as applicable, shall have the first right, but not the obligation, at its own expense and with
legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any
actual, alleged or threatened Infringement of the Ribomic SELEX Patent Rights. Archemix shall have
the right, at its own expense, to be represented in any such action by Ribomic by counsel of
Archemix’s own choice; provided, that, under no circumstances shall the foregoing affect the right
of Ribomic to control the suit as described in the first sentence of this Section 6.5.3. If
Ribomic and/or any such Sublicensee, as applicable, does not file any action or proceeding against
any such Infringement within [***] months (or [***] days in the case of an Infringement resulting
from the submission by any Third Party of an abbreviated new drug application under the
Hatch-Waxman Act or its equivalent outside the United States) after the later of (i) Ribomic’s
notice to Archemix under Section 6.5.1 above, (ii) Archemix’s notice to Ribomic under Section 6.5.1
above or (iii) a written request from Archemix to take action with respect to such Infringement,
then Archemix shall have the right (but not the obligation), at its own expense, to bring suit (or
take other appropriate legal action) against such actual, alleged or threatened infringement, with
legal counsel of its own choice. If a Party brings any such action or proceeding hereunder, the
other Party agrees to be joined as party plaintiff if necessary to prosecute such action or
proceeding, and to give the Party bringing such action or proceeding reasonable assistance and
authority to file and prosecute the suit; provided, that, neither Party shall be required to
transfer any right, title or interest in or to any property to the other Party or any Third Party
to confer standing on a Party hereunder. Any damages, monetary awards or

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-29

 

other amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding
or other legal action taken under this Section 6.5.3 shall belong to [***].

          16.5.4 Infringement of Joint Patent Rights. In the event of an Infringement of a
Joint Patent Right, the Parties shall enter into good faith discussions as to whether and how to
eliminate the Infringement. Each Party shall bear [***] of the cost of any action, suit or
proceeding instituted under this Section 6.5.4 and [***] of all amounts recovered shall be received
by each Party; provided, that, if the Parties are unable to determine whether and how to institute
an action, suit or proceeding for Infringement of any such Joint Patent Right, either Party shall
have the right to prosecute such Infringement, in which event that Party shall bear [***] and be
entitled to retain [***]. Each Party shall have the right to be represented by counsel of its own
selection in any action, suit or proceeding instituted under this Section 6.5.4 by the other Party.
If a Party lacks standing and the other Party has standing to bring any such action, suit or
proceeding, then the Party with standing shall bring such suit at the request and expense of the
other Party.

     16.6 Effect of Challenge. In further consideration of Archemix’s grant of the
licenses hereunder and except to the extent the following is unenforceable under the Applicable
Laws of a particular jurisdiction where a patent application within the Licensed Patent Rights is
pending or a patent within the Licensed Patent Rights issued, in the event that Ribomic, its
Affiliates and/or Sublicensees during the Full Royalty Term (a) determines to initiate a Challenge
or Ribomic, its Affiliates and/or Sublicensees determines to assist a Third Party in initiating a
Challenge, Ribomic will provide written notice to Archemix at least [***] days prior thereto, which
notice will include an identification of all prior art it believes invalidates any claim of the
Licensed Patent Rights; and (b) initiates a Challenge or assists a Third Party in initiating a
Challenge, (i) the exclusive license granted by Archemix to Ribomic hereunder shall, at the option
of the Archemix and upon written notice to Ribomic, be converted into non-exclusive licenses as of
the date of such notice, (ii) during the pendency of such Challenge, the royalty rates set forth in
Section 4.3 shall be increased by an additional two percentage points in the Territory during the
Full Royalty Term (i.e., a [***]% royalty rate shall be increased to [***]%) commencing on the date
of such initiation, (iii) should the outcome of such Challenge determine that any claim of the
Licensed Patent Rights that is the subject of the Challenge is valid or enforceable, the royalty
rates set forth in Section 4.3 shall be increased by an additional five percentage points in the
Territory during the Full Royalty Term (i.e., a [***]% royalty rate shall be increased to [***]%)
on condition that the non-exclusive license shall revert to the exclusive license as of the date of
such decision and (iv) should the outcome of any Challenge determine no claim of the Licensed
Patent Rights is valid or enforceable in a country, Ribomic, its Affiliates and/or Sublicensees
shall continue to pay royalties based on Net Sales of Licensed Products sold in such country at the
rate of [***] percent ([***]%) until the last day of the Royalty Term for such Licensed Product.

17. REPRESENTATIONS AND WARRANTIES; COVENANT REGARDING THIRD PARTY AGREEMENTS

     17.1 Mutual Representations and Warranties. Archemix and Ribomic each represents and
warrants to the other, as of the Effective Date, as follows:

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-30

 

          17.1.1 Organization. It is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, and has all requisite power and
authority, corporate or otherwise, to execute, deliver and perform this Agreement.

          17.1.2 Authorization. The execution and delivery of this Agreement and the
performance by it of the transactions contemplated hereby have been duly authorized by all
necessary corporate action and will not violate (a) such Party’s certificate of incorporation or
bylaws, (b) any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment,
injunction, decree, determination or award of any court or governmental agency presently in effect
applicable to such Party.

          17.1.3 Binding Agreement. This Agreement is a legal, valid and binding obligation of
such Party enforceable against it in accordance with its terms and conditions.

          17.1.4 No Inconsistent Obligation. It is not under any obligation, contractual or
otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of
this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder.

     17.2 Acknowledgment of Ribomic. Ribomic acknowledges that the licenses granted to
Ribomic hereunder are subject to certain limitations and restrictions set forth in the
Archemix-Gilead License Agreement and agrees that Ribomic shall comply with the terms of the
Archemix-Gilead License Agreement that Archemix is subject to thereunder.

     17.3 Additional Representations and Warranties.

          17.3.1 Additional Representations and Warranties of Archemix.

               (a) Authority. Archemix represents and warrants to Ribomic that Archemix Controls the
Licensed Patent Rights and has the right to grant the license granted to Ribomic on the terms set
forth herein.

               (b) No Litigation. Archemix represents and warrants to Ribomic that, as of the
Effective Date and with no further duty to update, to Archemix’s Knowledge, there is no pending
litigation against Archemix that seeks to invalidate or oppose any of the patents or patent
applications included in the Licensed Patent Rights.

               (c) Archemix-Gilead License Agreement. Archemix represents and warrants to Ribomic
that the Archemix-Gilead License Agreement as heretofore delivered by Archemix to Ribomic
represents the complete agreement and understanding between Gilead Sciences, Inc. and Archemix
relating to the Licensed Patent Rights which are the subject of the Archemix-Gilead License
Agreement; the Archemix-Gilead License Agreement has not been modified, supplemented or amended in
any manner that would adversely affect the rights granted to Ribomic under this Agreement, other
than by amendments thereto provided to Ribomic prior to the Effective Date; and the Archemix-Gilead
License Agreement is in full force and effect and Archemix is in compliance in all material
respects with its obligations thereunder.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-31

 

               (d) No Infringement. Archemix represents and warrants to Ribomic that to its
Knowledge, there is no litigation pending or threatened that alleges that (i) the practice of the
SELEX Process and/or the use of SELEX Technology as contemplated by this Agreement infringes the
Patent Rights of any Third Party, (ii) the Licensed Patent Rights are invalid or unenforceable; or
(iii) the use of the Licensed Patent Rights as contemplated by this Agreement infringes the Patent
Rights of any Third Party.

          17.3.2 Additional Representations and Warranties of Ribomic.

               (a) Authority. Ribomic represents and warrants to Archemix that Ribomic has the right
to grant the Archemix License granted to Archemix on the terms set forth herein.

               (b) No Litigation. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update (except as otherwise stated), there is no pending
litigation against Ribomic or any Affiliate of Ribomic that seeks to invalidate or oppose any of
the patents or patent applications included in the Ribomic SELEX Patent Rights.

               (c) No Conflict. Ribomic represents and warrants to Archemix that, as of the
Effective Date and with no further duty to update, it is not researching, developing or
commercializing Aptamers that bind to a Target other than its research, development and/or
commercialization of Aptamers pursuant to this Agreement and the Existing License Agreements.

18. INDEMNIFICATION AND INSURANCE

     18.1 Indemnification of Archemix by Ribomic. Ribomic shall indemnify, defend and hold
harmless Archemix, its Affiliates, their respective directors, officers, employees and agents, and
their respective successors, heirs and assigns (the “Archemix Indemnitees”), against any
liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of
litigation) incurred by or imposed upon the Archemix Indemnitees, or any one of them, as a direct
result of claims, suits, actions or demands by Third Parties (collectively, the “Claims”)
arising out of (a) the research, development, testing, production, manufacture, supply, promotion,
import, sale or use by any Person of any Licensed Product (or any component thereof) manufactured
or sold by Ribomic or any of its Affiliates or Sublicensees or (b) the gross negligence or willful
misconduct of Ribomic or any of its Affiliates or Sublicensees.

     18.2 Conditions to Indemnification. An Archemix Indemnitee seeking recovery under
this Article 8 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of
such Claim to the indemnifying party (the “Indemnifying Party”) and provided that the
Indemnifying Party is not contesting its obligation under this Article 8, shall permit the
Indemnifying Party to control any litigation relating to such Claim and the disposition of such
Claim (including without limitation any settlement thereof); provided, that, the Indemnifying Party
shall not settle or otherwise resolve such Claim without the prior written consent of such
Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed, unless
such settlement includes a full release of the Indemnified Party, in which case the indemnifying
Party may settle or otherwise resolve such Claim without the prior written consent of such
Indemnified Party. Each Indemnified Party shall cooperate with the Indemnifying Party in its
defense of any such Claim in all reasonable respects and shall have the right to be present

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-32

 

in person or through counsel at all legal proceedings with respect to such Claim.

     18.3 Indemnification of Gilead and UTC by Ribomic. If and solely to the extent,
legally required by the Archemix-Gilead License Agreement, Ribomic shall indemnify, defend and hold
harmless Gilead, its Affiliates and UTC and any of their respective directors, officers, employees
and agents (each, a “Gilead Indemnitee”), from and against any losses that are incurred by
a Gilead Indemnitee as a result of any Claims, to the extent such Claims arise out of the
possession, research, development, manufacture, use, offer for sale, sale or other
commercialization, distribution, administration, storage or transport, by Ribomic or its Affiliates
or Sublicensees of (a) any Aptamers or Licensed Products, or (b) any other products, services or
activities developed by Ribomic relating to the Licensed Patent Rights, including any Licensed
Products or Aptamers.

     18.4 Warranty Disclaimer. NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY
DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. NEITHER PARTY MAKES ANY
WARRANTIES AS TO THE VALIDITY OR ENFORCEABILITY OF THE PATENT RIGHTS LICENSED BY SUCH PARTY TO THE
OTHER PARTY.

     18.5 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT,
EXCEPT WITH RESPECT TO RIBOMIC’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 8.1 AND/OR 8.3, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST
REVENUES, OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER
ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

     18.6 Insurance. Ribomic will, at Ribomic’s expense, obtain and maintain in full force
and effect insurance with respect to the Development (to the extent it is related to the clinical
studies) and commercialization of Licensed Products in such amount as Japan-based biopharmaceutical
companies customarily maintain with respect to the clinical development and commercialization of
similar products. If Licensed Products are subject to clinical studies, then such insurance policy
or policies shall name Archemix as an additional named insured, shall be non-cancelable except upon
[***] days prior written notice to Archemix, and shall provide that as to any loss covered thereby
and also by any policies obtained by Archemix itself, Ribomic’s policies shall provide primary
coverage for Archemix and Archemix’ policies shall be considered excess coverage for Archemix.
Ribomic will forthwith after the obtaining of such insurance required by this Section 8.6, obtain
and deliver to Archemix certificates of and copies of, and at all times thereafter deliver without
further demand replacement certificates and copies of, all such insurance policies that are in
force and effect.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-33

 

19. TERM AND TERMINATION

     19.1 Term; Expiration. The term of this Agreement (the “Term”) shall commence
on the Effective Date and continue, unless earlier terminated as provided herein, until such time
as all Royalty Terms for all Licensed Products have ended. Upon expiration (but not upon
termination prior to the expiration) of the Royalty Term applicable to a Licensed Product in a
country, Ribomic’s rights and licenses hereunder with respect to such Licensed Product in such
country shall become fully paid-up, non-royalty bearing, non-exclusive, perpetual rights and
licenses.

     19.2 Termination.

          19.2.1 Unilateral Right to Terminate. Ribomic shall have the right to terminate this
Agreement, for any reason, upon (a) at least [***] days’ prior written notice to Archemix, such
notice to state the date following the date of receipt of such notice by Archemix upon which
termination is to be effective, and (b) the payment by Ribomic of all amounts due to Archemix
through such termination effective date.

          19.2.2 Termination for Challenge. In the event Ribomic, its Affiliates and/or
Sublicensees initiates a Challenge or assists a Third Party in initiating a Challenge, Archemix
shall have the right to terminate this Agreement, effective immediately upon written notice to
Ribomic.

          19.2.3 Termination for Breach. Except as set forth herein, either Party may terminate
this Agreement, effective immediately upon written notice to the other Party, for a material breach
by the other Party of this Agreement that, if curable, remains uncured for [***] days ([***] days
in the event that the breach is a failure of a Party to make any payment required hereunder) after
the non-breaching Party first gives written notice to the other Party of such breach and its intent
to terminate this Agreement if such breach is not cured.

          19.2.4 Termination for Insolvency. Each Party shall give the other Party reasonable
prior notice of the filing with respect to itself of any voluntary petition, and prompt notice of
the filing with respect to itself of any involuntary petition, under any bankruptcy laws. In the
event that either Party: (a) files for protection under bankruptcy laws; (b) makes an assignment of
all or substantially all of its assets for the benefit of creditors; (c) appoints or suffers
appointment of a receiver or trustee over all or substantially all of its assets; and (d) files a
petition under any bankruptcy or insolvency act or has any such petition filed against it which is
not discharged within [***] days of the filing thereof (each of (a)-(d), a “Bankruptcy
Action”), then the other Party may terminate this Agreement effective immediately upon written
notice to such Party. All rights and licenses granted under or pursuant to this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code. Further, upon filing such protection or petition by Archemix, Archemix shall, without any
delay, perform all necessary procedures under any then-applicable laws including, but not limited
to, Section 365(n) of the United States Bankruptcy Code, to protect all rights and licenses granted
to Ribomic under Section 2.1.1 hereof in order for retaining and defending such rights and license.
Notwithstanding any provision contained in this Agreement to the contrary, if any Bankruptcy

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-34

 

Action takes place with respect to Archemix, and the trustee in bankruptcy of Archemix, or
Archemix as a debtor-in-possession, properly elects to reject this Agreement, Ribomic may, pursuant
to Section 365(n) of the Bankruptcy Code, retain and enforce any and all rights hereunder granted
to Ribomic to the maximum extent permissible by law. All rights, powers and remedies of Ribomic,
as a licensee hereunder, provided herein are in addition to and not in substitution for any and all
other rights, powers and remedies now or hereafter existing at law or in equity (including, without
limitation, the Bankruptcy Code) in the event of the commencement of a Bankruptcy Action with
respect to Archemix. Ribomic, in addition to the rights, powers and remedies expressly provided
herein, shall be entitled to exercise all other such rights and powers and resort to all other such
remedies as may now or hereafter exist at law or in equity (including the Bankruptcy Code) in such
event.

     19.3 Consequences of Termination of Agreement. In the event of the termination of
this Agreement pursuant to this Article 9, the following provisions shall apply:

          19.3.1 If this Agreement is terminated by Ribomic pursuant to Section 9.2.1 or by Archemix
pursuant to Sections 9.2.2, 9.2.3 or 9.2.4:

               (a) all licenses granted by Archemix to Ribomic under this Agreement shall immediately
terminate and Archemix shall have no further obligations under Section 2.3.1(a);

               (b) all licenses granted by Ribomic to Archemix prior to the termination of this Agreement
hereunder shall continue and survive in full force and effect;

               (c) Ribomic shall promptly return all Confidential Information of Archemix; provided, that
Ribomic may retain one (1) copy of Confidential Information of Archemix in its archives solely for
the purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder;

               (d) each Sublicensee of Ribomic shall be considered a direct licensee of Archemix under this
Agreement; provided, that, (i) such Sublicensee is then in compliance with all terms and conditions
of its sublicense, (ii) all accrued payment obligations of such Sublicensee to Ribomic under the
Sublicense Agreement have been paid, and (iii) such Sublicensee agrees in writing to assume all
applicable obligations of Ribomic under this Agreement arising thereafter to the extent of the
scope of the sublicense;

               (e) upon request of Archemix, the Parties shall negotiate in good faith the terms of a
transition plan which shall provide for the terms pursuant to which Ribomic shall (i) transfer to
Archemix all of its right, title and interest in all regulatory filings and Regulatory Approvals
then in its name applicable to Licensed Products, if any, and all material aspects of Confidential
Information Controlled by it as of the date of termination relating to such regulatory filings and
Regulatory Approvals; (ii) notify the applicable regulatory authorities and take any other action
reasonably necessary to effect such transfer; (iii) provide Archemix with copies of all
correspondence between Ribomic and such regulatory authorities relating to such regulatory filings
and Regulatory Approvals; (iv) unless expressly prohibited by any regulatory authority, transfer
control to Archemix of all clinical trials of Licensed Products being conducted as of the effective
date of termination and continue to conduct such trials for up to six (6) months to enable

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-35

 

such transfer to be completed without interruption of any such trial; (v) assign (or cause its
Affiliates to assign) to Archemix all agreements with any Third Party with respect to the conduct
of clinical trials for Licensed Products including, without limitation, agreements with contract
research organizations, clinical sites and investigators, unless expressly prohibited by any such
agreement (in which case Ribomic shall cooperate with Archemix in all reasonable respects to secure
the consent of such Third Party to such assignment); (vi) provide Archemix with all supplies of
Licensed Products in the possession of Ribomic or any Affiliate or contractor of Ribomic; (vii)
provide Archemix with copies of all reports and data generated or obtained by Ribomic or its
Affiliates pursuant to this Agreement that relate to any Licensed Products that have not previously
been provided to Archemix; and (viii) supply Archemix with its requirements for Licensed Products
and intermediates for up to twenty-four (24) months following such termination at a transfer price
to be negotiated and included in such transition plan.

          19.3.2 If this Agreement is terminated by Ribomic pursuant to Sections 9.2.3 or 9.2.4, all
licenses granted by Archemix to Ribomic shall survive, subject to Ribomic’s continued payment of
all royalties, milestones, Sublicense Income Payments and other payments due and payable to
Archemix pursuant to Article 4; and Ribomic shall promptly return all Confidential Information of
Archemix that is not subject to a continuing license hereunder; provided, that Ribomic may retain
one (1) copy of each such Confidential Information of Archemix in it archives solely for the
purpose of establishing the contents thereof and ensuring compliance with its obligations
hereunder.

          19.3.3 If Ribomic breaches any of its Specific Diligence Obligations pursuant to Section
3.1.2(b), with respect to a given Licensed Product then, in lieu of termination of this Agreement
pursuant to Section 9.3.1, Archemix shall have the right, in its sole discretion, upon ten (10)
days written notice to Ribomic, to (a) convert the exclusive license granted to Ribomic for each
such Licensed Product to non-exclusive, in which case Section 2.3.1(a) shall no longer apply to
such Licensed Product or (b) exercise its rights pursuant to Section 9.3.1 only on a Licensed
Product-by-Licensed Product and country-by-country basis.

     19.4 Remedies. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article 9 are in addition to any other relief and remedies available
to either Party at law.

     19.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the
rights and obligations of the Parties set forth in Articles 5, 8 and 10 and Sections 4.6, 6.1, 6.2,
6.3, 6.4 6.5.4, 9.1 and 9.3, as well as any rights or obligations otherwise accrued hereunder
(including any accrued payment obligations), shall survive the expiration or termination of the
Term.

20. DISPUTES

     20.1 Negotiation. The Parties recognize that a bona fide dispute as to certain
matters may from time to time arise during the Term that relates to either Party’s rights and/or
obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by
written notice to the other Party, have such dispute referred to their respective senior officials
designated below or their successors or designees, for attempted resolution by good faith

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-36

 

negotiations within [***] days after such notice is received. Said designated senior
officials are as follows:

	 	 	 	 	 
	 

	 	For Ribomic:
	 	[***]
	 
	 	 	 	 
	 

	 	For Archemix:
	 	[***]

In the event the designated senior officials or their successors or designees are not able to
resolve such dispute within the [***] day period, either Party may invoke the provisions of
Section 10.2.

     20.2 Arbitration.

          20.2.1 Full Arbitration. Subject to Sections 10.1 and 10.2.3 below, any dispute,
controversy or claim initiated by either Party arising out of, resulting from or relating to this
Agreement or the performance by either Party of its obligations under this Agreement (excluding
actions under Article 9 and bona fide Third Party actions or proceedings filed or instituted in an
action or proceeding by a Third Party against a Party) (a “Dispute”), whether before or
after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a
Party shall decide to institute arbitration proceedings, it shall give written notice to that
effect to the other Party. Any such arbitration shall be conducted under the Commercial
Arbitration Rules of the American Arbitration Association (the “AAA”) by a panel of three
arbitrators appointed in accordance with such rules. Any such arbitration shall be held in Boston,
Massachusetts if such arbitration is demanded by Ribomic and in Honolulu, Hawaii if such
arbitration is demanded by Archemix. The method and manner of discovery in any such arbitration
proceeding shall be governed by the laws of the Commonwealth of Massachusetts. The arbitrator
shall have the authority to grant injunctions and/or specific performance and to allocate between
the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the
award so rendered may be entered in any court having jurisdiction or application may be made to
such court for judicial acceptance of any award and an order of enforcement, as the case may be.
In no event shall a demand for arbitration be made after the date when institution of a legal or
equitable proceeding based upon such claim, dispute or other matter in question would be barred by
the applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the
right, without waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional
relief that is necessary or desirable to protect the rights or property of such Party, pending the
selection of the arbitrator hereunder or pending the arbitrators’ determination of any dispute,
controversy or claim hereunder.

          20.2.2 Accelerated Arbitration. To the extent a Dispute submitted to arbitration by a
Party under Section 10.2.1 is claimed, by either Party, to involve matters covered by Sections
1.45, 1.70, 3.5, 3.6 or 4.2.5, the following procedures shall apply:

               (a) The Parties shall mutually select a single independent, conflict-free arbitrator (the
“Expert”), who shall have sufficient scientific background and financial experience to
resolve the Dispute. If the Parties are unable to reach agreement on the selection of an Expert
within [***] business days after submission to arbitration, then either or both Parties shall
immediately request that the AAA select an independent and impartial arbitrator with the requisite
scientific background, experience and expertise. The place of arbitration shall be Boston,
Massachusetts.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-37

 

               (b) Each Party shall prepare and submit a written summary of such Party’s position and any
relevant evidence in support thereof to the Expert within [***] days of the selection of the
Expert. Upon receipt of such summaries from each Party, the Expert shall provide copies of the
same to the other Party. Within [***] days of the delivery of such summaries by the Expert, each
Party shall submit a written rebuttal of the other Party’s summary and may also amend and re-submit
its original summary. Oral presentations shall not be permitted unless otherwise requested by the
Expert. The Expert shall make a final decision with respect to the Dispute within [***] days
following receipt of the last of such rebuttal statements submitted by the Parties. Each Party
shall bear its own costs and expenses and attorneys’ fees, and the Party that does not prevail in
the arbitration proceeding shall pay the Expert’s fees and any administrative fees of arbitration.

          20.2.3 Litigation; Venue; Jurisdiction. Each of the Parties hereto hereby (a)
irrevocably and unconditionally agrees that any action or proceeding in respect of any claim
arising out of or related to this Agreement or the transactions contained in or contemplated by
this Agreement that is not a Dispute, whether in tort or contract or at law or in equity, shall be
brought by such Party exclusively in the state and federal courts of the State of New York (the
“Chosen Courts”); (b) irrevocably submits to the exclusive jurisdiction of the Chosen
Courts; (c) waives any objection to laying of venue in any such action or proceeding in the Chosen
Courts; (d) waives any objection that the Chosen Courts are an inconvenient forum or do not have
jurisdiction over any Party hereto; (e) agrees that service of process upon such Party in any such
action or proceeding shall be effective if notice is given in accordance with this Agreement; and
(f) agrees that a final judgment in any such action or proceeding shall be conclusive and may be
enforced by suit on the judgment or in any other manner provided by Applicable Laws or at equity.

21. MISCELLANEOUS

     21.1 Notification. All notices, requests and other communications hereunder shall be
in writing, shall be addressed to the receiving Party’s address set forth below or to such other
address as a Party may designate by notice hereunder, and shall be either (a) delivered by hand,
(b) made by facsimile transmission, (c) sent by private courier service providing evidence of
receipt or (d) sent by registered or certified mail, return receipt requested, postage prepaid.
The addresses and other contact information for the parties are as follows:

	 	 	 
	If to Ribomic:

	 	If to Archemix:
	 
	Ribomic, Inc.

	 	Archemix Corp.
	Shirokanedai Usui-Building

	 	300 Third Street
	3-16-13 Shirokanedai

	 	Cambridge, MA 02142
	Minato-ku

	 	Tel: (617) 621-7700
	Tokyo 108-0071

	 	Fax: (617) 621-9300
	Japan

	 	Attention: Chief Executive Officer
	Tel: (03) 3440-3303

	 	Attention: Legal Department
	Fax: (03) 3440-3729
	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-38

 

	 	 	 
	Attention: President
	 	 
	Attention: Legal Department
	 	 
	 
	 	 
	 

	 	With a copy to:
	 
	 	 
	 

	 	Mintz Levin Cohn Ferris Glovsky
and Popeo, P.C.
	 

	 	One Financial Center
	 

	 	Boston, MA 02110
	 

	 	Tel: (617) 542-6000
	 

	 	Fax: (617) 542-2241
	 

	 	Attn: John J. Cheney, Esq.

     All notices, requests and other communications hereunder shall be deemed to have been given
either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of
such Party set forth above, (ii) if made by facsimile transmission, at the time that confirmation
of receipt thereof has been received by the Party delivering such notice, (iii) if sent by a
internationally recognized courier service which provides a delivery receipt on the day of actual
receipt by the recipient, or (iv) if sent by registered or certified mail, on the seventh
(7th) business day following the day such mailing is made.

     21.2 Governing Law. This Agreement will be construed, interpreted and applied in
accordance with the laws of the State of New York (excluding its body of law controlling conflicts
of law).

     21.3 English Language. All data, results and information that is in a language other
than English and that is provided by either Party to the other Party and/or to the DC under this
Agreement shall be provided both in its original format, without translation, and in an English
translation within ten (10) business days except for a Sublicense Agreement, if any, whose
translation shall be provided with thirty (30) business days (which translation shall be made at
the providing Party’s sole cost and expense).

     21.4 Limitations. Except as expressly set forth in this Agreement, neither Party
grants to the other Party any right or license to any of its intellectual property.

     21.5 Entire Agreement. This is the entire Agreement between the Parties with respect
to the subject matter hereof and supersedes all prior representations, understandings and
agreements between the Parties with respect to the subject matter hereof. No modification or
amendment shall be effective unless in writing with specific reference to this Agreement and signed
by the Parties.

     21.6 Waiver. The terms or conditions of this Agreement may be waived only by a
written instrument executed by the Party waiving compliance. The failure of either Party at any
time or times to require performance of any provision hereof shall in no manner affect its rights
at a later time to enforce the same. No waiver by either Party of any condition or term shall be
deemed as a continuing waiver of such condition or term or of another condition or term.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-39

 

     21.7 Headings. Section and subsection headings are inserted for convenience of
reference only and do not form part of this Agreement.

     21.8 Assignment. Neither this Agreement nor any right or obligation hereunder may be
assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior
express written consent of the other; provided, that, either Party may, without the written consent
of the other, assign this Agreement and its rights and delegate its obligations hereunder to its
Affiliates or in connection with the transfer or sale of all or substantially all of such Party’s
assets or business to which this Agreement relates or in the event of its merger, consolidation,
change in control or similar transaction. Any permitted assignee shall assume all obligations of
its assignor under this Agreement. Any purported assignment in violation of this Section 11.8
shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the
benefit of the permitted successors and assigns of the parties.

     21.9 Force Majeure. Neither Party shall be liable for failure of or delay in
performing obligations set forth in this Agreement, and neither shall be deemed in breach of its
obligations, if such failure or delay is due to natural disasters or any causes beyond the
reasonable control of such Party. In event of such force majeure, the Party affected thereby shall
use reasonable efforts to cure or overcome the same and resume performance of its obligations
hereunder.

     21.10 Construction. The Parties hereto acknowledge and agree that: (a) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have
contributed to its revision; (b) the rule of construction to the effect that any ambiguities are
resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties
hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement.

     21.11 Severability. If any provision(s) of this Agreement are or become invalid, are
ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current
applicable law from time to time in effect during the Term hereof, it is the intention of the
Parties that the remainder of this Agreement shall not be affected thereby; provided, that, a
Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and
agree to renegotiate any such term, covenant or application thereof in good faith in order to
provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or
the application thereof that is invalid, illegal or unenforceable, it being the intent of the
Parties that the basic purposes of this Agreement are to be effectuated.

     21.12 Status. Nothing in this Agreement is intended or shall be deemed to constitute
a partner, agency, employer-employee or joint venture relationship between the Parties.

     21.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-40

 

     21.14 Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

[Remainder of page intentionally left blank.]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-41

 

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective
duly authorized representative in 

two (2) originals.

	 	 	 	 	 	 	 
	RIBOMIC, INC.	 	ARCHEMIX CORP.
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-42

 

Schedule 1

Chemical Composition of Licensed Target

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 1-1
to Exhibit B

 

Schedule 2

Required Jurisdictions

[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Schedule 2-1
to Exhibit B

 

Exhibit A (dated May 19, 2008)

Licensed Patent Rights

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-1
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-2
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-3
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-4
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-5
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-6
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-7
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-8
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-9
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-10
to Exhibit B

 

	 	 	 	 	 	 	 	 	 	 	 
	IMATTERNO	 	COUNTRYID	 	SERIALNO	 	PATENTNO	 	TITLE	 	STATUS
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	 	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-11
to Exhibit B

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-12
to Exhibit B

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-13
to Exhibit B

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-14
to Exhibit B

 

	 	 	 	 	 	 	 	 	 
	Archemix Ref. No.	 	Status	 	Appl. Number	 	Country	 	Title
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	[***]	 	[***]	 	[***]

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit A-15
to Exhibit B

 

Exhibit B

Ribomic SELEX Patent Rights

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Appln No.	 	 	 	 	 	 	 	 	 	 
	COUNTRY	 	(Publn No)	 	Patent No.	 	Title	 	Status	 	File	 	Issue
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit B-1
to Exhibit B

 

Exhibit C

Ribomic SELEX Patent Rights

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Appln No.	 	 	 	 	 	 	 	 	 	 
	COUNTRY	 	(Publn No)	 	Patent No.	 	Title	 	Status	 	File	 	Issue
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 
	[***]
	 	[***]	 	 	 	[***]	 	[***]	 	[***]	 	 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
 Company’s application requesting confidential treatment under Rule 406 of the Securities Act.

Exhibit C-1exv10w51

Exhibit 10.51

As adopted by the Board of Directors on March 31, 2004

As approved by the shareholders on March 31, 2004

As amended by the Board of Directors on June 3, 2004

(shareholder approval not required)

As amended by the Board of Directors on December 22, 2005

As approved by the shareholders on December 22, 2005

As amended by the Board of Directors on May 5, 2008

As approved by the shareholders on May 16, 2008

ARCHEMIX CORP.

AMENDED & RESTATED

2001 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN

1. DEFINITIONS.

Unless otherwise specified or unless the context otherwise requires, the following terms, as
used in this Archemix Corp. 2001 Employee, Director and Consultant Stock Plan, have the
following meanings:

Administrator means the Board of Directors, unless it has delegated power to
act on its behalf to the Committee, in which case the Administrator means the
Committee.

Affiliate means a corporation which, for purposes of Section 424 of the
Code, is a parent or subsidiary of the Company, direct or indirect.

Board of Directors means the Board of Directors of the Company.

Code means the United States Internal Revenue Code of 1986, as amended.

Committee means the committee of the Board of Directors to which the Board
of Directors has delegated power to act under or pursuant to the provisions of the
Plan.

Common Stock means shares of the Company’s common stock, $.001 par value per
share.

Company means Archemix Corp., a Delaware corporation.

Disability or Disabled means permanent and total disability as
defined in Section 22(e)(3) of the Code.

 

 

Fair Market Value of a Share of Common Stock means:

(1) If the Common Stock is listed on a national securities exchange or traded in the
over-the-counter market and sales prices are regularly reported for the Common
Stock, the closing or last price of the Common Stock on the Composite Tape or other
comparable reporting system for the trading day immediately preceding the applicable
date;

(2) If the Common Stock is not traded on a national securities exchange but is
traded on the over-the-counter market, if sales prices are not regularly reported
for the Common Stock for the trading day referred to in clause (1), and if bid and
asked prices for the Common Stock are regularly reported, the mean between the bid
and the asked price for the Common Stock at the close of trading in the
over-the-counter market for the trading day on which Common Stock was traded
immediately preceding the applicable date; and

(3) If the Common Stock is neither listed on a national securities exchange nor
traded in the over-the-counter market, such value as the Administrator, in good
faith, shall determine.

ISO means an option meant to qualify as an incentive stock option under
Section 422 of the Code.

Key Employee means an employee of the Company or of an Affiliate (including,
without limitation, an employee who is also serving as an officer or director of the
Company or of an Affiliate), designated by the Administrator to be eligible to be
granted one or more Stock Rights under the Plan.

Non-Qualified Option means an option which is not intended to qualify as an
ISO.

Option means an ISO or Non-Qualified Option granted under the Plan.

Option Agreement means an agreement between the Company and a Participant
delivered pursuant to the Plan, in such form as the Administrator shall approve.

Participant means a Key Employee, director or consultant to whom one or more
Stock Rights are granted under the Plan. As used herein, “Participant” shall
include “Participant’s Survivors” where the context requires.

Plan means this Archemix Corp. 2001 Employee, Director and Consultant Stock
Plan.

Shares means shares of the Common Stock as to which Stock Rights have been
or may be granted under the Plan or any shares of capital stock into which the
Shares are changed or for which they are exchanged within the provisions of
Paragraph 3

2

 

of the Plan. The Shares issued under the Plan may be authorized and unissued shares
or shares held by the Company in its treasury, or both.

Stock Grant means a grant by the Company of Shares under the Plan.

Stock Grant Agreement means an agreement between the Company and a
Participant delivered pursuant to the Plan, in such form as the Administrator shall
approve.

Stock Right means a right to Shares of the Company granted pursuant to the
Plan — an ISO, a Non-Qualified Option or a Stock Grant.

Survivors means a deceased Participant’s legal representatives and/or any
person or persons who acquired the Participant’s rights to a Stock Right by will or
by the laws of descent and distribution.

2. PURPOSES OF THE PLAN.

     The Plan is intended to encourage ownership of Shares by Key Employees and directors of and
certain consultants to the Company in order to attract such people, to induce them to work for the
benefit of the Company or of an Affiliate and to provide additional incentive for them to promote
the success of the Company or of an Affiliate. The Plan provides for the granting of ISOs,
Non-Qualified Options and Stock Grants.

3. SHARES SUBJECT TO THE PLAN.

     The number of Shares which may be issued from time to time pursuant to this Plan shall be
Twenty Seven Million (27,000,000), or the equivalent of such number of Shares after the
Administrator, in its sole discretion, has interpreted the effect of any stock split, stock
dividend, combination, recapitalization or similar transaction in accordance with Paragraph 23 of
the Plan.

     If an Option ceases to be “outstanding”, in whole or in part, or if the Company shall
reacquire any Shares issued pursuant to a Stock Grant, the Shares which were subject to such Option
and any Shares so reacquired by the Company shall be available for the granting of other Stock
Rights under the Plan. Any Option shall be treated as “outstanding” until such Option is exercised
in full, or terminates or expires under the provisions of the Plan, or by agreement of the parties
to the pertinent Option Agreement.

3

 

4. ADMINISTRATION OF THE PLAN.

     The Administrator of the Plan will be the Board of Directors, except to the extent the Board
of Directors delegates its authority to the Committee, in which case the Committee shall be the
Administrator. Subject to the provisions of the Plan, the Administrator is authorized to:

	 	a.	 	Interpret the provisions of the Plan or of any Option or Stock Grant and to
make all rules and determinations which it deems necessary or advisable for the
administration of the Plan;
	 
	 	b.	 	Determine which employees of the Company or of an Affiliate shall be designated
as Key Employees and which of the Key Employees, directors and consultants shall be
granted Stock Rights;
	 
	 	c.	 	Determine the number of Shares for which a Stock Right or Stock Rights shall be
granted;
	 
	 	d.	 	Specify the terms and conditions upon which a Stock Right or Stock Rights may
be granted; and

e. Adopt any sub-plans applicable to residents of any specified jurisdiction as it deems necessary
or appropriate in order to comply with or take advantage of any tax laws applicable to the Company
or to Plan Participants or to otherwise facilitate the administration of the Plan, which sub-plans
may include additional restrictions or conditions applicable to Options or Shares acquired upon
exercise of Options;

provided, however, that all such interpretations, rules, determinations, terms and conditions shall
be made and prescribed in the context of preserving the tax status under Section 422 of the Code of
those Options which are designated as ISOs. Subject to the foregoing, the interpretation and
construction by the Administrator of any provisions of the Plan or of any Stock Right granted under
it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is
the Committee. In addition, if the Administrator is the Committee, the Board of Directors may take
any action under the Plan that would otherwise be the responsibility of the Committee.

     If permissible under applicable law, the Board of Directors or the Committee may allocate all
or any portion of its responsibilities and powers to any one or more of its members and may
delegate all or any portion of its responsibilities and powers to any other person selected by it.
Any such allocation or delegation may be revoked by the Board of Directors or the Committee at any
time.

5. ELIGIBILITY FOR PARTICIPATION.

     The Administrator will, in its sole discretion, name the Participants in the Plan, provided,
however, that each Participant must be a Key Employee, director or consultant of the Company

4

 

or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the
Administrator may authorize the grant of a Stock Right to a person not then an employee, director
or consultant of the Company or of an Affiliate; provided, however, that the actual grant of such
Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or
prior to the time of the delivery of the Agreement evidencing such Stock Right. ISOs may be
granted only to Key Employees. Non-Qualified Options and Stock Grants may be granted to any Key
Employee, director or consultant of the Company or an Affiliate. The granting of any Stock Right
to any individual shall neither entitle that individual to, nor disqualify him or her from,
participation in any other grant of Stock Rights.

6. TERMS AND CONDITIONS OF OPTIONS.

     Each Option shall be set forth in writing in an Option Agreement, duly executed by the Company
and, to the extent required by law or requested by the Company, by the Participant. The
Administrator may provide that Options be granted subject to such terms and conditions, consistent
with the terms and conditions specifically required under this Plan, as the Administrator may deem
appropriate including, without limitation, subsequent approval by the shareholders of the Company
of this Plan or any amendments thereto. The Option Agreements shall be subject to at least the
following terms and conditions:

	 	A.	 	Non-Qualified Options: Each Option intended to be a Non-Qualified
Option shall be subject to the terms and conditions which the Administrator determines
to be appropriate and in the best interest of the Company, subject to the following
minimum standards for any such Non-Qualified Option:

	 	a.	 	Option Price: Each Option Agreement shall state the option
price (per share) of the Shares covered by each Option, which option price
shall be determined by the Administrator but shall not be less than the par
value per share of Common Stock.
	 
	 	b.	 	Each Option Agreement shall state the number of Shares to which
it pertains;
	 
	 	c.	 	Each Option Agreement shall state the date or dates on which it
first is exercisable and the date after which it may no longer be exercised,
and may provide that the Option rights accrue or become exercisable in
installments over a period of months or years, or upon the occurrence of
certain conditions or the attainment of stated goals or events; and
	 
	 	d.	 	Exercise of any Option may be conditioned upon the
Participant’s execution of a Share purchase agreement in form satisfactory to
the Administrator providing for certain protections for the Company and its
other shareholders, including requirements that:

5

 

	 	i.	 	The Participant’s or the Participant’s
Survivors’ right to sell or transfer the Shares may be restricted; and
	 
	 	ii.	 	The Participant or the Participant’s Survivors
may be required to execute letters of investment intent and must also
acknowledge that the Shares will bear legends noting any applicable
restrictions.

	 	B.	 	ISOs: Each Option intended to be an ISO shall be issued only to a Key
Employee and be subject to the following terms and conditions, with such additional
restrictions or changes as the Administrator determines are appropriate but not in
conflict with Section 422 of the Code and relevant regulations and rulings of the
Internal Revenue Service:

	 	a.	 	Minimum standards: The ISO shall meet the minimum standards
required of Non-Qualified Options, as described in Paragraph 6(A) above, except
clauses (a) thereunder.
	 
	 	b.	 	Option Price: Immediately before the Option is granted, if the
Participant owns, directly or by reason of the applicable attribution rules in
Section 424(d) of the Code:

	 	i.	 	Ten percent (10%) or less of the total
combined voting power of all classes of stock of the Company or an
Affiliate, the Option price per share of the Shares covered by each
Option shall not be less than one hundred percent (100%) of the Fair
Market Value per share of the Shares on the date of the grant of the
Option.
	 
	 	ii.	 	More than ten percent (10%) of the total
combined voting power of all classes of stock of the Company or an
Affiliate, the Option price per share of the Shares covered by each
Option shall not be less than one hundred ten percent (110%) of the
said Fair Market Value on the date of grant.

	 	c.	 	Term of Option: For Participants who own

	 	i.	 	Ten percent (10%) or less of the total
combined voting power of all classes of stock of the Company or an
Affiliate, each Option shall terminate not more than ten (10) years
from the date of the grant or at such earlier time as the Option
Agreement may provide.
	 
	 	ii.	 	More than ten percent (10%) of the total
combined voting power of all classes of stock of the Company or an
Affiliate, each Option shall terminate not more than five (5) years
from the date of the grant or at such earlier time as the Option
Agreement may provide.

6

 

	 	d.	 	Limitation on Yearly Exercise: The Option Agreements shall
restrict the amount of Options which may be exercisable in any calendar year
(under this or any other ISO plan of the Company or an Affiliate) so that the
aggregate Fair Market Value (determined at the time each ISO is granted) of the
stock with respect to which ISOs are exercisable for the first time by the
Participant in any calendar year does not exceed one hundred thousand dollars
($100,000), provided that this subparagraph (d) shall have no force or effect
if its inclusion in the Plan is not necessary for Options issued as ISOs to
qualify as ISOs pursuant to Section 422(d) of the Code.

7. TERMS AND CONDITIONS OF STOCK GRANTS.

     Each offer of a Stock Grant to a Participant shall state the date prior to which the Stock
Grant must be accepted by the Participant, and the principal terms of each Stock Grant shall be set
forth in a Stock Grant Agreement, duly executed by the Company and, to the extent required by law
or requested by the Company, by the Participant. The Stock Grant Agreement shall be in a form
approved by the Administrator and shall contain terms and conditions which the Administrator
determines to be appropriate and in the best interest of the Company, subject to the following
minimum standards:

	 	(a)	 	Each Stock Grant Agreement shall state the purchase price (per share), if any,
of the Shares covered by each Stock Grant, which purchase price shall be determined by
the Administrator but shall not be less than the minimum consideration required by
Delaware General Corporation Law on the date of the grant of the Stock Grant;
	 
	 	(b)	 	Each Stock Grant Agreement shall state the number of Shares to which the Stock
Grant pertains; and
	 
	 	(c)	 	Each Stock Grant Agreement shall include the terms of any right of the Company
to reacquire the Shares subject to the Stock Grant, including the time and events upon
which such rights shall accrue and the purchase price therefore, if any.

8. EXERCISE OF OPTIONS AND ISSUE OF SHARES.

     An Option (or any part or installment thereof) shall be exercised by giving written notice to
the Company at its principal executive office address, together with provision for payment of the
full purchase price in accordance with this Paragraph for the Shares as to which the Option is
being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement.
Such written notice shall be signed by the person exercising the Option, shall state the number of
Shares with respect to which the Option is being exercised and shall contain any representation
required by the Plan or the Option Agreement. Payment of the purchase price for the Shares as to
which such Option is being exercised shall be made (a) in United States dollars

7

 

in cash or by check, or (b) at the discretion of the Administrator, through delivery of shares of
Common Stock having a Fair Market Value equal as of the date of the exercise to the cash exercise
price of the Option, or (c) at the discretion of the Administrator, by having the Company retain
from the shares otherwise issuable upon exercise of the Option, a number of shares having a Fair
Market Value equal as of the date of exercise to the exercise price of the Option, or (d) at the
discretion of the Administrator, by delivery of the grantee’s personal recourse note bearing
interest payable not less than annually at no less than 100% of the applicable Federal rate, as
defined in Section 1274(d) of the Code, or (e) at the discretion of the Administrator, in
accordance with a cashless exercise program established with a securities brokerage firm, and
approved by the Administrator, or (f) at the discretion of the Administrator, by any combination of
(a), (b), (c), (d) and (e) above. Notwithstanding the foregoing, the Administrator shall accept
only such payment on exercise of an ISO as is permitted by Section 422 of the Code.

     The Company shall then reasonably promptly deliver the Shares as to which such Option was
exercised to the Participant (or to the Participant’s Survivors, as the case may be). In
determining what constitutes “reasonably promptly,” it is expressly understood that the issuance
and delivery of the Shares may be delayed by the Company in order to comply with any law or
regulation (including, without limitation, state securities or “blue sky” laws) which requires the
Company to take any action with respect to the Shares prior to their issuance. The Shares shall,
upon delivery, be evidenced by an appropriate certificate or certificates for fully paid,
non-assessable Shares.

     The Administrator shall have the right to accelerate the date of exercise of any installment
of any Option; provided that the Administrator shall not accelerate the exercise date of any
installment of any Option granted to any Key Employee as an ISO (and not previously converted into
a Non-Qualified Option pursuant to Paragraph 26) if such acceleration would violate the annual
vesting limitation contained in Section 422(d) of the Code, as described in Paragraph 6.B.d.

     The Administrator may, in its discretion, amend any term or condition of an outstanding Option
provided (i) such term or condition as amended is permitted by the Plan, (ii) any such amendment
shall be made only with the consent of the Participant to whom the Option was granted, or in the
event of the death of the Participant, the Participant’s Survivors, if the amendment is adverse to
the Participant, and (iii) any such amendment of any ISO shall be made only after the
Administrator, after consulting the counsel for the Company, determines whether such amendment
would constitute a “modification” of any Option which is an ISO (as that term is defined in Section
424(h) of the Code) or would cause any adverse tax consequences for the holder of such ISO.

9. ACCEPTANCE OF STOCK GRANT AND ISSUE OF SHARES.

     A Stock Grant (or any part or installment thereof) shall be accepted by executing the Stock
Grant Agreement and delivering it to the Company at its principal office address, together with
provision for payment of the full purchase price, if any, in accordance with this Paragraph for the
Shares as to which such Stock Grant is being accepted, and upon compliance with any

8

 

other conditions set forth in the Stock Grant Agreement. Payment of the purchase price for the
Shares as to which such Stock Grant is being accepted shall be made (a) in United States dollars in
cash or by check, or (b) at the discretion of the Administrator, through delivery of shares of
Common Stock having a fair market value equal as of the date of acceptance of the Stock Grant to
the purchase price of the Stock Grant determined in good faith by the Administrator, or (c) at the
discretion of the Administrator, by delivery of the grantee’s personal recourse note bearing
interest payable not less than annually at no less than 100% of the applicable Federal rate, as
defined in Section 1274(d) of the Code, or (d) at the discretion of the Administrator, by any
combination of (a), (b) and (c) above.

     The Company shall then reasonably promptly deliver the Shares as to which such Stock Grant was
accepted to the Participant (or to the Participant’s Survivors, as the case may be), subject to any
escrow provision set forth in the Stock Grant Agreement. In determining what constitutes
“reasonably promptly,” it is expressly understood that the issuance and delivery of the Shares may
be delayed by the Company in order to comply with any law or regulation (including, without
limitation, state securities or “blue sky” laws) which requires the Company to take any action with
respect to the Shares prior to their issuance.

     The Administrator may, in its discretion, amend any term or condition of an outstanding Stock
Grant or Stock Grant Agreement provided (i) such term or condition as amended is permitted by the
Plan, and (ii) any such amendment shall be made only with the consent of the Participant to whom
the Stock Grant was made, if the amendment is adverse to the Participant.

10. RIGHTS AS A SHAREHOLDER.

     No Participant to whom a Stock Right has been granted shall have rights as a shareholder with
respect to any Shares covered by such Stock Right, except after due exercise of the Option or
acceptance of the Stock Grant and tender of the full purchase price, if any, for the Shares being
purchased pursuant to such exercise or acceptance and registration of the Shares in the Company’s
share register in the name of the Participant.

11. ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS.

     By its terms, a Stock Right granted to a Participant shall not be transferable by the
Participant other than (i) by will or by the laws of descent and distribution, or (ii) as otherwise
determined by the Administrator and set forth in the applicable Option Agreement or Stock Grant
Agreement. The designation of a beneficiary of a Stock Right by a Participant, with the prior
approval of the Administrator and in such form as the Administrator shall prescribe, shall not be
deemed a transfer prohibited by this Paragraph. Except as provided above, a Stock Right shall only
be exercisable or may only be accepted, during the Participant’s lifetime, by such Participant (or
by his or her legal representative) and shall not be assigned, pledged or hypothecated in any way
(whether by operation of law or otherwise) and shall not be subject to execution, attachment or
similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of
any Stock Right or of any rights granted thereunder

9

 

contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a
Stock Right, shall be null and void.

			
	12.	 	EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN “FOR CAUSE” OR DEATH OR
DISABILITY.

     Except as otherwise provided in the pertinent Option Agreement in the event of a termination
of service (whether as an employee, director or consultant) with the Company or an Affiliate before
the Participant has exercised an Option, the following rules apply:

	 	a.	 	A Participant who ceases to be an employee, director or consultant of the
Company or of an Affiliate (for any reason other than termination “for cause”,
Disability, or death for which events there are special rules in Paragraphs 13, 14, and
15, respectively), may exercise any Option granted to him or her to the extent that the
Option is exercisable on the date of such termination of service, but only within such
term as the Administrator has designated in the pertinent Option Agreement.
	 
	 	b.	 	Except as provided in Subparagraph (c) below, or Paragraph 14 or 15, in no
event may an Option Agreement provide, if an Option is intended to be an ISO, that the
time for exercise be later than three (3) months after the Participant’s termination of
employment.
	 
	 	c.	 	The provisions of this Paragraph, and not the provisions of Paragraph 14 or 15,
shall apply to a Participant who subsequently becomes Disabled or dies after the
termination of employment, director status or consultancy, provided, however, in the
case of a Participant’s Disability or death within three (3) months after the
termination of employment, director status or consultancy, the Participant or the
Participant’s Survivors may exercise the Option within one (1) year after the date of
the Participant’s termination of employment, but in no event after the date of
expiration of the term of the Option.
	 
	 	d.	 	Notwithstanding anything herein to the contrary, if subsequent to a
Participant’s termination of employment, termination of director status or termination
of consultancy, but prior to the exercise of an Option, the Board of Directors
determines that, either prior or subsequent to the Participant’s termination, the
Participant engaged in conduct which would constitute “cause”, then such Participant
shall forthwith cease to have any right to exercise any Option.
	 
	 	e.	 	A Participant to whom an Option has been granted under the Plan who is absent
from work with the Company or with an Affiliate because of temporary disability (any
disability other than a permanent and total Disability as defined in Paragraph 1
hereof), or who is on leave of absence for any purpose, shall not, during the period of
any such absence, be deemed, by virtue of such absence alone, to have terminated such
Participant’s employment, director status or consultancy with the

10

 

	 	 	 	Company or with an Affiliate, except as the Administrator may otherwise expressly
provide.
	 
	 	f.	 	Except as required by law or as set forth in the pertinent Option Agreement,
Options granted under the Plan shall not be affected by any change of a Participant’s
status within or among the Company and any Affiliates, so long as the Participant
continues to be an employee, director or consultant of the Company or any Affiliate.

13. EFFECT ON OPTIONS OF TERMINATION OF SERVICE “FOR CAUSE”.

     Except as otherwise provided in the pertinent Option Agreement, the following rules apply if
the Participant’s service (whether as an employee, director or consultant) with the Company or an
Affiliate is terminated “for cause” prior to the time that all his or her outstanding Options have
been exercised:

	 	a.	 	All outstanding and unexercised Options as of the time the Participant is
notified his or her service is terminated “for cause” will immediately be forfeited.
	 
	 	b.	 	For purposes of this Plan, “cause” shall include (and is not limited to):

	 	(i)	 	a violation of an important Company policy, the neglect of a
Participant’s duties or the gross or willful failure of a Participant to
perform his or her duties hereunder, which is not cured after five days notice.
	 
	 	(ii)	 	dishonesty, embezzlement, gross negligence, willful misconduct,
neglect, theft, fraud or breach of fiduciary duty to the Company;
	 
	 	(iii)	 	violation of federal or state securities laws;
	 
	 	(iv)	 	breach of an employment, consulting or other agreement
(including, without limitation, the Employee Noncompetition, Nondisclosure and
Development Agreement between a Participant and the Company, which breach
harms, damages, causes loss to or injures the business or reputation of the
Company;
	 
	 	(v)	 	the unauthorized disclosure of any trade secret or confidential
information of the Company;
	 
	 	(vi)	 	the commission of an act which constitutes unfair competition
with the Company or which induces any customer or supplier to breach a
contract with the Company;
	 
	 	(vii)	 	an act by a Participant which creates adverse publicity for
the Company; or

11

 

	 	(viii)	 	the conviction of a Participant for the commission of any felony including a
pleas of guilty or nolo contendere.

     The determination of the Administrator as to the existence of “cause” will be conclusive on
the Participant and the Company.

	 	c.	 	“Cause” is not limited to events which have occurred prior to a Participant’s
termination of service, nor is it necessary that the Administrator’s finding of “cause”
occur prior to termination. If the Administrator determines, subsequent to a
Participant’s termination of service but prior to the exercise of an Option, that
either prior or subsequent to the Participant’s termination the Participant engaged in
conduct which would constitute “cause”, then the right to exercise any Option is
forfeited.
	 
	 	d.	 	Any definition in an agreement between the Participant and the Company or an
Affiliate, which contains a conflicting definition of “cause” for termination and which
is in effect at the time of such termination, shall supersede the definition in this
Plan with respect to such Participant.

14. EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY.

     Except as otherwise provided in the pertinent Option Agreement, a Participant who ceases to be
an employee, director or consultant of the Company or of an Affiliate by reason of Disability may
exercise any Option granted to such Participant:

	 	a.	 	To the extent exercisable but not exercised on the date of Disability; and
	 
	 	b.	 	In the event rights to exercise the Option accrue periodically, to the extent
of a pro rata portion of any additional rights as would have accrued had the
Participant not become Disabled prior to the end of the accrual period which next ends
following the date of Disability. The proration shall be based upon the number of days
of such accrual period prior to the date of Disability.

     A Disabled Participant may exercise such rights only within the period ending one (1) year
after the date of the Participant’s termination of employment, directorship or consultancy, as the
case may be, notwithstanding that the Participant might have been able to exercise the Option as to
some or all of the Shares on a later date if the Participant had not become disabled and had
continued to be an employee, director or consultant or, if earlier, within the originally
prescribed term of the Option.

     The Administrator shall make the determination both of whether Disability has occurred and the
date of its occurrence (unless a procedure for such determination is set forth in another agreement
between the Company and such Participant, in which case such procedure shall be used for such
determination). If requested, the Participant shall be examined by a physician

12

 

selected or approved by the Administrator, the cost of which examination shall be paid for by the
Company.

15. EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.

     Except as otherwise provided in the pertinent Option Agreement, in the event of the death of a
Participant while the Participant is an employee, director or consultant of the Company or of an
Affiliate, such Option may be exercised by the Participant’s Survivors:

	 	a.	 	To the extent exercisable but not exercised on the date of death; and
	 
	 	b.	 	In the event rights to exercise the Option accrue periodically, to the extent
of a pro rata portion of any additional rights which would have accrued had the
Participant not died prior to the end of the accrual period which next ends following
the date of death. The proration shall be based upon the number of days of such
accrual period prior to the Participant’s death.

     If the Participant’s Survivors wish to exercise the Option, they must take all necessary steps
to exercise the Option within one (1) year after the date of death of such Participant,
notwithstanding that the decedent might have been able to exercise the Option as to some or all of
the Shares on a later date if he or she had not died and had continued to be an employee, director
or consultant or, if earlier, within the originally prescribed term of the Option.

16. EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS.

     In the event of a termination of service (whether as an employee, director or consultant) with
the Company or an Affiliate for any reason before the Participant has accepted a Stock Grant, such
offer shall terminate.

     For purposes of this Paragraph 16 and Paragraph 17 below, a Participant to whom a Stock Grant
has been offered under the Plan who is absent from work with the Company or with an Affiliate
because of temporary disability (any disability other than a permanent and total Disability as
defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during
the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such
Participant’s employment, director status or consultancy with the Company or with an Affiliate,
except as the Administrator may otherwise expressly provide.

     In addition, for purposes of this Paragraph 16 and Paragraph 17 below, any change of
employment or other service within or among the Company and any Affiliates shall not be treated as
a termination of employment, director status or consultancy so long as the Participant continues to
be an employee, director or consultant of the Company or any Affiliate.

13

 

			
	17.	 	EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE OTHER THAN “FOR CAUSE” OR DEATH OR
DISABILITY.

     Except as otherwise provided in the pertinent Stock Grant Agreement, in the event of a
termination of service (whether as an employee, director or consultant), other than termination
“for cause,” Disability, or death for which events there are special rules in Paragraphs 18, 19,
and 20, respectively, before all Company rights of repurchase shall have lapsed, then the Company
shall have the right to repurchase that number of Shares subject to a Stock Grant as to which the
Company’s repurchase rights have not lapsed.

18. EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE “FOR CAUSE”.

     Except as otherwise provided in the pertinent Stock Grant Agreement, the following rules apply
if the Participant’s service (whether as an employee, director or consultant) with the Company or
an Affiliate is terminated “for cause”:

	 	a.	 	All Shares subject to any Stock Grant shall be immediately subject to
repurchase by the Company at the purchase price, if any, thereof.
	 
	 	b.	 	For purposes of this Plan, “cause” shall include (and is not limited to)
dishonesty with respect to the employer, insubordination, substantial malfeasance or
non-feasance of duty, unauthorized disclosure of confidential information, and conduct
substantially prejudicial to the business of the Company or any Affiliate. The
determination of the Administrator as to the existence of “cause” will be conclusive on
the Participant and the Company.
	 
	 	c.	 	“Cause” is not limited to events which have occurred prior to a Participant’s
termination of service, nor is it necessary that the Administrator’s finding of “cause”
occur prior to termination. If the Administrator determines, subsequent to a
Participant’s termination of service, that either prior or subsequent to the
Participant’s termination the Participant engaged in conduct which would constitute
“cause,” then the Company’s right to repurchase all of such Participant’s Shares shall
apply.
	 
	 	d.	 	Any definition in an agreement between the Participant and the Company or an
Affiliate, which contains a conflicting definition of “cause” for termination and which
is in effect at the time of such termination, shall supersede the definition in this
Plan with respect to such Participant.

19. EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE FOR DISABILITY.

     Except as otherwise provided in the pertinent Stock Grant Agreement, the following rules apply
if a Participant ceases to be an employee, director or consultant of the Company or of an

14

 

Affiliate by reason of Disability: to the extent the Company’s rights of repurchase have not
lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event
such rights of repurchase lapse periodically, such rights shall lapse to the extent of a pro rata
portion of the Shares subject to such Stock Grant as would have lapsed had the Participant not
become Disabled prior to the end of the vesting period which next ends following the date of
Disability. The proration shall be based upon the number of days of such vesting period prior to
the date of Disability.

     The Administrator shall make the determination both of whether Disability has occurred and the
date of its occurrence (unless a procedure for such determination is set forth in another agreement
between the Company and such Participant, in which case such procedure shall be used for such
determination). If requested, the Participant shall be examined by a physician selected or
approved by the Administrator, the cost of which examination shall be paid for by the Company.

20. EFFECT ON STOCK GRANTS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.

     Except as otherwise provided in the pertinent Stock Grant Agreement, the following rules apply
in the event of the death of a Participant while the Participant is an employee, director or
consultant of the Company or of an Affiliate: to the extent the Company’s rights of repurchase
have not lapsed on the date of death, they shall be exercisable; provided, however, that in the
event such rights of repurchase lapse periodically, such rights shall lapse to the extent of a pro
rata portion of the Shares subject to such Stock Grant as would have lapsed had the Participant not
died prior to the end of the vesting period which next ends following the date of death. The
proration shall be based upon the number of days of such vesting period prior to the Participant’s
death.

21. PURCHASE FOR INVESTMENT.

     Unless the offering and sale of the Shares to be issued upon the particular exercise or
acceptance of a Stock Right shall have been effectively registered under the Securities Act of
1933, as now in force or hereafter amended (the “1933 Act”), the Company shall be under no
obligation to issue the Shares covered by such exercise unless and until the following conditions
have been fulfilled:

	 	a.	 	The person(s) who exercise(s) or accept(s) such Stock Right shall warrant to
the Company, prior to the receipt of such Shares, that such person(s) are acquiring
such Shares for their own respective accounts, for investment, and not with a view to,
or for sale in connection with, the distribution of any such Shares, in which event the
person(s) acquiring such Shares shall be bound by the provisions of the following
legend which shall be endorsed upon the certificate(s) evidencing their Shares issued
pursuant to such exercise or such grant:

15

 

“The shares represented by this certificate have been taken for investment
and they may not be sold or otherwise transferred by any person, including a
pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or
(b) the Company shall have received an opinion of counsel satisfactory to it
that an exemption from registration under such Act is then available, and
(2) there shall have been compliance with all applicable state securities
laws.”

	 	b.	 	At the discretion of the Administrator, the Company shall have received an
opinion of its counsel that the Shares may be issued upon such particular exercise or
acceptance in compliance with the 1933 Act without registration thereunder.

22. DISSOLUTION OR LIQUIDATION OF THE COMPANY.

     Upon the dissolution or liquidation of the Company, all Options granted under this Plan which
as of such date shall not have been exercised and all Stock Grants which have not been accepted
will terminate and become null and void; provided, however, that if the rights of a Participant or
a Participant’s Survivors have not otherwise terminated and expired, the Participant or the
Participant’s Survivors will have the right immediately prior to such dissolution or liquidation to
exercise or accept any Stock Right to the extent that the Stock Right is exercisable or subject to
acceptance as of the date immediately prior to such dissolution or liquidation.

23. ADJUSTMENTS.

     Upon the occurrence of any of the following events, a Participant’s rights with respect to any
Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided, unless
otherwise specifically provided in the pertinent Option Agreement or Stock Grant Agreement:

     A. Stock Dividends and Stock Splits. If (i) the shares of Common Stock shall be
subdivided or combined into a greater or smaller number of shares or if the Company shall issue any
shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional
shares or new or different shares or other securities of the Company or other non-cash assets are
distributed with respect to such shares of Common Stock, the number of shares of Common Stock
deliverable upon the exercise or acceptance of such Stock Right may be appropriately increased or
decreased proportionately, and appropriate adjustments may be made in the purchase price per share
to reflect such events.

     B. Consolidations or Mergers. If the Company is to be consolidated with or acquired
by another entity in a merger, sale of all or substantially all of the Company’s assets or
otherwise (an “Acquisition”), the Administrator or the board of directors of any entity assuming
the obligations of the Company hereunder (the “Successor Board”), shall, as to outstanding Options,
either (i) make appropriate provision for the continuation of such Options by substituting on an

16

 

equitable basis for the Shares then subject to such Options either the consideration payable with
respect to the outstanding shares of Common Stock in connection with the Acquisition or securities
of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that
all Options must be exercised (either to the extent then exercisable or, at the discretion of the
Administrator, all Options being made fully exercisable for purposes of this Subparagraph) at the
end of which period the Options shall terminate; or (iii) terminate all Options in exchange for a
cash payment equal to the excess of the Fair Market Value of the Shares subject to such Options
(either to the extent then exercisable or, at the discretion of the Administrator, all Options
being made fully exercisable for purposes of this Subparagraph) over the exercise price thereof.

     With respect to outstanding Stock Grants, the Administrator or the Successor Board, shall
either (i) make appropriate provisions for the continuation of such Stock Grants by substituting on
an equitable basis for the Shares then subject to such Stock Grants either the consideration
payable with respect to the outstanding Shares of Common Stock in connection with the Acquisition
or securities of any successor or acquiring entity; or (ii) upon written notice to the
Participants, provide that all Stock Grants must be accepted (to the extent then subject to
acceptance) within a specified number of days of the date of such notice, at the end of which
period the offer of the Stock Grants shall terminate; or (iii) terminate all Stock Grants in
exchange for a cash payment equal to the excess of the Fair Market Value of the Shares subject to
such Stock Grants over the purchase price thereof, if any. In addition, in the event of an
Acquisition, the Administrator may waive any or all Company repurchase rights with respect to
outstanding Stock Grants.

     C. Recapitalization or Reorganization. In the event of a recapitalization or
reorganization of the Company (other than a transaction described in Subparagraph B above) pursuant
to which securities of the Company or of another corporation are issued with respect to the
outstanding shares of Common Stock, a Participant upon exercising or accepting a Stock Right shall
be entitled to receive for the purchase price, if any, paid upon such exercise or acceptance the
securities which would have been received if such Stock Right had been exercised or accepted prior
to such recapitalization or reorganization.

     D. Modification of ISOs. Notwithstanding the foregoing, any adjustments made pursuant
to Subparagraph A, B or C with respect to ISOs shall be made only after the Administrator, after
consulting with counsel for the Company, determines whether such adjustments would constitute a
“modification” of such ISOs (as that term is defined in Section 424(h) of the Code) or would cause
any adverse tax consequences for the holders of such ISOs. If the Administrator determines that
such adjustments made with respect to ISOs would constitute a modification of such ISOs, it may
refrain from making such adjustments, unless the holder of an ISO specifically requests in writing
that such adjustment be made and such writing indicates that the holder has full knowledge of the
consequences of such “modification” on his or her income tax treatment with respect to the ISO.

17

 

24. ISSUANCES OF SECURITIES.

     Except as expressly provided herein, no issuance by the Company of shares of stock of any
class, or securities convertible into shares of stock of any class, shall affect, and no adjustment
by reason thereof shall be made with respect to, the number or price of shares subject to Stock
Rights. Except as expressly provided herein, no adjustments shall be made for dividends paid in
cash or in property (including without limitation, securities) of the Company prior to any issuance
of Shares pursuant to a Stock Right.

25. FRACTIONAL SHARES.

     No fractional shares shall be issued under the Plan and the person exercising a Stock Right
shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market
Value thereof.

26. CONVERSION OF ISOs INTO NON-QUALIFIED OPTIONS; TERMINATION OF ISOs.

     The Administrator, at the written request of any Participant, may in its discretion take such
actions as may be necessary to convert such Participant’s ISOs (or any portions thereof) that have
not been exercised on the date of conversion into Non-Qualified Options at any time prior to the
expiration of such ISOs, regardless of whether the Participant is an employee of the Company or an
Affiliate at the time of such conversion. Such actions may include, but not be limited to,
extending the exercise period or reducing the exercise price of the appropriate installments of
such Options. At the time of such conversion, the Administrator (with the consent of the
Participant) may impose such conditions on the exercise of the resulting Non-Qualified Options as
the Administrator in its discretion may determine, provided that such conditions shall not be
inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant the right
to have such Participant’s ISOs converted into Non-Qualified Options, and no such conversion shall
occur until and unless the Administrator takes appropriate action. The Administrator, with the
consent of the Participant, may also terminate any portion of any ISO that has not been exercised
at the time of such conversion.

27. WITHHOLDING.

     In the event that any federal, state, or local income taxes, employment taxes, Federal
Insurance Contributions Act (“F.I.C.A.”) withholdings or other amounts are required by applicable
law or governmental regulation to be withheld from the Participant’s salary, wages or other
remuneration in connection with the exercise or acceptance of a Stock Right or in connection with a
Disqualifying Disposition (as defined in Paragraph 28) or upon the lapsing of any right of
repurchase, the Company may withhold from the Participant’s compensation, if any, or may require
that the Participant advance in cash to the Company, or to any Affiliate of the Company which
employs or employed the Participant, the statutory minimum amount of such

18

 

withholdings unless a different withholding arrangement, including the use of shares of the
Company’s Common Stock or a promissory note, is authorized by the Administrator (and permitted by
law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll
withholding shall be determined in the manner provided in Paragraph 1 above, as of the most recent
practicable date prior to the date of exercise. If the fair market value of the shares withheld is
less than the amount of payroll withholdings required, the Participant may be required to advance
the difference in cash to the Company or the Affiliate employer. The Administrator in its
discretion may condition the exercise of an Option for less than the then Fair Market Value on the
Participant’s payment of such additional withholding.

28. NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION.

     Each Key Employee who receives an ISO must agree to notify the Company in writing immediately
after the Key Employee makes a Disqualifying Disposition of any shares acquired pursuant to the
exercise of an ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and
includes any disposition (including any sale or gift) of such shares before the later of (a) two
years after the date the Key Employee was granted the ISO, or (b) one year after the date the Key
Employee acquired Shares by exercising the ISO, except as otherwise provided in Section 424(c) of
the Code. If the Key Employee has died before such stock is sold, these holding period
requirements do not apply and no Disqualifying Disposition can occur thereafter.

29. TERMINATION OF THE PLAN.

     The Plan will terminate on March 31, 2014, the date which is ten (10) years from the
earlier of the date of its adoption by the Board of Directors and the date of its approval
by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the
shareholders or the Board of Directors of the Company; provided, however, that any such earlier
termination shall not affect any Option Agreements or Stock Grant Agreements executed prior to the
effective date of such termination.

30. AMENDMENT OF THE PLAN AND AGREEMENTS.

     The Plan may be amended by the shareholders of the Company. The Plan may also be amended by
the Administrator, including, without limitation, to the extent necessary to qualify any or all
outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for
favorable federal income tax treatment (including deferral of taxation upon exercise) as may be
afforded incentive stock options under Section 422 of the Code, and to the extent necessary to
qualify the shares issuable upon exercise or acceptance of any outstanding Stock Rights granted, or
Stock Rights to be granted, under the Plan for listing on any national securities exchange or
quotation in any national automated quotation system of securities dealers. Any amendment approved
by the Administrator which the Administrator determines is of a scope that requires shareholder
approval shall be subject to obtaining such shareholder approval. Any modification or amendment of
the Plan shall not, without the consent of a Participant, adversely

19

 

affect his or her rights under a Stock Right previously granted to him or her. With the consent of
the Participant affected, the Administrator may amend outstanding Option Agreements and Stock Grant
Agreements in a manner which may be adverse to the Participant but which is not inconsistent with
the Plan. In the discretion of the Administrator, outstanding Option Agreements and Stock Grant
Agreements may be amended by the Administrator in a manner which is not adverse to the Participant.

31. EMPLOYMENT OR OTHER RELATIONSHIP.

     Nothing in this Plan or any Option Agreement or Stock Grant Agreement shall be deemed to
prevent the Company or an Affiliate from terminating the employment, consultancy or director status
of a Participant, nor to prevent a Participant from terminating his or her own employment,
consultancy or director status or to give any Participant a right to be retained in employment or
other service by the Company or any Affiliate for any period of time.

32. GOVERNING LAW.

     This Plan shall be construed and enforced in accordance with the law of the State of Delaware.

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]